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1.1 Resumen 
El colangiocarcinoma (CCA) es un cáncer de las vías biliares maligno 
agresivo, y que constituye el segundo tumor primario de hígado más común. 
En Europa, se diagnostican alrededor de 13.000 nuevos casos de CCA por año. 
Sin embargo, la patogenia de CCA sigue siendo difícil de entender y la falta de 
herramientas de diagnóstico y tratamiento impiden un mejor resultado para los 
pacientes. En el presente estudio, utilizamos un nuevo modelo animales de 
CCA, para entender el mecanismo molecular. En el presente trabajo, 
planteamos la hipótesis de que la disfunción sinérgica de Jnk1 y Jnk2 en los 
hepatocitos impulsa el desarrollo de la colangiocarcinogénesis. Ratones con 
deleción específica de Jnk1/2 en hepatocitos Jnk∆hepa y ratones floxeados 
control (Jnkf/f) fueron sacrificaron en diferentes puntos de tiempo durante la 
progresión de la enfermedad hepática. Así mismo, diferentes modelos 
experimentales tóxicos (TAA，DE/TAA, DEN/CCl4) fueron utilizados. De manera 
interesante, los ratones Jnk∆hepa mostraron progresivamente una mayor 
expresión de BiP/GR78, XBP1 empalmado y regulación a la baja de pIRE1α, 
lo que sugiere que la activación de XBP1 asociada con BiP podría 
desencadenar la cistogénesis hepática y las primeras etapas de CCA. 
Simultáneamente, tras daño tóxico o en modelo genético de cáncer, en 
comparación con los ratones Jnkf/f, los marcadores séricos de daño hepático 
(ALT, AST, LDH) aumentaron significativamente en los ratones Jnk∆hepa tratad 
Estos resultados se acompañaron de un aumento significativo de células 
TUNEL-positivas, hiperproliferación de células hepáticas (Ki 67), fibrogénesis, 
depósito de colágeno y α-actina del músculo liso (αSMA) y citocinas 
proinflamatorias (por ejemplo, Tnf-α, Tgf-β1, IL-6). De acuerdo con esta 
detección, se produjo una activación prominente de necroptosis 
(RIP1/RIP3/MLKL) en el daño hepático JnkΔhepa. Concomitantemente, los 
biomarcadores de células ovales hepáticas y epitelio biliar (CK19, AFP, SOX9, 
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YAP1, MUCIN2, Notch1) se regularon significativamente al alza. Finalmente, 
la sobreexpresión de c-MYC puede ser carcinogénica para desencadenar la 
formación de CCA en el grupo experimental JnkΔhepa en comparación con el 
hígado Jnkf/f. En resumen, nuestros datos indican que la combinación de 
funciones de JNK en los hepatocitos es esencial para la homeostasis de los 
hepatocitos. La pérdida de función de JNK1/2 puede promover la activación de 
la XBP1 asociada con BiP involucrada en ER-estrés, desencadenar 
cistogénesis hepática y etapas tempranas de CCA. La sobreexpresión de 
JNK1/2 promueve la formación de HCC, mientras que la falta de JNK1/2 
promueve la formación de CCA en la estimulación hepática crónica. 
Colectivamente, las JNK juegan un papel vital en el equilibrio de la 
diferenciación y transformación de hepatocitos y colangiocitos. Nuestra 
investigación reveló la nueva función de JNK en el destino de los hepatocitos 
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1.2 Abstract  
Cholangiocarcinoma (CCA) is an aggressive malignant bile duct cancer, and 
the second most common primary liver tumor In Europe, around 13,000 new 
CCA cases were diagnosed per year. However, the pathogenesis of CCA 
remains elusive and lack of diagnostic as well as treatment tools impede a 
better outcome for patients. In the present study, we use a new animal model 
of CCA, to understand the molecular mechanism. In the present work, we 
hypothesize that the synergistic dysfunction of Jnk1 and Jnk2 in hepatocytes 
drives the development of cholangiocarcinogenesis. Mice with specific deletion 
of Jnk1/2 in hepatocytes (Jnk∆hepa) and floxed (Jnkf/f) control mice were 
sacrificed at different time points during liver disease progression. Likewise, 
different toxicity treatments (i.e., TAA, DEN/TAA and DEN/CCl4) and 
experimental models were used. Interestingly, Jnk∆hepa mice showed 
progressively higher expression of BiP/GR78, combined with spliced XBP1, 
and down-regulation of pIRE1α, suggesting that BiP-associated activation of 
XBP1 could trigger liver cystogenesis and early stages of CCA. Simultaneously, 
after toxicity damage or in the genetic model of cancer, compared to the Jnkf/f 
mice, the serum markers of liver damage (ALT, AST, LDH) significantly 
increased in Jnk∆hepa mice after the treatments. These results were 
accompanied by a significantly increased number of TUNEL-positive cells, 
hyperproliferation of liver cells (Ki 67), fibrogenesis, deposition of collagen and 
α-smooth muscle actin (αSMA), and pro-inflammatory cytokines (e.g., Tnf-α, 
Tgf-β1, IL-6). In line with these detection, prominent activation of necroptosis 
(RIP1/RIP3/MLKL) occurred in JnkΔhepa liver damage. Concomitantly, the 
biomarkers of liver oval cells and biliary epithelium (CK19, AFP, SOX9, YAP1, 
MUCIN2, Notch1) were significantly upregulated. Finally, the overexpression of 
c-MYC may be carcinogenic to trigger the formation of CCA in the JnkΔhepa 
experimental group compared to the Jnkf/f liver. In summary, our data indicate 
that the combination of JNK functions in hepatocytes is essential for hepatocyte 
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homeostasis. Loss function of JNK1/2 may promote the activation of the XBP1 
associated with BiP involved in ER-stress, trigger hepatic cystogenesis and 
early stages of CCA. Overexpression of JNK1/2 promotes formation of HCC, 
while the lack of JNK1/2 promotes the formation of CCA in chronic liver 
stimulation. Collectively, JNKs play a vital role in balancing the differentiation 
and transformation of hepatocytes and cholangiocytes. Our research revealed 
the new function of JNK in the fate of hepatocytes and cholangiocytes, opening 
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2.1. List of Abbreviations 
Abbreviation Significance 
ADPKD Autosomal dominant polycystic kidney disease 
ADPLD Autosomal dominant polycystic liver disease 
AFP Alpha-fetoprotein 
aHSCs Activated hepatic stellate cells 
ALP Alkaline phosphatase 
ALT Alanine-aminotransferase 
ANOVA Analysis of variance 
APAP Acetaminophen 
APS Ammonium Persulfate 
ARPKD Autosomal recessive polycystic kidney disease 
αSMA α-Smooth muscle actin 
AST Aspartate aminotransferase 
BECs Biliary epithelial cells 
BSA Bovine Serum Albumin 
Caspase Cysteine dependent aspartate directed protease 
CCA Cholangiocarcinoma 
CCl4 Carbon tetrachloride  
CCK-8 Cell counting kit 8 
CDK4 Cyclin-dependent kinase 4 
cDNA Complementary DNA 
CHF Congenital hepatic fibrosis 
CK19 Cytokeratin 19 
CLD Chronic liver disease 
CoH Canals of Hering 
CS Caroli’s syndrome 
CST Cell Signaling Technology 
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dCCA distal cholangiocarcinoma 
DEN Diethylnitrosamine 
Δhepa Deleted in hepatocytes 
DMEM: Dulbecco´s modified Eagle´s medium 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
DR Ductular reaction 
DTT Dithiothreitol 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
eIF2α Eukaryotic initiation factor-α 
EMT Epithelial mesenchymal transition 
ER Endoplasmic reticulum 
ErbB2 Human epidermal growth factor receptor 2 
ERK Extracellular signal-regulated kinases 
EtOH Ethanol 
18FDG-PET 18F-fluorodeoxyglucose positron emission tomography 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GEF Guanine nucleotide exchange factor 
GLDH Glutamate dehydrogenase. 
GPCR G protein-coupled receptor 
GRP78 Glucose-regulated protein 78 
GS Glutamine Synthetase 
HCC Hepatocellular carcinoma 
H&E  Hematoxylin and eosin 
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HGF Hepatocyte growth factor 
HNFs Hepatocyte nuclear factors 
HPC Hepatic progenitor cell 
HRP Horseradish peroxidase 
HSCs Hepatic stellate cells 
iCCA intrahepatic cholangiocarcinoma 
IF Immunofluorescence staining 
IGF Insulin like growth factor 
IHC Immunohistochemistry 
IP Intraperitoneal 
JNK c-Jun NH2-terminal kinase 
Ki 67 Cell cycle specific protein encoded by the MKI 67 gene 
KCs Kupffer cells  
KLF6 Krüppel-like factor 6 
LSECs Liver sinusoidal endothelial cells 
LPS lipopolysaccharide 
MAPK Mitogen-activated protein kinase 
MF Myofibroblast 
MgCl2 Magnesium chloride 
mRNA Messenger RNA 
NK cells Natural killer cells 
NPCs Non-parenchymal cells 
OD Optical density 
PAS Periodic Acid Schiff 
PBC primary biliary cholangitis 
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline supplemented with Tween 20 
pCCA perihilar cholangiocarcinoma 
PCNA Proliferating cell nuclear antigen 
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PDGF Platelet-derived growth factor 
PFA Paraformaldehyde 
pJNK1/2 Phospho-c-Jun N-terminal Kinases1/2 
PKA Protein kinase A 
PLD Polycystic liver disease 
PSC primary sclerosing cholangitis 
qHSCs Quiescence hepatic stellate cells 
qRT-PCR Quantitative polymerase chain reaction 
RDCs Reactive ductal cells 
RIP Receptor-interacting protein kinase 
RNA Ribonucleic acid 
RT Room temperature 
SDS Sodium dodecyl sulphate 
SEM standard error of the mean 
SOS Son of sevenless 
SOX9 Sex-determining region Y-box (SRY-box) containing gene 9  
SR Sirius Red 
TAA Thioacetamide 
TAE Tris Acetate EDTA Buffer 
TBS Tris buffered saline 
TBS-T Tris buffered saline supplemented with Tween 20 
TEMED N´, N, N´, N´-Tetramethyl diamine 
TGF-β Transforming growth factor β 
TGR5 G-protein coupled bile acid receptor-1 
TNF-α Tumor necrosis factor-α 
Tris 2-Amino-2(hydroxymethyl)-1,3-propandiol 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end 
labeling 
Tween 20 Polyoxyethylene (20) Sorbitan Monolaurate 
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VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
WB Western blot 
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3.1 Liver anatomy and Function 
3.1.1. Liver structure 
The liver is the largest organ and gland in the human body and weighs on 
average 1200-1500 g, which makes up around 2% of the whole-body weight. 
However, the liver complies about 4.5% of the total bodyweight in mice. Most 
of the liver is located in the right quarter and upper ventral region, and a small 
part is located in the left quarter. A significant feature of the liver is its dual blood 
supply. The blood supply to the liver comes from the hepatic artery (20%-40%) 
and the portal vein (60%-80%). The blood flow of the liver is 1500-2000ml/min, 
accounting for about 30-40% of cardiac output. Blood flows out of the liver 
through the hepatic vein into the portal vein. The liver is highly vascularized and 
receives about a quarter of the cardiac output. The blood entering the liver is a 
mixture of 25% oxygen-rich blood from the hepatic artery and 75% oxygen-poor 
blood entering through the portal vein. The portal vein carries visceral nutrients 
and potentially or obviously harmful substances. These substances will be 
monitored and cleared by the liver when needed to ensure that the blood 
leaving the liver is compatible with normal homeostasis. The hepatic lobule is 
the most basic structural and functional unit of the liver. A complete hepatic 
lobule is composed of the central vein, hepatocytes, bile ducts, liver plate, 
hepatic sinusoids, peri-sinus space, and hepatic macrophages. The porta 
hepatis is a fissure structure that contains the entrance to the hepatic artery, 
portal vein, and common bile duct. Arterial, venous, and bile duct catheters 
follow the septum throughout the liver and correspondingly extend into multiple 
intralobular branches. In human, the Glisson system consists of the intrinsic 
arteries, portal vein and intrahepatic bile duct, and divides the liver into 4 lobes 
(including Right (largest), left, caudate, quadrate) and 8 segments1, 2 (Fig. 1). 
The right lobe and left lobe of the liver are further divided into 8 segments 
according to the distribution of portal scissure. At hilus, the right portal vein goes 
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through a short course (1-1.5 cm) before entering the liver. Once in the liver 
parenchyma, the portal vein divides into a right anterior branch, which arches 
vertically in the front of the liver, and a posterior branch moves along the 
posterolateral side. The right portal vein supplies the anterior (or anteromedial) 
and posterior (or posterolateral) portions of the right lobe. The branching pattern 
of these portal veins divides the right liver into 4 segments, the anterior segment 
is segment V (anterior and inferior) and segment VIII (front and upper), while 
segment VI (rear and inferior) and segment VII (rear and upper) form the 
posterior sector3. The portal vein is the main blood vessel of the portal system 
formed by the confluence of the spleen and superior mesenteric vein. It is 
excreted directly into the liver and accounts for about 75% of its blood flow4. 
Hemodynamic watersheds or cracks separate the incoming and outgoing large 
blood vessel segments, allowing the surgical removal of single or adjacent large 
blood vessel segments5. 
The liver is an active, bidirectional biological filter that participates in 
maintaining the body's homeostasis. Because it not only filters the portal blood 
that transports nutrients and toxic compounds from the environment through 
the gastrointestinal tract, but also filters the blood of the whole body (the body's 
own products, such as bilirubin which is produced when the liver breaks down 
old red blood cells), and it also provides the only channel of human bile 
transportation, the biliary system, which allows the bile to enter into the intestine 
and assist food digestion. It is classified as an active filter because it can quickly 
metabolize most nutrient compounds, and it can also neutralize and remove 
toxic exogenous (xenobiotics) and endogenous substances6. Although the liver 
is powerful, it also causes the liver to be constantly exposed to strong microbial 
and antigen stimuli. These stimuli require the functions of the innate immune 
system and the adaptive immune system. These different functions are 
completed by a complex structure, a multiple cellular tissue with unique 
vascular structure and the comprehensive activities of the participants. 
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The liver has not only two main cell types-hepatocytes and biliary cells (or 
cholangiocytes), but also liver sinusoidal cells (see chapter 3.1.2). Hepatocytes 
are parenchymal cells in liver tissue. They do not constitute a homogeneous 
cell population. They are highly polarized cells (e.g., molecular specializations 
of various surface membranes, such as receptors, pumps, transport channels, 
and carrier proteins). Their functions and morphology are opposite to a certain 
extent, and their position in parenchyma. This polarization allows them to 
perform the most complex metabolic tasks in the mammalian organism. 
 
Figure 1.  The segments and vascular structure of the liver. The right hepatic vein 
divides the right lobe into anterior and posterior lobes. The middle hepatic vein divides 
the liver into left and right lobes (or left and right hemiliver). This plane extends from 
the inferior vena cava to the fossa gallbladder. The falciform ligament divides the left 
lobe into medial segment IV and lateral segment II and III, and the portal vein divides 
the liver into upper and lower segments. The left and right portal veins branch up and 
down, extending into the center of each segment. Portal vein, Hepatic artery and Bile 
duct make up to the formation of Glisson system2. 
3.1.2. Function of liver cells 
Hepatic parenchymal cells are arranged in a hexagon around the central vein, 
forming a single layer of thick epithelium, thereby generating hepatic lobule. 
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Then, the hepatic lobule is composed of the central terminal hepatic vein, 
surrounded by 4-6 terminal portal vein triads, forming a polygonal unit, which in 
turn forms the structural and functional unit of the liver. The liver has 
approximately 50,000-100,000 functional units, and each of them radiates 
around the central vein. Blood flows from the portal venous tract to the 
peripheral small veins of the liver to form a so-called "sinusoid". The sinusoidal 
cells, including hepatic stellate cells (HSCs), liver sinusoidal endothelial cells 
(LSECs), and liver Kupffer cells (KCs) and pit cells (or natural killer cells (NK 
cells)), together with the sinusoidal morphology of liver cells constitute a 
functional and histological unit (Fig. 2). These cells interact with other signaling 
mechanisms through cytokines. Whilst the liver cells around the portal vein 
closer to the portal vein are functionally different from the central hepatic cells 
near the central small vein of the liver7.  
Hepatocytes account for the vast majority of the total liver mass, 
approximately 80% of the liver cell volume, and liver non-parenchymal cells 
(NPCs) account for approximately 6.3%, including HSCs, LSECs and KCs, 
accounted for about 1.4%, 2.8% and 2.1% respectively8. The cytoplasm of 
hepatocyte is eosinophilic and the nucleus is round, including mitochondria and 
endoplasmic reticulum (ER) ribosomes. Hepatocytes can be regenerated and 
the average life span of them is 5 months. In addition to being responsible for 
their typical liver histology, these cells are the main functional cells and play a 
vital role in protein synthesis, detoxification, bile salt and phospholipid synthesis, 
lipid and carbohydrate metabolism as well as modification and excretion of bile 
formation and secretion9. 
HSCs, or liver myofibroblasts, also named Ito cells, store vitamin A, and 
produce extracellular matrix and collagen10. HSCs play a role in the complex 
mechanisms of liver fibrosis and cirrhosis. They are also distributed between 
endothelial cells, but it is difficult to observe through an optical microscope. 
Other pit cells or liver-related natural killer cells, whose main functions include 
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local host defense and maintenance of immune balance11, 12. In response to 
injury, quiescence HSCs (qHSCs) differentiate into activated HSCs (aHSCs), 
characterized by the expression of α-actin smooth muscle (αSMA), fibrogenic 
and mitogenic sensitive, and has the ability to actively secrete extracellular 
matrix (ECM) proteins (especially laminin, collagen I and III). This results in 
changes in the normal composition of the matrix, including cell-matrix 
interaction and the deposition of growth factors13, 14. 
LSECs form the sinusoidal endothelial layer, and play a key regulatory role 
in all aspects of intra-and transendothelial transport. In liver pathobiology, 
LSECs play central roles in liver fibrosis, cancer metastasis, and liver toxicology. 
Less than 20% of the ATP produced by LSECs and KCs from exogenous 
substrates comes from glucose metabolism, and the main energy source in 
these cells is the oxidation of glutamine and palmitate15.  
KCs or liver macrophages, which are mainly present on the sinus wall of the 
portal vein, are the first line of defense formed by removing foreign substances 
that enter the liver circulation. They are also part of the reticuloendothelial 
system and engulf aging red blood cells. They can also secrete cytokines, 
which may damage liver cells and take part in the remodeling of the ECM.  
Cholangiocytes or biliary epithelial cells (BECs), account for much less than 
1% of the total liver parenchymal cells, because most of them are located in the 
portal bile duct16. Only the smallest bile duct penetrates the parenchyma of the 
portal vein and connects to the bile duct in the liver plate. The connection point 
between the catheter and the liver plate is defined by a tubular structure called 
the Canals of Hering (CoH), which is composed of cholangiocytes and 
hepatocytes. Furthermore, the biliary tree was first generally recognized for its 
function of transporting and modifying primary bile secreted by hepatocytes, but 
now it is generally believed that the bile duct tree is actually a complex structure 
with many different biological functions, which is reflected in the morphological 
and functional specialization of BECs17. Changes in bile composition can trigger 
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a series of events, such as the formation of bile obstruction, the accumulation 
of toxicities, damage to BECs, causing focal cholangiocytes inflammation 
changes, which then may progress to sclerosing cholangitis, eventually 
cirrhosis18.  
Fibrosis is a reversible scar formation process caused by chronic liver injury, 
which is characterized by excessive deposition of ECM. HSCs are the main 
source of ECM in normal and fibrotic livers, while LSECs and KCs stimulate this 
process through activation of transforming growth factor β (TGF-β) signaling, 
and the production of pro-inflammatory molecules19. In liver fibrosis, TGF-β is 
a main factor mainly secreted by fibroblasts and macrophages, and has the 
function of activating HSCs, which is responsible for the deposition of most 
(about 80%) matrix proteins20. In addition to inflammatory cells, it is related to 
the crosstalk between cells of mesenchymal origin, especially KCs and portal 
vein fibroblasts. They are the main effector of fibrosis and the stimulus of ECM 
deposition. After the stimulation of toxicity carbon tetrachloride (CCl4), the 
composition of ECM in the liver has changed greatly, similar to that detected in 
human liver diseases.  
There is a complex interaction between KCs and endothelial cells, sinusoidal 
cells and hepatocytes (Fig. 2). These cells play an important role in the 
metabolic homeostasis of the whole organism by coordinating the absorption, 
reprocessing and distribution of nutrients and their subsequent energy products. 
The liver is the main filter of the human body, which can not only detoxify, but 
also remove many exogenous and endogenous compounds21.  
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Figure 2. Function of the distinct parenchymal and non-parenchymal liver cells. 
The hepatocyte population can be divided into two families: (i) parenchymal cells or 
hepatocytes (A) and (ii) nonparenchymal cells or sinusoidal cells (B-E). A) 
Hepatocytes are the dominant cells, accounting for 80% of the volume of liver tissue. 
In addition to producing typical liver histological features, these cells are also the main 
functional cells, playing an important role in protein synthesis, detoxification, lipid- and 
carbohydrate metabolism. B) LSECs form the endothelial lining of the sinusoids, and 
play a key regulatory role in all aspects of intra- and trans-endothelial transport. C) 
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KCs or hepatic macrophages, which are mainly attached to the wall of the portal sinus, 
are the first line of defense to eliminate foreign bodies entering the hepatic circulation. 
D) Stellate cells or liver fibroblasts are the storage cells of vitamin A and play a role in 
the complex mechanisms of liver fibrosis and cirrhosis. E) Pit cells or liver-related 
natural killer cells, whose main functions include local host defense and maintaining 
immune balance. Courtesy of Filip Braet et al11. 
3.1.3. Cholangiocytes: Embryology and Function 
Cholangiocytes are arranged in extrahepatic and intrahepatic bile ducts, and 
modify bile from hepatic cell tubules through the intrahepatic biliary tree. From 
the 12th week to the 16th week of gestation, the ductal plate replicated in the 
discrete region, inhibited the expression of hepatocyte markers, and began to 
express K7 and K19, biliary phenotype commitment markers22.  
The function of cholangiocytes has both of secretion and absorption, 
regulated to the volume, fluidity and basicity of primary bile secreted by 
hepatocytes. Thus, the bile duct epithelium can reabsorb water, glucose, 
glutathione, bile acids and electrolytes23. The biliary system is a complex 
network of small tubes surrounded by cholangiocyte. Cholangiocytes starts 
from the CoH in the hepatic lobule (intrahepatic bile duct tree), continues to the 
extrahepatic (extrahepatic bile duct tree), and terminates into the ampulla of 
hepatic Vater. In addition to its role in liver development, the biliary system is 
also at the center of discussions about liver regeneration and repair, partly due 
to the recognition that the biliary tree may hide hepatic progenitor cells (HPCs) 
in the terminal ductulus and CoH. The maintenance of a normal liver requires 
only occasional self-replication of existing adult epithelial cells (hepatocytes 
and cholangiocytes) via mitosis, rather than HPCs differentiation24, 25 (Fig. 3). 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 25 / 179 
 
Figure 3. Potential sources of cholangiocytes in development and liver 
regeneration. A) Cholangiocytes develop by differentiating into hepatocytes in 
response to the developmental morphogen. B) The homeostasis of cholangiocytes is 
based on the self-replication of existing mature cholangiocytes. C) Cholangiocytes 
regeneration is achieved by accelerating the replication of regeneration hormones, 
growth factors and cytokines. D) The differentiation of cholangiocytes from HPCs can 
occur during biliary damage and repair after reactivation of developmental pathways25. 
 
Cholangiocytes can be activated by a variety of injuries, including infection, 
cholestasis, ischemia, and xenobiotics26. Activated cholangiocytes are also 
involved in the recruitment and crosstalk of immune cells, vascular and 
mesenchymal cells, as well as the development of bile duct fibrosis and 
cholangiocarcinoma (CCA) underwent chronic stimulus. In many 
cholangiopathies, including primary sclerosing cholangitis (PSC) and primary 
biliary cholangitis (PBC), but activation of liver injury is unknown. Features of 
activated BECs/cholangiocytes include increased proliferation, pro-fibrosis, and 
pro-inflammatory secretions27. Depending on the type of the injuries, a series 
of morphogenetic signals and transcription factors are also involved and/or 
activated, including Notch, IL-6 and Wnt/β-catenin pathways, TGF-β and 
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hepatocyte nuclear factors (HNFs)28.  
Reactive ductal cells (RDCs), the epithelial component of the catheter 
response, show a biliary phenotype and are organized into irregularly shaped 
structures29. RDCs are a completely different cell population from HPCs and 
have a repair function rather than a regeneration function. Some studies have 
shown that there is a strong correlation between RDCs and portal fibrosis30. 
RDCs may be partly derived from BECs/cholangiocyte, and this has been 
clearly shown in CCA31. The neonatal expression of epithelial to mesenchymal 
transition (EMT) markers was observed in RDCs, and the ability of RDCs to 
express EMT markers and increase mobility is necessary for wound repair25, 32. 
Most of the evidences show that during the repair of liver injury, cholangiocytes 
lose part of epithelial characteristics, thus obtaining some biological and 
immunophenotypic characteristics of mesenchymal cells, such as motility and 
collagen deposition ability. However, they do not completely transition to 
mesenchymal phenotype and BECs, only obtain some functional 
characteristics conducive to the repair of liver injury25, 32, 33. 
Recent studies have also shown that SOX4 and SOX9 are involved in 
development of primary cilia, and the normal formation, elongation, and 
branching of bile duct trees34. These two factors cooperatively control the 
expression of mediators of TGF-β, Notch, and Hippo/Yes-associated protein 1 
(YAP1) signaling pathways, which are required for normal biliary development. 
They’re also related to the Wnt/β-catenin signaling pathway and involved in the 
liver cilia disease35, such as polycystic liver disease(PLD) 36.  
3.2 Polycystic liver disease (PLD) 
PLD is a hereditary biliary disease characterized by multiple hepatic cysts of 
different shapes and sizes, which are filled with cystic fluid 37. The pathogenesis 
of PLD is still unclear. Currently, it is believed that the mainly cystic changes 
caused by the loss of related gene functions due to the malformation of the duct 
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plate and the second mutation during the embryonic development of the liver38, 
and the related genes to PLD, including PKD1, PKD2, GANAB, PRKCSH, 
SEC63, SEC61B, LRP5, GANAB, ALG8 and PKHD1 as published39, 40. The 
incidence of PLD varies from 1/1,000,000 to 1/400, according to different sub-
classifications associated with or without polycystic kidney disease, divided into 
autosomal dominant polycystic liver disease (ADPLD, ~1:100,000), autosomal 
dominant polycystic kidney disease (ADPKD, ~1:400–1:1,000), and autosomal 
recessive polycystic kidney disease (ARPKD) as well as congenital hepatic 
fibrosis (CHF)/ Caroli’s syndrome (CS, 1/1,000,000~1/20,000)41. These 
diseases that encode fibrocystin can cause severe portal hypertension and may 
be complicated by acute and/or chronic cholangitis, intra/extrahepatic bile duct 
stones, and eventually induced to CCA42. 
Proliferation of cystic duct epithelial cells is a sign of disease progression or 
regression, which is considered to be one of the main mechanisms of hepatic 
cystogenesis43. The proliferation of cholangiocytes is not only the basis for 
maintaining the normal internal environment balance of the bile duct tree, but 
also the response to liver injury. The development of cysts after birth is closely 
followed by proliferation-dependent cyst expansion. Basically, cholangiocytes 
show excessive proliferation during cyst expansion as shown by positive 
staining, such as proliferating cell nuclear antigen (PCNA). However, the 
proliferation of cholangiocytes decreased in the well-established disease. 
Different cytokines and growth factors, such as IL-6, tyrosine kinase receptors 
(EGF), vascular endothelial growth factor (VEGF) and insulin like growth factor 
(IGF), promote cholangiocytes proliferation through ERK/PI3K/AKT signaling 
pathway. These cytokines and growth factors are present the cystic fluid and/or 
secreted by the BECs44, 45. 
   The overexpression of cAMP in PLD cholangiocytes is considered to be one 
of the main mechanisms driving the occurrence of liver cysts. Bile duct epithelial 
cell proliferation involves multiple cAMP downstream effectors, including 
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cAMP-activated exchange protein, protein kinase A (PKA), and the mitogen-
activated protein kinase/extracellular signal-regulated kinase (MAPK / ERK1/2) 
38, 46. 
3.3 Cholangiocarcinoma (CCA) 
In recent years, the incidence of liver tumors has been continuously rising, 
including two main common types of hepatic malignancies, Hepatocellular 
carcinoma (HCC) which is the fifth most common malignant tumor, and CCA 
the incidence of which is rising up to 2.1 cases per 100,000 people in Western 
countries. Recently, CCA, the cancer of gallbladder and biliary tract are matters 
of great concern.  
Depending on the anatomical location, CCA is basically divided into three 
categories: intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) 47, 48. It is 
noteworthy that although these three CCA subtypes share common features, 
they also have important inter-tumor and intra-tumoral differences that may 
affect the pathogenesis and outcomes49-52. The complexity of the pathogenesis 
and the apparent heterogeneity of CCA have hindered clinical therapeutic effect 
in their management 53-55. 
Especially CCA, not only lack of specific biomarkers makes early diagnosis 
much more difficult in the early stage, but also patients would have a poor 
prognosis. Surgery seems to be the only effective treatment, but the vast 
majority of patients are found to be advanced and have a high rate of recurrence 
after surgery. At the same time, CCA lacks sensitivity of radiotherapy and 
chemotherapy. Despite the variety of treatment options, the 5-year survival rate 
of CCA has not been improved, still 5-10% during the past 30 years56. It is 
considered fortunately for patients diagnosed with CCA to have a 5-year 
survival after radical surgery, while unfortunately to patients in advanced stage 
usually less than 12 months57, 58. At present, the diagnosis and treatments of 
CCA has become a worldwide problem, especially in patients with recurrent and 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 29 / 179 
 
unresectable CCA even treated with advanced medical methods51.  
Previously data showed that c-Jun N-terminal kinases (JNK)/ Cyclin-
dependent kinase-4 (CDK4)-dependent pSmad3L signaling pathway was 
involved in the development of polycystic kidney disease in cpk mice which is 
a model of autosomal recessive PKD59. Interestingly, Cubero60 group showed 
a novel function of JNK1/2 in cholangiocyte hyperproliferation in recent 
published paper. Loss function of JNK1/2 in hepatocytes triggers biliary 
hyperproliferation and ductular dilation in chronic liver disease animal models, 
eventually inducing the formation of CCA after sustained treatment of toxicity. 
At the same time, JnkΔhepa mice progressed into CCA with continuous 
stimulation60. Furthermore, recent studies also suggest that the formation of 
liver cancer is associated with the dysfunction of JNK signaling pathway, 
including both HCC61 and CCA60, 62. Based on previously studies, we believe 
that JNK1/2 play an important role in triggering the formation of CCA. 
3.4 EMT Transition in CCA 
In 1968, Hay63 pointed out that during the development of chicken embryos, 
epithelial cells underwent through several stages of differentiation and de-
differentiation, and migrated a considerable distance in the body. All these 
processes require the mutual transformation between epithelial cells and 
mesenchymal cell phenotypes (including "multipotent", mesenchymal stem 
cells), called EMT, and the opposite process is mesenchymal epithelial 
transformation (MET). EMT is a special physiological process in which epithelial 
cells lose their polarity and show a mesenchymal phenotype. Subsequently, 
multiple in vivo studies were reported. EMT is essential for embryonic 
development, wound healing, stem cell biology and plays a key role in 
tumorigenesis64, 65. 
Previously, it was generally believed that HCC originated from hepatocytes 
and that CCA originates from BECs66. Moreover, cholangiocytes may be 
involved in liver fibrosis67. In CCA, developmental changes seen in 
cholangiocytes may be due to the activation of hepatic stem/progenitor cells, 
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the proliferation of bile duct cells, or through ductal metaplasia of mature 
hepatocytes 29, 68. However, alongside the progress seen in histopathological 
studies, there is now a better understanding of the origins of BECs. Both HPCs 
69 and CCA stem cells 66 seem to be capable of differentiating into BECs, whilst 
CCA stem cells can also originate from HPCs 66, 70, 71. These indicate that CCA 
can be derived from common HPCs, which can differentiate into both 
hepatocytes and cholangiocytes 72, 73.  
At the biochemical level, various morphogenetic and environmental signals 
including TGF-β, Wnt, EGFR, Notch and platelet-derived growth factor (PDGF), 
inflammatory cytokines and integrin receptor ligands promote EMT 74, 75. TGF-
β is also involved in several steps of cancer progression, from tumorigenesis to 
metastasis, which promotes cancer cell invasion and metastasis through an 
EMT process, although at later stages 76-80. Similarly, the TGF-β-induced 
ERK/MAPKs pathway contributes to EMT induction, as ERK is required to 
remove cell adhesion junctions, which leads to increased cell migration 74, 81, 82. 
In other words, EMT plays an important role in CCA progression83. 
3.5 JNK/MAPKs and liver cancer 
In normal liver, the JNK family is minimally or transiently activated, the latter 
usually physiological, whereas sustained activation is pathological. In addition 
to playing an important role in liver physiological reactions (such as cell death, 
apoptosis and cell cycle regulation) 84, 85, JNK also plays a carcinogenic role by 
promoting inflammation, proliferation, invasion and angiogenesis, depending 
on the specific situation and duration of JNK signaling pathway activation86, 87. 
Previous studies have reported that the JNK signaling pathway plays a vital role 
in hepatocarcinogenesis88, 89. Das et al90 showed that JNK play a dual role in 
the development of HCC. Another study suggested that lack of JNK1 and JNK2 
in hepatocytes may increase the tumor development, and the pro-tumor effect 
of JNK on HCC is related to inflammation91. While the other data indicated that 
the JNKs, particularly JNK1, contribute to malignant transformation and tumor 
growth 92. Possibly, JNK1 has a larger role than JNK2 in development of liver 
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tumor 93. In human HCC tissue samples, JNK1 activation was associated with 
tumor size. In fact, by knockdown of JNK1 rather than JNK2, the proliferation 
of human HCC occurs through the upregulation of c-MYC and downregulation 
of p21 90, 94. 
The JNK signaling pathway is also involved in the development of CCA 
according to the recent studies. JNKs play a key role in regulating the 
interaction between different pro-apoptotic proteins and anti-apoptotic 
proteins95.  
Feng et al96. reported that JNK exerted its carcinogenic effect in human CCA 
cells. In human CCA, high expression of TNF-α was found in the cells near the 
lesion of CCA, and the overexpression of JNKs in phosphorylated 
cholangiocytes (80% related the patients with CCA) as well as the accumulation 
of ROS around hepatocytes been observed. ROS accumulation leads to 
Caspase-3-dependent apoptosis through JNK signaling pathway. Yuan's 
group55 suggested that mitochondrial dysfunction and oxidative stress promote 
the excessive growth of CCA and tumorigenesis. While, Sabio62 group found 
that liver JNK deficiency can alter cholesterol metabolism and bile acid 
synthesis, binding and transport, leading to cholestasis, increased BECs 
proliferation and formation of CCA. Nishikawa97 group have demonstrated that, 
within collagen-rich matrix, TNF-α specifically stimulated branching 
morphogenesis associated with the expression of bile duct/ductular markers, 
including cytokeratin 19 (CK 19). Meanwhile, the phosphorylation of JNKs and 
c-Jun increased during collagen gel culture, and TNF-α strongly enhanced bile 
duct transdifferentiation of hepatocytes, especially by inhibiting hepatocyte 
differentiation and enhancing ductular morphogenesis. These results also 
suggest that activation of JNK/c-Jun signaling pathway may occur during 
“ductular reaction” (DR) which is closely related to the formation of CCA. 
As mentioned above, the JNK/MAPKs signaling pathway may be a key target 
for the treatment of CCA. However, more research is needed to test this 
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possibility. Therefore, new mice model links to JNK signaling pathway seems a 
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In the present work, we hypothesize that the synergistic function of Jnk1 and 
Jnk2 in hepatocytes drives the development of cholangiocarcinogenesis. The 
main Objectives are as follow: 
 
1) To understand the role of JNK in undifferentiated hepatocytes and its 
differentiation into hepatocytes and cholangiocytes. 
2) To evaluate the molecular mechanisms driving the early stages of 
cholangiocyte pathology in a JnkΔhepa knockout mice. 
3) To evaluate the potential therapeutic value of JNK-deletion in 
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5.1 Materials 
Table 5.1.1 Chemicals 
Reagent Manufacturer Catalog 





Agarose Electrophoresis Grade Sigma-Aldrich, 
Darmstadt, Germany 
A9539 
BSA (Bovine Serum Albumin, 




Calcium chloride Sigma-Aldrich, 
Darmstadt, Germany 
C5670 
Cell Counting Kit – 8 Sigma-Aldrich, 
Darmstadt, Germany 
96992 
Cell incubator clean reagent Panreac AppliChem, 
München, Germany 
A5230,1000 
Chloroform AppliChem, Munich, 
Germany 
A3691.1000 





DJNKI1 MedChem Express, 
Monmouth Junction, USA 
HY-P0069 
DMEM with High Glucose, 
without L-Glutamine, with Sodium 
Pyruvate 
GE Healthcare, Munich, 
Germany 
SH30285.01 
DNA Ladder (50 bp) Thermo Fisher Scientific, 
Massachusetts, USA 
10416014 
Direct Red 80 Sigma-Aldrich, 
Darmstadt, Germany 
365548 
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di-Sodium Hydrogen Phosphate 




DMSO (Dimethyl sulfoxide) Sigma-Aldrich, 
Darmstadt, Germany 
D4540 
DTT (Dithiothreitol) Thermo Fisher Scientific, 
Massachusetts, USA 
20291 
Eosin Y Sigma-Aldrich, 
Darmstadt, Germany 
E4009 
Ethanol absolute for analysis AppliChem (Dismalab), 
Barcelona, Spain 
131086.1214 
FBS (Fetal Bovine Serum) Thermo Fisher Scientific, 
Massachusetts, USA 
10270106 
Formaldehyde stabilized with 




Gelatin from bovine skin, Type B Sigma-Aldrich, 
Darmstadt, Germany 
G6650-500G 
Glycine for molecular biology AppliChem, München, 
Germany 
A1067,5000 





Gibco™ Goat Serum, New 
Zealand origin, Standard (Sterile-
Filtered) 
Thermo Fisher Scientific, 
Massachusetts, USA 
11530526 
Gibco™ MEM Non-Essential 
Amino Acids Solution (100X) 





Thermo Fisher Scientific, 
Massachusetts, USA 
12090216 
HepaRG Maintenance and 
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with Antibiotics 
HyClone L Glutamine Thermo Fisher Scientific, 
Massachusetts, USA 
SH3003401 
HyClone Trypsin Protease Thermo Fisher Scientific, 
Massachusetts, USA 
SH3023602 





30%Hydrogen Peroxide AppliChem (Dismalab), 
Barcelona, Spain 
121076.1211 
Isopropanol AppliChem (Dismalab), 
Barcelona, Spain 
131090.1612 
Isoflutek Karizoo, Barcelona, 
Spain 
586259.0 
Mayer's Hematoxylin AppliChem (Dismalab), 
Barcelona, Spain 
254766.1611 
Methanol BioChemica AppliChem, Munich, 
Germany 
A3493.5000 
Nonfat dried milk powder AppliChem, Munich, 
Germany 
A0830,0500 
Nonidet P-40 AppliChem, Munich, 
Germany 
A1694,0250 
Ponceau S solution Sigma-Aldrich, 
Darmstadt, Germany 
P7170 
Potassium chloride> 99.0%(KCL) Sigma-Aldrich, 
Darmstadt, Germany 
P9541-500G 
Restore Western Blot Stripping 
Buffer 500ml 
Thermo Fisher Scientific, 
Massachusetts, USA 
21059 
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Sodium fluoride Sigma-Aldrich, 
Darmstadt, Germany 
215309 
SDS (Sodium dodecyl sulfate) AppliChem, Munich, 
Germany 
A2572,0500 
Trizol Reagent  Thermo Fisher Scientific, 
Massachusetts, USA 
5596018 
Triton X-100 AppliChem, Munich, 
Germany 
A4975,0100 




Table 5.1.2 Primer sequences used for genotyping PCR 











Table 5.1.3 Primer sequences used for qRT-PCR 
Gene Forward Reverse 
AFP AGTTTCCAGAACCTGCCGAG ACCTTGTCGTACTGAGCAGC 
Albumin GCAGATGACAGGGCGGAACTTG CAGCAGCAATGGCAGGCAGA
T 
αSMA CCCCTGAAGAGCATCGGACA TGGCGGGGACATTGAAGGT 
CD133 TCTGTTCAGCATTTCCTCAC TCAGTATCGAGACGGGTC 
CK19 GGGGGTTCAGTACGCATTGG GAGGACGAGGTCACGAAGC 
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c-Myc AGTGCTGCATGAGGAGACAC GGTTTGCCTCTTCTCCACAG 
Cyclin A2 AACTGTAAGGTTGAAAGCTTAGC TCTGTTGTGCCAATGACTCAG
G 
Cyclin D1 AAGCATGCACAGACCTTTGTGG TTCAGGCCTTGCATCGCAGC 
Cyclin E1 TCCACGCATGCTGAATTATC TTGCAAGACCCAGATGAAGA 
DMBT1 GCCACATCCCAATGACTTCT GCACCGTGAGGAGGTATCAT 
ErbB2 ACAGCTCGGAGACCTGCTA GTAGTGGGCACAAGCCTCA 
GAPDH TGTTGAAGTCACAGGAGACAACCT AACCTGCCAAGTATGATGACA
TCA 
GABRP GCGCCTTGCTCAGTACACAA ACGTTCCTCCGAAGCTCAAAT 
Hes1 CCCCAGCCAGTGTCAACAC TGTGCTCAGAGGCCGTCTT 
Hey1 GGGAGGGTCAGCAAAGCA GCTGCGCATCTGATTTGTCA 







Klf6 CGGACGCACACAGGAGAAAA CGGTGTGCTTTCGGAAGTG 
MUC1 CTGTTCACCACCACCATGAC CTTGGAAGGGCAAGAAAACC 
Notch1 CCAGCAGATGATCTTCCCGTAC TAGACAATGGAGCCACGGAT
GT 





TGFβ1 GCTCGCTTTGTACAACAGCACC GCGGTCCACCATTAGCACG 
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Table 5.1.4 Primary Antibodies used for Immunostaining (IHC/IF) and/or 
Western blot 
Product Manufacturer Catalog Concentration 
αSMA  Sigma-Aldrich, 
Darmstadt, Germany 
A2547 1:100 (IHC/IF) 
1:1000 (WB) 
pAKT CST, Massachusetts, 
USA 
9271s 1:1000 (WB) 
AKT CST, Massachusetts, 
USA 
9272s 1:1000 (WB) 
BiP CST, Massachusetts, 
USA) 





9561 1:1000 (WB) 
β-Catenin CST, Massachusetts, 
USA 
9562 1:1000 (WB) 
Chop CST, Massachusetts, 
USA 
2895S 1:1000 (WB) 
CK19 Abcam, Cambridge, 
UK 
ab15463 1:100 (IHC/IF) 
1:1000 (WB) 
Cleaved Caspase3 CST, Massachusetts, 
USA 
9661S 1:1000 (WB) 
Cleaved Caspase8 CST, Massachusetts, 
USA 
8592S 1:1000 (WB) 
c-MYC Abcam, Cambridge, 
UK 
ab32072 1:100 (IHC) 
1:1000 (WB) 
peIF2α CST, Massachusetts, 3398S 1:1000 (WB) 
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USA 
pERK1/2 CST, Massachusetts, 
USA 
9101S 1:1000 (WB) 
ERK1/2 CST, Massachusetts, 
USA 
4696S 1:1000 (WB) 
GAPDH Bio-Rad, Kentucky, 
USA 
MCA4739 1:5000 (WB) 
GS Abcam, Cambridge, 
UK 
ab73593 1:100 (IHC) 






IRE1α CST, Massachusetts, 
USA 
3294S 1:1000 (WB) 
Ki 67 Abcam, Cambridge, 
UK 
ab16667 1:100 (IHC/IF) 
pJNK CST, Massachusetts, 
USA 
9251S 1:1000 (WB) 
JNK CST, Massachusetts, 
USA 
9252S 1:1000 (WB) 






JNK1 CST, Massachusetts, 
USA 
3708S 1:1000 (WB) 






JNK2 CST, Massachusetts, 4572s 1:1000 (WB) 
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USA 
pMLKL Abcam, Cambridge, 
UK 
ab196436 1:1000 (WB) 
MUCIN 2 (F-2) Santa Cruz, 
Heidelberg, Germany 
sc-515032 1:100 (IHC) 
Notch1(A6) Abcam, Cambridge, 
UK 
ab44986 1:100 (IHC) 
PCNA Thermo Fisher 
Scientific, 
Massachusetts, USA 
13-3900 1:100 (IHC) 
pRIP CST, Massachusetts, 
USA 
31122S 1:1000 (WB) 
RIP Biosciences, San 
Diego, USA 
610459 1:1000 (WB) 
pRIP3 CST, Massachusetts, 
USA 
57220S 1:1000 (WB) 
RIP3 ProSci, California, 
USA 
2283 1:1000 (WB) 
SOX9 Abcam, Cambridge, 
UK 
ab185966 1:1000 (IHC) 
1:100 (IF) 
 
Table 5.1.5 Secondary antibodies used for Immunostaining (IHC/IF) and/or 
Western blot 




7074S 1:3000 (WB) 
Anti-Mouse-HRP Bio-Rad, Kentucky, 
USA 
STAR207P 1:5000 (WB) 
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A-21206 1:500 (IF) 
 
Table 5.1.6 Analytical chemicals, reagents, enzymes and kits 
Product Manufacturer Catalog 
30% Acrylamide/Bis Solution, 
29:1 
Bio-Rad, Kentucky, USA 1610156 
AEBSF Hydrochloride (White 
to Off white Crystals) 
Thermo Fisher Scientific, 
Massachusetts, USA 
BP635-100 
Ammonium Persulfate (APS) Bio-Rad, Kentucky, USA 1610700 
BIO-RAD Protein Assay Dye 
Reagent  
Bio-Rad, Kentucky, USA 5000006 
Blasticidin S HCl Thermo Fisher Scientific, 
Massachusetts, USA 
A1113903 
CCL4 (Carbon tetrachloride) Sigma-Aldrich, Darmstadt, 289116 
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Germany 
Clariom™ S Assay, mouse Thermo Fisher Scientific, 
Massachusetts, USA 
902930 





DAB (ImmPACT® DAB 




DAKO PEN Agilent, California, USA S200230-2 
DAPI (VECTASHIELD® 





N-Nitrosodiethylamine Sigma-Aldrich, Darmstadt, 
Germany 
N0756 
ECL™ Prime Western Blotting 
System 
GE Healthcare, München, 
Germany 
RPN2232 
Eppendorf tubes 1.5ml Sigma-Aldrich, Darmstadt, 
Germany 
Z606316-1000EA 
Eppendorf tubes 2.0ml Sigma-Aldrich, Darmstadt, 
Germany 
Z606324-1000EA 
High Capacity cDNA Reverse 
Transcription Kit 
Thermo Fisher Scientific, 
Massachusetts, USA 
43-688-13 





4x Laemmli Sample Buffer Bio-Rad, Kentucky, USA 1610747 
Leica Microsystems Surgipath 
Paraplast Tissue Embedding 
Medium 
Leica, Illinois, USA 39602004 
Midori Green Advance Nippongenetics, Düren, 
Germany 
MG04 
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Carl Roth, Karlsruhe, 
Germany 
Art. No. T160.1 








Precision Plus Protein™ Dual 
Color Standards, 500 µl 
Bio-Rad, Kentucky, USA 1610374 
Proteinase K – Solution AppliChem，München, 
Germany 
A4392,0010 
Powerup SYBR Green Master 
Mix (50 ml) 
Thermo Fisher Scientific, 
Massachusetts, USA 
15360929 








Schiff's reagent Sigma-Aldrich, Darmstadt, 
Germany 
3952016-500ML 
TAA(Thioacetamide) Sigma-Aldrich, Darmstadt, 
Germany 
163678 
Tissue-Tek Sakura, Heppenheim, 
Germany 
4583 
Tris Buffer grade AppliChem，München, 
Germany 
A2264,5000 
Tri-Sodium Citrate 2-hydrate 




TUNEL Label Mix Sigma-Aldrich, Darmstadt, 
Germany 
11767291910 
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Table 5.1.7 Instruments and Equipment 
Product Manufacturer 
Adobe Photoshop CS6 13.0*32 Adobe Systems, California, USA 
AxioVision SE64. Rel.4.9 Carl Zeiss Microscopy GmbH, 
Munich, Germany 
Centrifuge 5415 D Eppendorf AG, Hamburg, 
Germany 
Centrifuge 5804/5804R Eppendorf AG, Hamburg, 
Germany 
Centrifuge 5920 R Eppendorf AG, Hamburg, 
Germany 
Centrifuge 4K15 10740 Sigma, DJB Labcare Ltd, UK 
Centrifuge Z233M-2 and Refrigerated 
Z233MK-2 
Hermle LaborTechnik GmbH, 
Wehingen, Germany 
Class II Bio II Advance Plus Microbiological 
Safety Cabinet 
Azbil Telstar Technologies Slu, 
Barcelona, Spain 
Digital microscope camera Moticam 2500 Ryf AG, Bettlachstrasse, 
Switzerland 
Gel Doc 2000 System  Bio-Rad, Kentucky, USA 
GraphPad Prism 8.0 software GraphPad Software, California, 
USA 
ImageJ Version 1.52u LOCI, University of Wisconsin, 
Wisconsin, USA 
LAS mini 4000 Chemiluminescence scanner  FUJIFILM, super CCD, 
Marlborough, USA 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 52 / 179 
 
 
Table 5.1.8 Other Equipment 
Plastic and Glassware Manufacturer Catalog 
Big flacon 50ml Dismalab, Madrid, Spain PTGP-E050-500 
Blue tips 1ml Dismalab, Madrid, Spain 740290 
Cell culture plate sterile, 96 
Well, F-bottom with lid 
Dismalab, Madrid, Spain 655180 
CellStar® Cell Culture 




Leica EG1160 Embedding Center, Dispenser 
+ hot Plate (HistoCore Arcadia) 
Leica Biosystems Nussloch 
GmbH, Nußloch, Germany 
Leica MZ16 Stereomicroscope with Leica 
DFC480 Digital Camera 
Leica Microsystems, 
Cambridge, UK 
Microsoft Excel  Microsoft Corp., Redmond, 
Washington, USA 
Microtome (Model HI1210 RM2125RTS) Leica Biosystems Nussloch 
GmbH, Nußloch, Germany 
Nanodrop (A30221) Thermo Fisher Scientific, 
Massachusetts, USA 
7300 Real Time PCR System AND 
Sequence Detection Software Version 1.3.1 
Applied Biosystems, 
Massachusetts, USA 
2100-Retriever Aptum Biologics, Kassel, 
Germany 
Thermo Scientific Forma Steri-Cycle i250 
C02 incubator 
Thermo Fisher Scientific, 
Massachusetts, USA 
UV-transilluminator (Gel Doc 2000 System) Bio-Rad, Kentucky, USA 
Vertical laminar flow workbench, Mini- 
V/PCR 
Azbil Telstar Technologies Slu, 
Barcelona, Spain 
Water bath (STANDARD of 12877) DILABO, London, UK 
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CELLSTAR® Cell Culture 






Labbox, Madrid, Spain PTGP-E50-025 
Coverslips Dismalab, Madrid, Spain 8000120 
Cryogenic tubes Thermo Fisher Scientific, 
Massachusetts, USA 
375353PK 
Easypet 3 electronic pipetting Eppendorf, Madrid, Spain 4430000018 
Eppendorf® Reference® 2 G 
single-channel, fixed, volume 
(10 μl) 
Eppendorf, Madrid, Spain EP4925000049 
Eppendorf® Reference® 2 G 
single-channel, fixed, volume 
(100 μl) 
Eppendorf, Madrid, Spain EP4925000103 
Micro tube 1.1 ml Sarstedt, Carolina, USA 41.1500.005 
Eppendorf® Reference® 2 G 
single-channel, fixed, volume 
(1000 μl) 
Eppendorf, Madrid, Spain EP4925000154 
Eppendorf™ Tubes (1.5ml) Thermo Fisher Scientific, 
Massachusetts, USA 
10398031 
Falcon Tissue Culture Treated 
Flasks(50ml) 
Thermo Fisher Scientific, 
Massachusetts, USA 
10634501 
Falcon Tissue Culture Treated 
Flasks(250ml) 
Thermo Fisher Scientific, 
Massachusetts, USA 
10537161 





MicroAmp Fast Optical 96 Well 
Reaction Plate, 0.1ml 
Thermo Fisher Scientific, 
Massachusetts, USA 
43-469-06 
MicroAmp Optical Adhesive Thermo Fisher Scientific, 43-119-71 
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Film Massachusetts, USA 
MicroAmp Optical 8-Tube Strip 
with attached optical caps 




Electrophoretic Transfer Cell 
Bio-Rad, Kentucky, USA 170-3930 
Pipettes 5 ml Dismalab, Madrid, Spain 606107 
Pipettes 10ml Dismalab, Madrid, Spain 607180 
Polyvinylidene difluoride 
(PVDF) membrane 
Bio-Rad, Kentucky, USA 1620264 
Sarstedt Inc PC MTUBE 
1.1ML SER-GEL/PK100 
Thermo Fisher Scientific, 
Massachusetts, USA 
NC9436363 
Slides Klinipath, Darmstadt, 
Germany 
PR-S-100 
Syringes 1 mL Luer (BD 
Plastipak) 
Dismalab, Madrid, Spain 303172 
Small falcon 15ml Dismalab, Madrid, Spain PTGP-E15-500 
Syringe 1 ml with 27 × 13 
needle 
Dismalab, Madrid, Spain 300635 
Whatman® paper(Thick Blot 
Filter Paper, For WB） 
Bio-Rad, Kentucky, USA 1704085 
Yellow tips 200μl Dismalab, Madrid, Spain 739290 
5.2 Methods 
5.2.1 Animal experiments 
All animal experiments in the project are designed and carried out under 
appropriate supervision and in accordance with Spanish animal protection laws 
and regulations. All procedures have been approved by the Consejería de 
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Medio Ambiente, Administración Local y Ordenación del Territorio (PROEX- 
125.1/20). 
5.2.1.2 Housing, breeding and generation of mice 
All mouse strains were raised in cages with filters and bred in pathogen-free, 
temperature and humidity-free facilities of the Institute of Biology Animal 
Sciences (ILAS), University of Complutense, for a 12-hour cycle of light and 
shade and free access to standard food and water. All the procedures have 
been approved by the relevant Spanish authorities. Animals experiments 
followed the guidelines of the animal health institution of Complutense 
University School of Medicine, and with the standard humanitarian care outlined 
in the "Guide for the Care and Use of Laboratory Animals" prepared and 
published by National Research Council (US) Committee98. 
5.2.1.3 Mice strain 
The generation of hepatocyte specific Jnk1/2 knock-out mice (JnkΔhepa) was 
described in published paper in a C57BL/6 background99, as well as described 
in Chapter 6.1. Cre negative Jnkf/f mice were used as controls. All male mice 
were housed for experiments. All studies were performed using C57BL/6J 
background, age matched, male mice. Alb Cre transgenic mice (expressing Cre 
recombinase under the control of Albumin promotor) in a C57BL/6 background 
were purchased from the Jackson Laboratory (Bar Harbor, ME). Moreover, 
Jnk1/2Δhepa (double mutants with ubiquitous deficiency of JNK2 and ablation of 
JNK1 only in hepatocytes) were generated by crossing Alb Cre mice with 
Jnk1/2LoxP/LoxP mice. This approach enabled the simultaneous genetic 
inactivation of JNK1 and JNK2 in hepatocytes.  
5.2.1.4 Genotyping of transgenic mice 
First, all of the tails were freshly cut from the mice when they were separated 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 56 / 179 
 
from their mother aging 4 weeks old. The correct genotype was confirmed by 
PCR analysis. The tail was digested in the NID buffer (Table 5.2.1) 200μl mixed 
with 2μl Proteinase K (AppliChem, Munich, Germany) inside the thermomixer 
and shaken overnight at 56°C. The second day, enzyme activity was stopped 
by heating at 95°C for 10min. Subsequently, the tubes containing digested tails 
were centrifuged via 12000 rpm for 10 min at room temperature (RT). Each 2 
μl supernatant of the samples was used for PCR reaction (Table 5.2.2, Table 
5.2.3). Program procedures of PCR reaction and preparation of genotyping Gel 
for Jnk1, Jnk2, Total-Cre are listed in Table 5.2.4, Table 5.2.5, and Table 5.2.6, 
separately. 
After PCR reaction, the procedure was started. Total 100ml Tris Acetate EDTA 
Buffer (TAE) Buffer/PCR-running Buffer with Agarose 2g were prepared to be 
mixed in a final (w/v) concentration of 2% in the beaker. Then the solution inside 
the microwave was boiled for 4 min. Later, Midori Green Advance buffer 10μl 
(Nippon genetics, Düren, Germany) was added, and the solution completely 
mixed before poured into an electrophoresis chamber/tank, until a solid gel was 
formed. The PCR products were added into each well, 1kbp DNA markers were 
used to determine the specific size of fragments, and the electrophoresis 
completed with 110 V for 35 min. Finally, the gel was placed under the UV-
transilluminator (Gel Doc 2000 System, BIO-RAD, Kentucky, USA) and the 
PCR products were visualized and recorded by using BioDoc Analyze software 
(Biometra, Jena, Germany).  
 
Table 5.2.1 NID buffer mixture was prepared as follows: 
Reagent Final Concentration PH value 
KCl 0.05 M  
 
pH=8.3 
Tris 0.01 M 
MgCl2 2 mM 
Gelatine Type B 0.1 mg/ml 
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NP-40 0.45 % 
Tween-20 0.45 % 
 





Red taq 12.5μl 
DEPC H2O 8.5μl 
TOTAL 25μl 
 
Table 5.2.3 Mixture for genotyping PCR Total-Cre: 
Reagent Volume 
DNA 2μl 
Primer CRE Forward 01 1μl 
Primer CRE Reverse 01 1μl 
Primer CRE Forward 02 1μl 
Primer CRE Reverse 02 1μl 
RedTaq 12.5μl 
DEPC H2O 6.5μl 
TOTAL 25μl 
 




Time Cycles Gel 
1 94 3 min  Agarose 2% 
2 93 30 sec  Size 100ML 
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4 72 1 min  
5 Step Circulation  2→4 
6 72 10 min  
7 4 ∞ Pause 
 




Time Cycles Gel 
1 96 15 min  Agarose 2% 





3 60 30 sec Midori 10μL 
4 72 45 sec  
5 Step Circulation  2→4 
6 72 10 min  
7 4 ∞ Pause 
 




Time Cycles Gel 
1 95 3 min  Agarose 2% 





3 60 10 sec Midori 10μL 
4 72 20 sec  
5 Step Circulation  2→4 
6 72 1 min  
7 4 ∞ Pause 
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5.2.1.5 Diethylnitrosamine (DEN) injection 
DEN liquid solution (Sigma-Aldrich, Darmstadt, Germany, N0756) was diluted 
in sterile 0.9% sodium chloride solution with a fixed working concentration. Mice 
were received a fixed dosage of 25mg/Kg via intraperitoneal injection (IP) 
according to the body weight at the 14th day postpartum (n=5-8 per group). The 
vehicle groups received the same IP injection with a volume of sterile 0.9% 
sodium chloride solution. Mice were carefully observed in the following days 
until sacrificed. 
5.2.1.6 Thioacetamide (TAA) drinking water preparation 
TAA was dissolved in sterilized water completely before the usage, and 8-
week-old male mice were administrated with a fixed dose of TAA (300 mg/L) by 
oral-drinking over a period around 24 weeks according to the experimental 
models (n=5-8 per group). TAA oral-drinking water was refreshed per week with 
the same dosage. The vehicle groups received the same volume of vehicle 
sterilized water. Mice were carefully observed in the following days until 
sacrificed.  
5.2.1.7 Carbon tetrachloride (CCl4) injection 
CCl4 was diluted in corn oil and vortexed completely for usage. 8-week-old 
male mice were received a fixed concentration of 0.5ml/Kg via IP injection with 
continuing 14 weeks (n=5-8 per group). CCl4 working solution was prepared 
freshly before IP injection every week. The vehicle groups received the same 
volume of vehicle corn oil. Mice were carefully observed in the following days 
until sacrificed. 
5.2.1.8 Blood and liver sampling 
In order to collect blood and liver tissue, mice were sacrificed using isoflurane 
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under brief anesthesia. Total body weights were recorded. First, the abdominal 
cavity was cut along the linea alba. Subsequently, the two sidewall incisions 
along the abdominal wall were relaxed. Blood samples were collected from the 
portal vein with a 1 ml syringe (27G needle), the blood samples were collected 
in serum tubes and centrifuged at 12000 rpm for 10 min. The supernatant was 
serum, and transferred to a new cryotube stored at -80°C for further 
experiments. 
 The whole liver was carefully taken out after the ligament was cut, and 
immediately immersed in ice-cold PBS buffer. Liver weight of each mouse was 
measured and recorded. The whole liver was sliced on ice with a scalpel. The 
liver lobes were separated and cut into small pieces for further analysis. Take 
two slices of different liver lobes of similar size, fixed them in 4% 
paraformaldehyde (PFA) for 24-48 hours, and embedded them in paraffin 
cassettes. The other two slices were placed in Tissue-Tek O.C.T. compound 
(Sakura, Heppenheim, Germany) and stored at minus 80°C for frozen 
sectioning. The remaining liver samples are cut into small pieces, transferred 
to cryotubes, quickly frozen in liquid nitrogen, and stored at - 80°C for other 
studies such as RNA and protein isolation. Blood samples were analyzed at the 
Hepatology and Gastroenterology Research Laboratory of the Hospital 
Gregorio Marañón by using automated standard procedures. Serum 
parameters determined in this study were alanine Aminotransferase (ALT), 
Aspartate Aminotransferase (AST), alkaline phosphatase (ALP) and Lactate 
Dehydrogenase (LDH), which are markers for general liver injury. 
5.2.2 Cell culture and molecular methods 
5.2.2.1 Cell culture 
HepG2 cells, as previously described100, were cultured in Dulbecco's modified 
Eagle medium (DMEM, GE Healthcare, Munich, Germany) containing 10% fetal 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 61 / 179 
 
bovine serum (Thermo Fisher Scientific, Massachusetts, USA), 1% L-
Glutamine, 1% Non-Essential Amino Acids Solution and 1% 
Penicillin/Streptomycin at 37°C in a moist atmosphere containing 5% CO2. 
HepaRG cells, as previously described101. Undifferentiated HepaRG cells were 
cultured in HepaRG Maintenance and Metabolism Medium Supplement with 
Antibiotics. Working medium was prepared by adding 15 ml/75 ml HepaRG™ 
Supplement to 100 ml/500 ml of Williams’ Medium E. Working medium should 
be stored at 4°C for a maximum of one month. Medium was changed every 2-
3 days. Cells were differentiated after changed into differentiated medium 
incubation at 37°C for at least 14 days within 21% O2 and 5% CO2 in a moist 
atmosphere. 
The number and viability of cells was determined by Neubauer counting 
chamber and trypan blue staining method. Cells were passed and cultivated in 
6 or 12 wells plates with or without coverslips in each well. After proper cell 
adhesion, TAA with or without DJNKI1 (MedChem Express, Monmouth 
Junction, USA) were added into the culture medium with a final concentration 
of 0mM, 10mM, 20mM, 30mM, 40mM, separately, and the treatment groups of 
HepG2 and undifferentiated/differentiated HepaRG cells for 18 to 24 h. Cell 
RNA was isolated and protein was extracted for further experiments (see below 
RNA and protein experiments). 
5.2.2.2 Cell viability assay  
Cell viability was measured by a cell counting kit 8 assay (CCK-8) that was 
purchased from Sigma-Aldrich according to the instructions of the manufacture. 
Briefly, both HepG2 and undifferentiated HepaRG cells were seeded in 96 well 
plates at 5×103 cells per well in 0.1 mL medium and cultured for 24 h. The cells 
were treated with different concentrations of TAA (0, 10mM, 20mM, 30mM, 
40mM) for 18h and 24h, separately. In parallel, the kit reagent CCK-8 was 
added to the wells with the final concentration of 10%, and the cells were 
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protected from light and incubated for 1 h at 37°C. Then the optical density (OD) 
at 450 nm was measured using a microplate reader, results were sent to Excel 
and calculated by mathematics according to the instruction of manufacturer. 
5.2.3 Molecular mRNA methods 
5.2.3.1 RNA isolation 
RNA isolation (cells and liver tissues) was first done before quantitative 
polymerase chain reaction (qRT-PCR) procedure program. At the beginning of 
the experiment, sterilized tubes and 70% ethanol (EtOH) (prepared with MiliQ 
water, EtOH: MiliQ water = 7:3) for cleaning homogenizer were prepared. The 
hood, homogenizer and the bench used for isolation procedure were disinfected 
with 70% EtOH.  
Lysis of both cells and tissues was performed using Trizol reagent. For cells, 
an appropriate volume of Trizol reagent was added into 6-well or 12-well plate 
and incubated for 30 min at RT. While for liver tissues, 50-80mg liver tissues 
were homogenized completely in 1ml Trizol reagent using an electronic 
homogenizer. After the cells or liver tissues were homogenized completely, 
each eppendorf was kept still under RT 30 mins. Then 200μl chloroform was 
added into the each eppendorf and vortexed completely. After incubation on the 
bench for at another 20 mins at RT, eppendorfs were centrifuged for 10 min, 
12000 rcf at 4°C. Then, 400μl supernatant of each eppendorf was transferred 
into a new sterilized eppendorf, following with another 400μl of isopropanol 
(AppliChem, Dismalab, Barcelona, Spain) was added into each eppendorf and 
mixed completely one by one. This step was followed by keeping eppendorfs 
15 min at RT. The tubes were centrifuged 10 min, 12000 rcf at 4°C, the 
supernatant discarded and the pellet would be underneath. 70% Ethanol was 
used to clean the pellet inside the eppendorf, via vortex and centrifuged 3x 10 
min, 12000 rcf at 4°C. Then, the supernatant was discarded and the pellet dried 
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completely at RT. The pellet was diluted with DEPC water and vortexed 20 to 
30 seconds at 65°C max RPM in the Thermomixer. Each sample was measured 
by Nanodrop at an OD of 260 nm combined with using DEPC water as blank. 
The concentration is calculated spectrophotometry at an OD of 260nm and the 
purity of the sample is determined according to the E260/E280 ratio. Therefore, 
the purity of the mRNA ranges from 1.8 to 2.0 is relatively high. RNA samples 
were stored at -80°C. 
5.2.3.2 Real time PCR: Reverse transcription 
Single stranded mRNA is reverse transcribed into complementary DNA 
(cDNA). Reverse transcription was performed using an Applied Biosystems™ 
High-Capacity cDNA Reverse Transcription Kit according to the manufacturer’s 
recommendations (Table 5.2.7, Table 5.2.8). Afterwards, cDNA was diluted 
with a comfortable concentration (85 µl DEPC+ cDNA). cDNA samples were 
stored at -20°C or directly used for qRT-PCR. 
 
Table 5.2.7 Reverse transcription system 
Reagents Volume (μl) 
RNA sample with DEPC WATER Total 10 
DEPC WATER 4.2 
10x buffer RT 2 
25x dNTPs 0.8 
10X random PRIMER 2 
Enzyme Reverse transcriptase 1 
Total volume 20 
 
Table 5.2.8 Reverse transcription procedure: 
Program: RT-applied Bio-Rad machine    
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25C      10 min 
37C 120 min 
8C    5 min 
4C      ∞ 
5.2.3.3 Quantitative real-time PCR 
SYBR Green Master Mix was used to analyze under the 7300 Real Time 
PCR System and Sequence Detection Software Version 1.3.1(Applied 
Biosystems, Massachusetts, USA).  RT-PCR was repeated with a volume of 
20μl reaction mixture according to the instruction of manufacturer (Table 5.2.9). 
After reaction, the Ct values were exported to Microsoft Excel (Microsoft Corp., 
Redmond, Washington, USA) for analysis. The Sequence Detection Software 
Version 1.3.1 was used for calculating the CT value for each reaction. Relative 
mRNA expressions were calculated according to the ΔΔCT method102. Each 
CT value of the reaction was compared with the untreated control group and 
compared with GAPDH gene expression serving as an internal reference. 
 
Table 5.2.9 Details for RT-PCR reaction mixture are given as follows: 
Reagents  Volume (µl) 
cDNA 5 
Forward primer 1 
Reverse primer 1 
SYBR green master mix 10 
DEPC water 3 
Total reaction volume 20 
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5.2.4 Molecular protein extraction and analysis 
5.2.4.1 Extraction of whole-cell proteins from the cells or the liver tissue 
For cell extraction, 100-200µl freshly complete NP40 lysis buffer (Table 
5.2.10, Table 5.2.11) was added into each well in the cell culture plates (6-well 
or 12-well). For liver tissue protein extraction, approximately 50 mg frozen liver 
tissue was homogenized by homogenizer on the ice within 500 µl freshly 
complete NP40 lysis buffer holding in 2 ml eppendorf tube. Samples of protein 
were homogenized on the ice. After incubated on the ice for 30 min and 
centrifuged 10 min 12000 rpm at 4°C. The supernatant was transferred into a 
new tube and the concentration was determined (see below protein 
quantification), or store at -80°C for future use. 
 
Table 5.2.10 NP40 buffer shown as follows: 
NP40-Buffer Volume Final concentration 
Tris/HCl 7.5 pH (1 M) 25 ml 50 mM 
NaCl (5 M) 15 ml 150 mM 
Nonidet P-40 2.5 ml 0.5% 
Sodium Fluoride 1.05 g 50 mM 
dH2O added to 500 ml  
 
Table 5.2.11 Freshly complete NP40 lysis buffer as follows: 
Freshly added components Volume 
AEBSF Hydrochloride (100mM) 100 μl 
Complete Mini (protease inhibitors) 1 tablet 
DTT (1M) 20 μl 
PhosSTOP 1 tablet 
NP40 buffer added to 10 ml 
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5.2.4.2 Protein quantification 
According to Bradford's method, protein concentrations in the whole liver 
tissue lysate, cytoplasm and mitochondria were measured using Bio-Rad 
protein analysis reagent following with the manufacturer's instructions103. For 
the purpose of determination, 2 μl of each liver protein sample was mixed with 
998 μl Bio-Rad protein reagent, which had been diluted in DEPC water with the 
final concentration of 20%. To generate the standard curve, BSA was diluted 
into 0.5 mg/ml, 1 mg/ml, 1.5 mg/ml, 2 mg/ml, 4 mg/ml, 6 mg/ml, 8 mg/ml, 10 
mg/ml, separately in the same way as the samples. NP40 buffer was used as 
blank control. BSA standards of pre-adjusted concentrations together with 
protein samples were measured at the same time approach to use a 
spectrophotometer at OD630. The concentration of the sample was calculated 
by comparing with the standard curve from the OD630 value of BSA standard 
protein. Before Western blot (WB) analysis, the final concentration of the protein 
solution was adjusted to 4 μg/μl for liver and 1-2 μg/μl for cells with complete 
NP40 lysis buffer. 
5.2.4.3 Western blot (WB) 
 Proteins samples were denatured for 5 min 300 rpm at 95°C in the 
thermomixer after adding loading buffer (1/4 total volume), following with 
proteins centrifuged for another 5 min, 300 rpm at RT. Samples were loaded on 
a handmade gel which containing 5% polyacrylamide stacking gel (Table 5.2.12) 
and separating gel that range from 8% to 15% (Table 5.2.13) according to the 
molecular weight of the target proteins. Quantity of the uploading protein, for 
cells range from 30 to 80 µg and for liver tissue range from 80 to 150 µg 
separately (according to the different target proteins). Protein samples were 
separated at 80-120 V for approximately two hours in one-fold SDS-Running 
buffer (Table 5.2.14).  
After electrophoresis, the separated proteins were transferred from the 
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polyacrylamide gel onto a PVDF membrane in the wet blotting chamber for 2 
hours at 300 mA (Current) and 4°C (ice around). Whatman® paper, PVDF 
membrane and polyacrylamide gel were made as a sandwich then immersed 
in 1-fold transfer buffer (Table 5.2.15). The transfer was carried out in 
accordance with standard procedures104. Ponceau S solution was used for 
confirming proteins successfully transferred. After rinsing out the Ponceau S 
solution with 1% TBS-Tween 20 (TBST) buffer, the membrane was incubated 
in 5% BSA/1% TBST or 5% non-fat dry milk/1% TBST for 1 h at RT to block the 
unspecific binding sites. Subsequently, the membrane was shortly washed and 
incubated in the primary antibody diluted with an appropriate concentration in 
1% BSA/TBST or 2.5% nonfat dry milk/TBST solution shaken overnight at 4°C. 
The primary antibodies and concentrations of working dilutions are listed in 
Table 5.1.4. 
On the following day, the membrane was washed 3x 10 min in 1%TBST 
solution. Then the membrane was incubated in secondary antibody with the 
fixed concentration diluted in 5% BSA/1%TBST or 5% non-fat dry milk/1%TBST 
for 1 hour at RT, the concentrations of working dilution are listed in Table 5.1.5. 
Subsequently, the membrane was washed 3x 10 min in 1%TBST solution. 
Target signals were visualized using ECL™ Prime Western Blotting System. 
After incubation for 3-5 min, the membrane was developed in a LAS mini 4000 
Chemiluminescence scanner (FUJIFILM, super CCD, Marlborough, USA). 
 
Table 5.2.12 Handmade stacking gel as follows: 
Stacking Gel Volume 
dH2O 4.5ml 
30% Acrylamide/Bis Solution 1.3ml 
APS 10 % 80μl 
SDS 10% 80μl 
Tris/HCL PH=6.8 2ml 
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TEMED 8 μl 
Total volume 8ml 
 
Table 5.2.13 Handmade separating gel as follows: 
Separating Gel 8% 10 % 12 % 15 % 
dH2O  9.3ml 7.9ml 6.6ml 4.6ml 
30% Acrylamide/Bis 
Solution 
5.3ml 6.7ml 8.0ml 10.0ml 
APS 10 %  200μl 200μl 200μl 200μl 
SDS 10% 200μl 200μl 200μl 200μl 
Tris/HCL PH=8.8 5.0ml 5.0ml 5.0ml 5.0ml 
TEMED 12ul 8ul 8ul 8ul 
Total volume 20ml 20ml 20ml 20ml 
 
Table 5.2.14 SDS-Running buffer mixture as follows: 




dH2O add to 1L 
 
Table 5.2.15 10x Transfer Buffer mixture as follows: 
10x Transfer Buffer Volume/Quality 
Tris 30.3g 
Glycine 144.13g 
dH2O add to 1L 
1x Transfer Buffer Volume/Quality 
10x Transfer Buffer 100 ml 
Methanol 200ml 
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dH2O add to 1L 
5.2.5 Histological analysis 
5.2.5.1 Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) Staining 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling 
(TUNEL) staining is an established method for in situ labelling of DNA strand 
breaks that occur early during apoptosis. First, cryopreserved liver samples 
were cut into 5 µm thick, cells were cultured on the surface of the coverslips 
with an approximately concentration of 105/cm2. The slides/coverslips were 
then dried for 30 min at RT and then slides/coverslips were fixed in 4% PFA for 
20 min at RT. After fixation, the slides/coverslips were washed 3x 10 min in PBS. 
During this period, 10% hydrogen peroxide (H2O2) was prepared by mixing 30% 
H2O with methanol (1:9). The slides/coverslips were incubated in 10% H2O in 
dark condition for 10 min. This step was followed by incubation for another 10 
min PBS solution. In order to have access to the DNA, the nuclei were 
permeabilized in 150mM Na-Citrate (Table 5.2.16) in PBS solution for 2 min at 
4ºC in the fridge. The permeabilization solution was removed by washing the 
slides/coverslips 2x 10 min in PBS solution. Subsequently, 100µl of labelling 
mixture reaction (Table 5.2.17) was spread on each section/coverslip and 
incubated overnight at 4ºC in the fridge. The second day, the slides/coverslips 
were washed 4x 10 min in PBS solution. Then, the slides/coverslips were 
mounted with DAPI for nuclear counterstaining with coverslips covering the 
sample, and keep them in dark at 4ºC in the fridge 15 minutes. Observe the 
samples under the microscope and calculate the positive cells by using the 
AxioVision© software and photographs saved in the format “. zvi”. Photographs 
were analyzed by software ImageJ Version 1.52u (LOCI, University of 
Wisconsin, Wisconsin, USA). 
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Table 5.2.16 Precool the mixture together with glass tank as follows: 
Reagent Volume(ml)/Quality(g) 
150mM Na-Citrate 8.8g 
PBS solution 200ml 
10-fold Triton-100 0.2ml 
PH value pH= 6.0  
 
Table 5.2.17 The labelling mixture solution was composed as follows: 
Reagent Volume(µL) for 1 section  
Enzyme Solution (blue cap) 1 
10X TUNEL Diluent Buffer (20ml bottle) 10 
TUNEL Labeling Solution (violet cap) 89 
Total 100 
5.2.5.2 Immunofluorescence staining (IF) 
Freshly 5µm thickness of the cryosections made from the liver of the mice 
(cells coverslips) were used for IF staining. First, liver tissue sections or cells 
coverslips were incubated in 4% PFA 15 min at RT. This step was followed by 
washing slides 3x 10 min in PBS. Non-specific binding sites of the tissue were 
incubated in blocking solution (10%Goat serum, 0.3%Triton-100, 1-fold PBS 
buffer) 1 h at RT. Subsequently, incubate the tissue overnight at 4 ºC (in the 
fridge) with the primary antibody mixed with blocking solution which was 
prepared according to the instruction of the manufacturer (Table 5.1.4). The 
second day, samples were washed 3x 10 min in PBS solution. Then, tissues 
were incubated with the secondary antibody prepared with blocking solution 1 
h at RT (Table 5.1.5). After washing the samples 3x 10 min in PBS solution, 
DAPI was used not only as mounting medium for mounting the samples, but 
also to visualize the nuclei. Pictures were taken using AxioVision© software 
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after incubating the stained sections at 4 ºC in the fridge 15 min, photographs 
were analyzed by software ImageJ Version 1.52u, subsequently.  
5.2.5.3 Paraffin Embedding 
After fixation in 4% PFA for 24-48 h, mice liver specimens were kept in PBS 
solution at 4 ºC in the fridge before embedding. We first washed the 
specimens/cassettes under running tap-water for 30 min. Then tissues were 
dehydrated sequentially by waxing cassettes in 50%, 70%, 85% and 95% EtOH 
for 0.5-h, 1 h, 1 h and 1 h, separately. Then, cassettes were incubated in 95% 
EtOH overnight. On the following day, the specimens were continued to be 
dehydrated via waxing cassettes in 100% EtOH for 2x 0.5 h. Clearing the 
tissues sequentially by waxing cassettes in the mixture buffer (EtOH absolute: 
Xylene=1:1) for 0.5 h, combined with waxing cassettes in xylene 2x 0.5 h at RT. 
Subsequently, waxing cassettes were put in liquid paraffin 3x 1 h at 70 ºC. 
Finally, tissue embedding was completed with paraffin by using the system 
Leica EG1160 Embedding Center Dispenser plus hot Plate (Leica Biosystems 
Nussloch GmbH, Nußloch, Germany) and paraffin blocks were kept at RT for 
future experiments. 
5.2.5.4 Hematoxylin and eosin (H&E) staining 
Paraffin embedded liver samples were cut 5 µm thick and slides were baked 
in the oven at 60 ºC for 1 h. Then, sections were incubated 2x 5 mins in xylene. 
This step was followed by incubating sections 2x 5 min in 100% ethanol. Then 
the sections were incubated into 96%, 90%, 85% EtOH for 3 min, 3 min, 3 min, 
consecutively. Later, sections were rinse under flowing tap-water for another 2 
min. Then, the sections were incubated in hematoxylin 2 min followed by rinsing 
the sections under flowing warm tap-water for 10 min. Sections were turned 
into 1% hydrochloric acid alcohol incubated 2 seconds. Next, the sections were 
rinsed under flowing warm tap-water 15 min. After that, the sections were 
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incubated in 70%, 85%, 90% EtOH for 3 min, 3 min, 2 min, consecutively. 
Subsequently, sections were incubated in eosin 2 min in a dark environment. 
Sections were rinsed with 95% EtOH 3 sec to make sure the eosin was 
removed. This step was followed by waxing the sections 2x 3 min in 100% EtOH. 
Then, the sections were cleaned 2x 10 min in xylene. Finally, slides were 
mounted by mounting medium and dried in a fume hood. Photographs were 
taken using microscopy. 
5.2.5.5 Sirius Red Staining 
Sirius Red (SR) is one of the best techniques for detecting collagen deposition. 
Paraffin liver samples were cut 5 µm thick made into sections, and immersed 
in the respective solutions 2x 5 min xylene, 2x 5 min 100% ethanol, 2x 5 min 
95% ethanol, 2x 5 min 80% ethanol, 2x 5 min distilled water, separately. This 
step was followed by waxing the sections in Picro-Sirius Red solution (Table 
5.2.18) for 60 min at RT. Then, sections were followed by rinsing in acidified 
Water (Table 5.2.19) for 4 min at RT. The sections were rinsed 2x 30 seconds 
in 100% EtOH, 2x min in xylene, separately. Finally, the sections were mounted 
by mounting medium and dried in a fume hood. Photographs were taken by 
using microscopy and analyzed by software ImageJ Version 1.52u. 
 
Table 5.2.18 Picro-Sirius Red solution was prepared as follows: 
Reagent Volume/Quality 
Sirius Red OR Direct Red 80 0.25 g 
Picric acid saturated aqueous solution 250 ml 
 
Table 5.2.19 Acidified Water was prepared freshly as follows: 
Reagent Volume(ml) 
Acetic Acid 1.5 
Distilled water 300 
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5.2.5.6 Immunohistochemistry (IHC) 
Paraffin liver samples were cut 5 µm thick made into slides/sections. The 
sections were preheating at 60°C for 30-40 min in the oven. The paraffin-
embedded sections were deparaffinized and rehydrated with a reduced 
concentration of xylene and a series of ethanol solutions, immersed 2x 10 min 
in xylene, followed by incubated 2x 5 min in 100%, 96%, 70% ethanol, and 
dH2O, consecutively. In order to improve the utilization of antigens, antigen 
retrieval was performed by cooking the sections in 10mM sodium citrate buffer 
(Citrate/PBST, PH = 6.0) using a pressure-cooker 2100-Retriever (Aptum 
Biologics, Kassel, Germany), with the slides kept wet. After one complete cycle 
(2 h) according to the instruction of the Retriever manufacturer, including cool 
the sections completely, the slides were taken outside of the pressure cooker 
and rinsed 3x 5 min in dH2O. The sections were treated with 3% H2O2 for 10 
min to quench endogenous peroxidases. The next step consisted of rinsing the 
sections 2x 5 min in dH2O and 5 min in PBS. After blocking each section with 
100 μl 2.5% normal horse serum (Vector Laboratories, California, USA) for 30 
min at RT, 100 μl primary antibody solution (concentration listed in Table 5.1.4) 
was added to each section and incubated overnight at 4ºC. The following day, 
the primary antibody solution was removed and sections were washed in PBS 
3x 5 min, then 100μl secondary antibody was added (concentration listed in 
Table 5.1.5) to each section incubating for 1 h at RT. Secondary antibody was 
removed and sections washed 3x 5 min in PBS. Staining was developed by 
using DAB as the manufacturer suggested, accompanied by counterstaining 
cell nuclear with hematoxylin 2 min. Sections were washed under running tap-
water for 15 mi and 2x 5 min in dH2O. 
After sections were dehydrated in an ascending ethanol series (2x 10 sec in 
96%, 2x 10 sec in 100% EtOH), cleared 2x 5 min in xylene and mounted with 
the mounting medium. Photographs were taken by using microscopy after the 
sections dried. 
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5.2.5.7 Periodic Acid-Schiff (PAS) staining 
Paraffin embedded liver samples were cut 5 µm thick. Before using Periodic 
Acid solution and Schiff’s Reagent, they need to be pre-warmed at RT 10 min. 
Paraffin-embedded sections were deparaffinized in xylene (2x 5 min) and 
rehydrated with a reduced concentration of EtOH (2x 5 min in 100%, 96%, 70% 
ethanol, and dH2O, consecutively). Then, sections were immersed in Periodic 
Acid solution for 5 min at RT and after rinsing slides 3x 5 min in dH2O. After 
immersing in Schiff’s Reagent for 15 min at RT, sections were rinsed under 
running tap water for 5 min. Counterstain slides in Hematoxylin Solution for 2 
min followed by rinsing the sections in running warm tap water 15 min. 
Subsequently, sections were dehydrated performed in increasing percentages 
of EtOH (2x 5 min in 95%, 100%, separately), cleared 2x 5 min in xylene and 
mounted with the mounting medium. Photographs were taken by using 
microscopy after the sections dried completely. 
5.3 Statistical analysis 
 All data were expressed as mean ± standard deviation of the mean. The 
standard error of the mean (SEM) was calculated from the average of at least 
3 independent samples per condition. Statistical significance was determined 
via using GraphPad Prism 8.0 software (GraphPad Software, California, USA), 
followed by a Student’s t-test (unpaired, two-tailed test) or via one-way analysis 
of variance (ANOVA) including Tukey's multiple comparisons test, P values less 
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6.1 Construction and generation of the JnkΔhepa knockout 
mice 
 Alb (Albumin)-Cre and Jnk2 deficient mice in the C57BL/6 background were 
purchased from the Jackson Laboratory (Bar Harbor, ME). By homologous 
recombination in embryonic stem (ES) cells, mice with a floxed allele of Jnk1/2 
were constructed Jnk1/2LoxP/LoxP (Jnkf/f) according to the previously published 
studies, Alb-Cre mice were crossed to Jnk1/2LoxP/LoxP to generate mice 
Jnk1/2Δhepa (JnkΔhepa)99, 105, 106. Both of Jnkf/f mice and JnkΔhepa mice were fed to 
keep old without any treatment, and raised in cages with filters and bred in 
pathogen-free, temperature and humidity-free facilities of the Animal Facility at 
School of Biology, UCM, for a 12-hour cycle of light and shade and free access 
to standard food and water. Compared with Jnkf/f mice, JnkΔhepa mice were 
difficult to survive more than 72-week-old, the survival rate of these mice was 
approximately 43.75% (7/16, survival data not shown), Both of the strains were 
kept older with age, and sacrificed at two different time points (32-week-old and 
52-week-old, separately (Fig. 4A). PCR amplimers (described in chapter Table 
5.1.2) were used to examine the genomic DNA to distinguish the controlled and 
the deleted (Jnk1Δhepa) alleles, so that with Alb-Cre (Total-Cre 01/02) detected 
though genotyping test making sure Jnkf/f mice Alb-Cre positive, which means 
JnkΔhepa (Fig. 4B). In order to confirm the effectiveness of the Jnk1/2 deletion in 
the hepatocytes, WB from total liver tissue extracts. The proteins of the livers 
from JnkΔhepa mice were extracted to be detected and probed with mouse-
specific JNK1 and JNK2 antibodies, the results are clearly presented in Fig. 4C. 
Compared with the JnkΔhepa mice, Jnkf/f mice were used as control group mice.  
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Figure 4. Efficient Jnk1/2 deletion in hepatocytes Jnkf/f mice. A) Compared with 
the JnkΔhepa mice, Jnkf/f mice were used as control group mice. Mice were sacrificed at 
different time points, 32-week-old and 52-week-old, separately. B) Ethidium Bromide 
gel showed the respective PCR results from mice tails DNA derived from 
Jnk1Δhepa/Jnk2Δhepa mice. C) WB was presented to prove the deletion of Jnk1/2 in 
hepatocytes of the liver. Expression of pJNK1, JNK1 and pJNK2 and JNK2 were 
assessed via WB. Numbers were denoted as the molecular weight (KDa) of proteins. 
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6.2 Characterization of JnkΔhepa mice 
  We first focused on the phenotype of livers during the progression of liver 
disease starting at 32-week-old in both Jnkf/f and JnkΔhepa. Previously, we had 
shown that livers of JnkΔhepa mice are characterized by small cyst-like structure 
at 32-week-old60, and 33.7% mice showed the same results according to the 
frequency of cysts combined with ductular reaction (Arrows indicate positive areas) 
as observed by H&E staining (Fig. 5A-B). In our study, the altered phenotype 
of characteristic structures in the liver is consistent with the photographs of H&E 
staining (Fig. 5B). Compared with Jnkf/f and JnkΔhepa mice, the difference 
between body weight (BW) and liver vs body weight (LW/BW) ratio were not 
significant in 32-week time point, but liver weight (LW) interestingly decreased 
(Fig. 5C-E). Serum markers of liver damage AST and ALT, as well as LDH were 
upregulated (Fig. 5F-H), but no difference in ALP (Data not shown). These 
results suggested that liver injury was induced after deletion of Jnk1/2 in 
hepatocytes combined with phenotypic changes in liver structure. Altogether, 
target deletion of Jnk1/2 in hepatocytes induces liver biliary hamartoma 
accompanied with liver dysfunction, related to hepatocellular vacuolation and 
exacerbated proliferation of biliary epithelial cells (BECs) triggering dilation of 
the ductular tracts (Figure 5).  
 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 81 / 179 
 
Figure 5. Presence of liver cysts and serum markers of hepatic damage in 
JnkΔhepa mice. A) 32-week-old male mice, both Jnkf/f (n=8) and JnkΔhepa (n=8) mice in 
a C57BL/6 background were sacrificed, livers were harvested and photographed. B) 
Compared with Jnkf/f mice, JnkΔhepa mice showed the phenotype of multiple liver cysts 
dilatations with varying sizes according to H&E staining. Scale bars, 100µm. C) LW of 
Jnkf/f and JnkΔhepa mice were annotated in 32-week-old mice, and results were graphed 
as well as D) BW, and E) LW/BW ratio. Serum markers of liver damage in both groups 
were analyzed, F) ALT, G) AST, H) LDH were represented and graphed. Data were 
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6.3 Cell death and fibrosis are increased in JnkΔhepa mice 
 In order detect hepatocyte damage in JnkΔhepa livers, TUNEL staining was 
accessed to detect cell death in both 32-week-old JnkΔhepa and JnkΔhepa mice, 
photographs were taken and results were calculated. Cell death was increased 
by calculating TUNEL-positive cells in JnkΔhepa mice group compared with Jnkf/f 
animals, and with significant statistical difference (Fig. 6A, C). According to SR 
staining, these results were also in line with the progression of fibrogenesis in 
JnkΔhepa compared with JnkΔhepa at 32 weeks of age (Fig. 6B). SR staining 
showed fibrosis characterized with multiple cysts of ductular dilation in the liver, 
which suggested that fibrosis may promote the ductular reaction in JnkΔhepa 
livers. Positive stained areas were calculated by ImageJ (Fig. 6D). These 
results suggested that cell death combined with fibrosis is increased by the 
progression of biliary hamartoma after the deletion of Jnk1/2 in hepatocytes. 
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Figure 6. Cell death combined with fibrosis increased in JnkΔhepa mice. A) Cell 
death was performed using TUNEL staining in both Jnkf/f and JnkΔhepa (n=8) mice at 
32-week time point. Scale bars, 50μm. B) Fibrosis was also detected by SR staining 
in both Jnkf/f and JnkΔhepa mice groups. Scale bars, 500μm. Data of C) TUNEL and D) 
SR staining, were represented as the mean ± SEM and graphed (*p <0.05; **** p 
<0.0001).  
6.4 Presence of biliary hamartomas during the progression 
of liver disease in JnkΔhepa mice 
 Mesenchymal hamartoma is a rare, benign, developmental tumor of the liver, 
with occasional risk of malignancy. Histologically, it appears as a disordered 
arrangement of the mesenchyme, bile ducts, and hepatic parenchyma. The 
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understand the progression of liver disease in older JnkΔhepa mice, 52-week-old 
mice were sacrificed. Livers were harvested and photographs taken. 
Hepatocyte-specific deletion of Jnk1/2 (JnkΔhepa) showed that the liver 
parenchyma is characterized by multiple cyst-like structures of different sizes 
ranging from 25um to 1560um according to the measurement of H&E staining, 
accompanied by fluid-filled in the cysts, when they grow up to 52-week-old 
(97.33%) according to the frequency of cysts in H&E staining (Fig. 7A-B). 
Histopathology of the liver was performed using H&E staining (Fig. 7B). 
Moreover, appearance of cysts was accompanied by proliferation of BECs. At 
the same time, LW and LW/BW ratio were obviously increased at the 52-week 
time point in JnkΔhepa mice (Fig. 7C-E). Serum markers of liver damage AST 
and ALT, as well as LDH were markedly elevated (Fig. 7F-H). These results are 
in line with the results of serum in 32-week-old mice. These results show that 
the JnkΔhepa mice are an interesting model of PLD41 that could mimic the human 
situation.   
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Figure 7. Liver biliary hamartoma progression in older JnkΔhepa mice. A) 52-week-
old male mice, both Jnkf/f and JnkΔhepa mice (n=8) with C57BL/6 background were 
sacrificed, livers were harvested and photographed. B) Compared with Jnkf/f mice, 
JnkΔhepa mice showed the phenotype of multiple liver cysts dilatations with varying sizes 
according to H&E staining. Scale bars, 100µm. C) LW of Jnkf/f and JnkΔhepa mice were 
annotated in 52-week-old mice, results were graphed as well as D) BW, and E) LW/BW. 
Results of serum in both groups were detected, F) ALT, G) AST, H) LDH were 
represented and graphed. Data were represented as the mean ± SEM and graphed. 
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 6.5 Deletion of Jnk1/2 in hepatocytes does not trigger 
polycystic kidney disease (PKD) 
Since PLD is associated with polycystic kidney disease (PKD)40, we checked 
detected the anatomy and microscopy of kidneys at the same time points we 
sacrificed the mice during the progression of chronic liver disease (32 and 52 
weeks) (Fig. 8). H&E staining showed normal anatomy and histology of kidneys 
of Jnkf/f and JnkΔhepa, accompanied by no cysts or biliary strictures at 32 and 52 
weeks of age (Fig. 8A). Fibrous deposition measured by Sirius red (SR) 
staining was performed in kidneys of Jnkf/f and JnkΔhepa mice. Concomitantly, 
no obvious fibrosis in the kidney of Jnkf/f and JnkΔhepa was observed neither at 
32 weeks or at 52 weeks (Fig. 8B-C). These results suggested that target 
deletion of Jnk1/2 in hepatocytes did not cause PKD.  
Figure 8. Anatomy and histopathology of kidneys in Jnkf/f and JnkΔhepa mice. A) 
The phenotype of kidney was presented by both Jnkf/f and JnkΔhepa mice at 32 and 52 
weeks (n=8), separately. B) Kidneys of 32 and 52-week-old Jnkf/f and JnkΔhepa mice 
were accessed through H&E staining (Scale bars, 100µm), as well as C) Sirius red 
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6.6 Cell death and fibrosis progression in older JnkΔhepa 
mice 
Hepatocyte death and liver fibrogenesis are hallmarks of the progression of 
liver disease108. Cell death was obviously increased as age progressed with a 
statistically significant difference between Jnkf/f and JnkΔhepa mice (Fig. 9A). 
According to SR staining, these results were also in line with the progression of 
fibrosis in the liver with age. SR staining displayed larger multiple cysts in the 
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Figure 9. Cell death and liver fibrogenesis are increased in JnkΔhepa mice. A) Cell 
death was accessed via TUNEL staining in both Jnkf/f and JnkΔhepa mice groups (n=8-
10) at 32-week time point. Scale bars, 50μm. B) Fibrosis was also analyzed by SR 
staining in both Jnkf/f and JnkΔhepa mice groups. Scale bars, 500μm. Data of C) TUNEL 
and D) SR staining, were represented as the mean ± SEM and graphed. E) The 
frequency of cysts was detected calculated by the photographs of H&E staining and 
represented as the mean ± SEM and graphed (***p <0.001; ****p <0.0001). 
6.7 A pro-inflammatory environment is characteristic of 
disease progression in JnkΔhepa mice 
 Based on the fibrosis detected in JnkΔhepa mice as described above, we 
subsequently studied the expression of αSMA, a marker of hepatic stellate cell 
(HSC) activation109, using immunoblotting. The results showed that 
overexpression of αSMA was significantly increased in the JnkΔhepa group 
compared to Jnkf/f mice, at 32 weeks of age (Fig. 10A). Next, we evaluated the 
pro-inflammatory environment by examining the mRNA transcripts for pro-
inflammatory cytokines (Tnf-α, IL-6, Tgf-β1) were analyzed using qRT-PCR. 
qRT-PCR results revealed that deletion of Jnk1/2 in hepatocytes caused 
obviously upregulation of pro-inflammatory cytokines Tnf-α and IL-6 in JnkΔhepa 
mice group compared to Jnkf/f livers. Tnf-α was significantly increased 7-fold 
compared to Jnkf/f mice, accompanied with increased 3-fold in IL-6. Tgf-β1 
showed increase of nearly 2-fold, while difference was not significant with 
expression of mRNA pdgf-α in JnkΔhepa mice (Fig. 10B-E). Therefore, the 
progression of hepatic cystogenesis is associated to a proinflammatory 
environment. 
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Figure 10. A proinflammatory environment favors the development of hepatic 
cystogenesis in JnkΔhepa mice. A) Expression of protein αSMA was accessed via WB 
with 32-week-old JnkΔhepa mice, compared to Jnkf/f mice. Numbers were denoted as the 
molecular weight (KDa) of proteins. GAPDH was used as a loading control. B-E) 
Expression of mRNA Tnf-α, IL-6, Tgf-β1 and pdgf-α were accessed through qRT-PCR. 
The data were normalized for the amount of Gapdh mRNA in each sample. Data were 
represented as the mean ± SEM and graphed, separately. (***p <0.001; ****p <0.0001) 
6.8 Hepatic oval cells are strongly activated in JnkΔhepa 
livers 
 As presented above, we detected the multiple liver cysts were formatted 
coincide with ductular dilation in JnkΔhepa mice with age, fibrosis was promoted 
as well. We hypothesized that oval cells are potentially activated and contribute 
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Therefore, we examined the expression of oval cell related genes in 32-week-
old mice. Oval cells are similar to fetal hepatoblasts in that they are bipotential. 
Therefore, biomarkers of hepatic oval cells and biliary epithelium were 
discriminated, such as CK19110, SOX9111, Notch1112, IGF2BP3 and YAP1113(Fig. 
11A-E). Simultaneously, the ligand of Notch1 Jag1, as well as Hey1 which was 
also a downstream transcriptional target of Notch1, were also detected via qRT-
PCR (Fig. 11F-G). Biomarkers of cholangiocytes CK19, SOX9, Notch1 were 
expressed via IHC staining, positive areas are obviously overexpression in 
JnkΔhepa mice (Fig. 11A). Expression of mRNA Ck19 were upregulated 1.85-
fold which was in line with the overexpression of protein CK19 in JnkΔhepa mice 
(Fig. 11B), while mRNA of Notch1 was increased 1.25-fold but without 
statistical difference compared to Jnkf/f mice. Furthermore, expression of mRNA 
Jag1 was upregulated to 1.58-fold. This was in line with the upregulation of the 
cytokine Hey1 via qRT-PCR (2.5-fold) (Fig. 11F-G). Biomarker YAP1 was also 
associated with transdifferentiation of hepatoblasts, mRNA of Yap1 was 
upregulated. However, Igf2bp3 was decreased in JnkΔhepa mice via qRT-PCR 
(Fig. 11C-D). All of these results suggested that loss function of JNK1/2 in 
hepatocytes might activate the oval cells and contribute to transdifferentiation 
of cholangiocytes, trigger the formation of fibrosis. 
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Figure 11. Biomarkers of hepatic oval cells were activated in JnkΔhepa mice. A) 
Expression of CK19, SOX9 and Notch1 were accessed via IHC staining in Jnkf/f (n=6) 
and JnkΔhepa (n=6) livers. Scale bars, 100µm. B-G) Biomarkers of oval cells and biliary 
epithelium, mRNA Ck19, Yap1, Igf2bp3, Notch1, Jag1 and Hey1 were accessed 
according to the results of qRT-PCR. The data were normalized for the amount of 
Gapdh mRNA in each sample. Data were represented as the mean ± SEM and 
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6.9 Activation of ER-stress trigger cyst formation in 
JnkΔhepa liver.  
 Furthermore, we need to know what happened to these mice which were 
significantly different from PCK rats114, which is a typical PLD animal model as 
described before. We suspected that loss function of Jnk1/2 in hepatocytes may 
activate a special signaling pathway so that trigger the formation of liver cysts 
when JnkΔhepa mice grow old. According to the previous studies, hepatic 
cystogenesis may affect the hepatobiliary ducts by disfunction of encoded ER-
resident proteins115. The abnormal deformation of the ER may subsequently 
activate the unfolded protein response signaling cascade, which consists of 
sensors (i.e., IRE1α, PERK and ATF6) and effector (i.e., CHOP, BiP/GRP78 
and XBP1) proteins to promote protein folding, ER-associated protein 
degradation, and activation of pro-survival mechanisms116, 117. we focused on 
the 32-week-old mice. The investigation of ER-stress signaling pathway was 
detected. Overexpression of protein BiP/P62/peIF2α/Chop, and XBP1s, but not 
IRE1α, via WB (Fig. 12). The expression of these proteins showed us a new 
direction that ER-stress signaling pathway was activated in the formation of 
multiple liver cysts in JnkΔhepa mice. These results suggested that 
overexpression of XBP1s showed interaction with upregulated BiP, and ER-
stress may be activated after loss function of Jnk1/2 in hepatocytes, and trigger 
the progression of liver cysts. 
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Figure 12. Activation of ER-stress associated with liver cystogenesis in JnkΔhepa 
liver. Activation of ER-stress was evaluated by WB, expression of proteins 
BiP/P62/peIF2α/Chop, interaction with XBP1 and IRE1α, was analyzed. Numbers 
were denoted as the molecular weight (KDa) of proteins. GAPDH was used as a 
loading control.  
6.10 The JNK signaling pathway is activated in HPR101 
after TAA treatment 
Based on the characteristic of JnkΔhepa liver, we planned to promote the hepatic 
cells by external stress. Since TAA induces liver cirrhosis, and is a well-known 
model of induction of liver fibrosis, development of acute liver injury and liver 
failure118. In 1946, it was first declared hepatotoxic119, and widely used for 
experiments both in vitro120 and in vivo118. Similarly, we not only studied the 
profibrogenic action of TAA in vitro in cells, but also was challenged in vivo by 
using JnkΔhepa mice (The data is shown below).  First our goal was to analyze 
in vitro using undifferentiated HepaRG cells (HPR 101) the mechanisms 
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Cell death was increased in line with the increasing concentration of TAA 
according to the tests of CCK-8 as well as TUNEL staining (Fig. 13A-B). The 
median lethal dose (LD50) of TAA, approximately 36mM (36.11mM), was 
evaluated (Fig. 13C). In order to know what happened to these cells, we 
harvested the cells at the same time points and extracted the proteins of the 
cells. JNK signaling pathway was detected by WB in undifferentiated HepaRG 
cells (105/cm2). Activation of pJNKs, specifically pJNK1 was observed (Fig. 
13D).  
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Figure 13. Cell viability and activation of the JNK in undifferentiated hepatocytes 
after TAA treatment. A) TUNEL staining was assessed in presence of different 
concentrations of TAA (0-40 mM) in HepaRG cells (HPR101). Scale bars, 50µm. B) 
The median lethal dose (LD50) and C) CCK-8 of cell death in TAA was assessed and 
calculated in HepaRG. D) Expression of proteins associated to MAPK8 (JNK1) and 
MAPK9 (JNK2) were performed using WB and GAPDH was used as a loading control 
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molecular weight (KDa) of proteins. 
6.11 Activation of JNKs during hepatoblasts differentiation 
 Undifferentiated HepaRG cells, are hepatoblasts, normally have the ability of 
transdifferentiating into cholangiocytes and/or hepatocytes. We hypothesized 
that transdifferentiation of hepatoblasts to BECs might take place due to JNK 
signaling pathway. In order to inhibit JNK, the peptide inhibitor of JNK DJNKI-1 
(also known as XG-102) was used in our experiment. A dose of TAA [0-40mM] 
was used to treat the undifferentiated HepaRG cells (105/cm2) for 18 h, together 
in presence of DJNKI1 [2µM]. TUNEL staining showed that the increase in cell 
death was in line with the dose of TAA, but was suppressed with DJNKI1 (Fig. 
14A).  At the same time, cells were fixed with 4% PFA after the treatment, IF 
staining were completed with different biomarkers of transdifferentiation, such 
as Sex-determining region Y-box (SRY-box) containing gene 9 (SOX9) and 
hepatocyte nuclear factor-4α (HNF4α). SOX9 belongs to the SOX family of 
transcription factors121. HNF4α is a nuclear receptor rich in liver, which plays an 
important role in the early morphogenesis, fetal liver development, liver 
differentiation and metabolism122. Upregulation of SOX9 and HNF4α coincided 
with TUNEL staining under the treatment of TAA, but it was blocked by JNK 
inhibitor DJNKI1 (Fig.14B-C). Undifferentiated HepaRG cells, hepatoblasts, 
were induced to transdifferentiate into cholangiocytes via the toxicity of TAA 
which may be accompanied with the activation of JNK signaling pathway, but 
this was suppressed by JNK inhibitor. These results also suggested that 
inhibition of JNK signaling pathway via DJNKI1 could revert hepatoblasts 
transdifferentiation. Collectively, JNKs might play an important role in hepatic 
cell fatal of transdifferentiation. 
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Figure 14. Transdifferentiation of hepatoblasts induced by the treatment of TAA 
was suppressed by JNK inhibitor, DJNKI1. A) TUNEL staining was shown the cell 
death of hepatoblasts under the treatment of TAA with or without JNK inhibitor DJNKI1. 
Representative IF staining for SOX9 and HNF4α was assessed. B-C) Expression of 
SOX9 and HNF4α upregulated after TAA treatment, but inhibited by JNK inhibitor, 
DJNKI1. Scale bars, 50µm. D-F) Positive cells of TUNEL, SOX9 and HNF4α were 
calculated, data were represented as the mean ± SEM and graphed (*p <0.05; ****p 
<0.0001). 
6.12 Understanding fibrogenesis in JnkΔhepa using TAA 



































TAA (0 mM) TAA (20 mM) TAA (40 mM)
























































































ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 98 / 179 
 
the mice. As discussed above, loss function of Jnk1/2 in hepatocytes gradually 
triggers the formation of biliary hamartomas in the liver, a condition known to 
be a precedent for the development of cholangiocarcinoma (CCA)60. TAA is a 
toxic drug that promotes the development of fibrosis and liver cancer as 
previously published123. Eight-week-old Jnkf/f and Jnk∆hepa mice were fed with a 
fixed concentration of TAA (300 mg/L) in the drinking water. All mice were 
sacrificed 24 weeks later, at the age of 32-week-old (Fig. 15A). Liver and blood 
were harvested, and nodules were calculated as well. Liver histology, serum 
parameters as well as LW/BW ratio were analyzed. LW/BW ratio was increased 
in TAA experimental groups compared to vehicle groups (Fig. 15C-E). TAA-
treated JnkΔhepa mice showed significant increased levels of AST, ALT, ALP, as 
well as LDH, compared to Jnkf/f mice (Fig. 15F-I). Overall, these results showed 
that liver injury might be worse in JnkΔhepa mice, after TAA challenge.  
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Figure 15. Markers of liver injury in Jnkf/f and JnkΔhepa mice after 24 weeks of TAA. 
A) 8-week-old Jnkf/f and JnkΔhepa male mice were used for the experiments with the 
administration of TAA in drinking water(300mg/L), Jnkf/f and JnkΔhepa male mice treated 
as vehicle, all of the mice were sacrificed at 32-weeks (n=8-13). B) Phenotypes of the 
livers are shown. C) BW, D) LW, and E) LW/BW ratio of Jnkf/f and JnkΔhepa mice were 
calculated as well as control littermates. F-I) Analysis of serum levels of were analyzed 
and graphed ALT, AST, ALP and LDH, separately. Data were represented as the mean 
± SEM and graphed (#p <0.05; **/##p <0.01; ***p <0.001; ****/####p <0.0001). 
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6.13 Liver fibrogenesis in Jnkf/f and JnkΔhepa, 24 weeks after 
TAA   
 Based on cell damage presented above, we then focused on the detection of 
fibrosis, since TAA is a potential inducer of collagen deposit. Histologically, 
Sirius Red (SR) staining is used to detect the degree of fibrosis of inflammation 
caused by cancer, vascular or metabolic diseases124. It can be observed under 
a bright field microscope. The nucleus and the cytoplasm are shown as yellow, 
but collagen fibers displayed red color. Fibrosis was induced in both experiment 
mice group after the treatment of TAA as observed by SR staining. Compared 
with Jnkf/f mice, JnkΔhepa mice developed more liver fibrosis. After treatment with 
TAA, SR showed a very interesting and different pattern of SR staining in livers 
of Jnkf/f and JnkΔhepa mice. Whilst TAA-induced bridging fibrosis in Jnkf/f livers, 
the hepatic parenchyma of JnkΔhepa livers displayed peribiliary-like fibrosis (Fig. 
16A). The positive areas of SR were calculated and graphed, accordingly (Fig. 
16D). Simultaneously, αSMA, a marker of hepatic stellate cells (HSCs) 
activation109, was detected via IHC and IF staining (Fig. 16B-C). 
Overexpression of αSMA was also detected via WB which was in line with IHC 
and IF staining (Fig. 16E). Compared with Jnkf/f mice, activated fibrotic 
response area was upregulated in JnkΔhepa mice. This phenomenon was more 
significantly in both Jnkf/f and JnkΔhepa livers after the treatment of TAA. While, 
TAA JnkΔhepa liver showed especially significantly positive areas around biliary 
ducts compared with TAA-induced Jnkf/f mice (Fig. 16B-D). These results 
suggest that loss function of Jnk1/2 in hepatocytes promoted biliary tract 
proliferation and exacerbated liver fibrosis. 
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Figure 16. TAA induces significantly higher liver fibrogenesis in mice with Jnk1/2 
in hepatocytes. A) Representative Sirius Red staining of paraffin sections from the 
indicated livers after the treatment of TAA as well as vehicle group mice (n=6-8). Scale 
bars, 500µm. B) Expression of αSMA was accessed via IHC staining. Scale bars, 
100µm. C) αSMA was detected by IF staining at the same time. Scale bars, 50µm. D) 
Positive area of fibrosis was calculated by ImageJ with photographs of SR staining, 
data were represented as the mean ± SEM and graphed (****p <0.0001). E) 
Expression of protein αSMA was also detected via WB. Numbers were denoted as the 
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6.14 Inflammation in Jnkf/f and JnkΔhepa mice challenged 
with TAA 
 Based on the results we described above, such as cell death and fibrosis, we 
next detected inflammation in mice after the treatment with TAA. One biomarker 
of pro-inflammatory cytokines Tnf-α, as well as regulator of inflammatory 
processes Tgf-β1 were detected via qRT-PCR. After the treatment of TAA, 
expression of mRNA Tnf-α was increased 7.1-fold in JnkΔhepa liver, and 
obviously upregulated 10.4-fold in Jnkf/f liver. Compared with JnkΔhepa mice, 
mRNA Tnf-α expression increased only 3.4-fold in JnkΔhepa mice (Fig. 17A). 
However, mRNA Tgf-β1 expression was significantly increased 3.6-fold in 
JnkΔhepa mice after treated by TAA, but only 1.6-fold in Jnkf/f liver (Fig. 17B). 
These results suggested that TAA induces a strong proinflammatory milieu in 
JnkΔhepa mice.  
Figure 17. Inflammation was involved in JnkΔhepa mice under the treatment of TAA. 
Expression of mRNA A) Tnf-α expression was accessed via qRT-PCR as well as B) 
Tgf-β1 (n=6). Data were represented as the mean ± SEM and graphed (*p <0.05; 
***/###p <0.001; ****/####p <0.0001). 
6.15 Hepatocellular damage in JnkΔhepa and Jnkf/f mice, after 
24 weeks 
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apoptosis and necroptosis125 in each group, photographs were taken and data 
calculated (Fig. 18A-B). Expectedly, cell death increased in experimental group 
mice compared with the vehicle group. We further explored protein expression 
associated with cell death by WB. We focused on the proteins associated with 
JNK signaling pathway-induced cell death. Overexpression of both cleaved 
caspase-3 (CC3) and -8 (CC8) proteins was evident in JnkΔhepa compared with 
Jnkf/f mice after 24 weeks of TAA(Fig.18C). Additionally, pRIP1, pRIP3 and 
pMLKL were clearly induced in JnkΔhepa compared with Jnkf/f mice after 24 
weeks of TAA (Fig. 18C). These results suggested that prominent activation of 
necroptosis occur in JnkΔhepa mice, 24 weeks after TAA, and contribute to the 
liver phenotype of these mice. 
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Figure 18. Hepatocellular injury in Jnkf/f and JnkΔhepa mice, 24 weeks after TAA. 
A) Cell death was performed using TUNEL staining after the treatment of TAA in both 
Jnkf/f and JnkΔhepa mice groups (n=6). Arrows (→) indicate positive cells. Scale bars, 
50μm. B) Data were represented as the mean ± SEM and graphed (####p <0.0001). 
C) The expression of cleaved-Caspase 3 (CC3), cleaved-Caspase 8 (CC8), pRIP1/3 
and pMLKL, were demonstrated via WB. Numbers were denoted as the molecular 
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6.16 Hepatocellular proliferation in Jnkf/f and JnkΔhepa, 24 
weeks after TAA 
 Compensatory proliferation is linked with increased cell death during liver 
injury89, 126. Proliferation was detected using IF and IHC staining for Ki 67 (Fig. 
19A-B). Our data revealed that expression of positive Ki 67 cells was less than 
1% in Jnkf/f vehicle group, but increased up to nearly 3% in JnkΔhepa vehicle 
group. However, the number of positive Ki 67 cells increased compared in both 
Jnkf/f and JnkΔhepa mice, after TAA treatment. We found positive Ki 67 cells 
increased to approximately 17.5% in TAA-treated Jnkf/f livers, and reached up 
to 20% of positive Ki 67 cells in TAA-challenged JnkΔhepa animals. In Jnkf/f group, 
positive Ki 67 cells mainly expressed inside the nodule area by hepatocytes 
combined with less positive cholangiocytes, most of them maybe hepatocellular 
carcinoma stem cells. Statistically significant difference between vehicle group 
and experimental group was calculated and graphed with a p-value less than 
0.0001 (Fig. 19C). These results suggest that Jnk1/2 in hepatocytes promotes 
hepatocellular hyperproliferation in response to the liver damage by TAA. 
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Figure 19.  Hepatocellular proliferation of Jnkf/f and JnkΔhepa livers, 24 weeks 
after TAA. A) Expression of Ki 67 was evaluated by IF staining (n=7). Scale bars, 
50μm. B) Expression of Ki 67 was also accessed by IHC staining accompanied by 
expression of C) Positive Ki 67 cells were calculated by ImageJ. Data were 
represented as the mean ± SEM and graphed (****p <0.0001). 
6.17 Cholangiocytes were strongly activated in JnkΔhepa 
livers 24 weeks after TAA 
  We next investigated the cell type that was clearly differentiated between 
Jnkf/f and Jnk∆hepa livers. Typical markers of oval cells and biliary epithelium 
were evaluated including, CK19, SOX9, Notch1, AFP, YAP1 and MUCIN2 (Fig. 
20). First, CK19, SOX9, Notch1 and MUCIN2 were investigated by IHC staining. 
The results presented that these markers were upregulated in TAA groups, 
compared to vehicle groups. However, they were significantly upregulated in 
TAA-treated JnkΔhepa liver compared with Jnkf/f livers (Fig. 20A-D). Expression 





































Vehicle TAA Vehicle TAA
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 107 / 179 
 
JnkΔhepa mice compared to 2.5-fold in TAA Jnkf/f mice, and increased more 
significantly 3.7-fold in TAA JnkΔhepa mice, which was in line with IHC results 
(Fig. 20E). Additionally, the mRNA of Afp was upregulated 3.1-fold in JnkΔhepa 
mice, and 2.9-fold in TAA Jnkf/f mice, while significantly upregulated 153.3-fold 
in TAA-treated JnkΔhepa mice (Fig. 20F). Expression of mRNA of Yap1 was 
upregulated 3.8-fold in JnkΔhepa mice, and 1.2-fold in TAA Jnkf/f mice, while 
significantly upregulated 5.4-fold in TAA-treated JnkΔhepa mice (Fig. 20G). At the 
same time, protein CK19 was analyzed by WB, and it was consistent with IHC 
(Fig. 20H). In short, biomarkers of cholangiocyte/BECs were strongly activated 
after treatment with TAA, and much more significantly in JnkΔhepa liver. These 
results suggested that oval cell proliferation was characteristic of JnkΔhepa liver 
livers, after TAA.  
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 108 / 179 
 
Figure 20. Cholangiocytes/BECs are activated in JnkΔhepa liver, after TAA. A-D) 
Representative IHC staining for markers of cholangiocytes, CK19, SOX9, Notcch1 and 
MUCIN2 were evaluated. Scale bars, 100µm. E-G) Expression of mRNA Ck19, as well 
as Afp and Yap1 were investigated by qRT-PCR (n=6) and graphed (#p <0.05; **/##p 
<0.01; ***p <0.001; ****/####p <0.0001). H) Expression of protein CK19 was accessed 
via WB. Numbers were denoted as the molecular weight (KDa) of proteins. GAPDH 
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6.18 Liver carcinogenesis in JnkΔhepa vs Jnkf/f mice, after 
TAA 
 Histological examination of the livers by H&E staining after TAA treatment was 
performed in JnkΔhepa mice and Jnkf/f mice. Whilst hepatocellular damage and 
an infiltration of inflammatory cells was obvious in Jnkf/f mice, compared to 
vehicle-treated animals. Moreover, the cells in the lesion area of Jnkf/f mice 
presented as prominent acinar pattern, small cell changes, combined with 
cytologic atypia under the treatment of TAA (Fig. 21A). However, in JnkΔhepa 
mice, nuclear of the cells in the lesion area were abnormally presented 
accompanied with multiple ductular dilations. At the same time, the ductular 
dilations and cell nuclei mitosis in the lesion area of the liver in TAA JnkΔhepa 
mice were significantly different, compared with the structural characteristics of 
spontaneous cystic dilatation of the ductular tracts in vehicle group (Fig. 21A). 
Additionally, periodic-acid Schiff stain (PAS) is a method used for the staining 
of structures containing high proportion of carbohydrate macromolecules, such 
as glycogen, glycoprotein, proteoglycans, and mucins in tissue127. It is widely 
believed that that HCC does not produce mucins, whereas CCA may produce 
glycoproteins128, PAS staining areas are characteristic. Normally, positive 
routine stains for hepatocytes (PAS without diastase) as show in Jnkf/f vehicle 
group, but glycogen was rich produced combined with positive mucin in Jnkf/f 
experimental group. In the JnkΔhepa experimental group, positive PAS stain was 
presented accompanied by positive mucins secreted around the hyperplastic 
cholangiocellular and ductular dilation (Fig. 21B). Collectively, these results 
suggested that, whilst 24 weeks of TAA treatment triggered HCC formation in 
Jnkf/f livers, malignancy of biliary hamartomas compatible with CCA was 
observed in animals with deletion of Jnk1/2 in hepatocytes. 
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Figure 21. Liver carcinogenesis associated to TAA challenge in JnkΔhepa animals 
A) Pathology of the liver were analyzed using H&E staining in each experimental group. 
B) PAS staining was use to describe structures containing high proportion of 
carbohydrate macromolecules. Scale bars, 100µm.  
6.19 Overexpression of c-MYC is involved in TAA-induced 
phenotype in JnkΔhepa mice 
Overexpression of c-MYC might trigger tumorigenesis, especially in the 
formation of CCA as described recently129. Similarly, c-MYC is one of the most 
frequently mutated genes in tumors and an important regulator of cell cycle and 
apoptosis, its dysregulated expression could be associated with many 
malignancies130. In TAA experiment group, expression of protein c-MYC was 
demonstrated in IHC staining together with mRNA c-Myc (Fig. 22A-B). The 
expression of mRNA c-Myc was upregulated in TAA-treated animals compared 
with vehicle groups, and more significantly (5.3-fold) in JnkΔhepa mice (Fig. 22B). 
Simultaneously, the mRNA transcripts of Krüppel-like factor 6 (Klf6), a 
transcription factor involved in the regulation of several cellular processes, 
considered as a tumor suppressor131. Was significantly upregulated with an 
approximately 12.7-fold increase in Jnkf/f mice, while exhibited an around 1.1-
fold expression in JnkΔhepa mice (Fig. 22C). P21, functions as a regulator of cell 
cycle progression and acting as tumor suppressor132, 133. Expression of p21 was 
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JnkΔhepa experimental group. However, p21 was strongly increased 13.7-fold in 
Jnkf/f mice challenged with TAA (Fig. 22D). Therefore, deletion of Jnk1/2 in 
hepatocytes promoted the formation of CCA in chronic liver injury via the 
activation of c-MYC. Furthermore, results of p21 were in line with Klf6, 
indicating these two gene maybe expressed as tumor suppressors in the 
formation of CCA.  
Figure 22. Overexpression of c-MYC involved in CCA. A) Representative IHC 
staining for c-MYC was analyzed. Scale bars, 100µm. B) Expression of mRNA c-Myc 
was detected by qRT-PCR, as well as C) Klf6 and D) p21. Data were represented as 
the mean ± SEM and graphed (*/#p <0.05; ****/####p <0.0001). 
6.20 Liver tumorigenesis in JnkΔhepa mice challenged with 
DEN/TAA 
Since loss function of JNK1/2 in hepatocytes gradually triggers the 
progression of hepatic cystogenesis to CCA development in a model of 
spontaneous carcinogenesis, the NEMO mice, we next sought to understand if 
in a chemical model of HCC- the DEN model- in a setting of a profibrotic milieu 
triggered by TAA would alter the formation of liver tumorigenesis60. After the 
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without hepatocarcinogenesis60. At the same time, deletion of Jnk1/2 in 
hepatocytes contributed to peribiliary fibrosis under TAA treatment. Therefore, 
Jnkf/f and JnkΔhepa mice were challenged with the carcinogen DEN combined 
with TAA. Controls were treated with vehicle. A fixed dosage of 25mg/Kg was 
used to treat the mice via intraperitoneal injection (IP) according to the body 
weight at the 14th day postpartum. Later, mice were fed with a fixed 
concentration of TAA (300 mg/L) from 8-week-old in drinking water, water was 
changed every week. All mice were sacrificed at 26 weeks, liver and blood were 
harvested, and number of nodules was annotated (Fig. 23A). Liver morphology, 
combined with LW, BW, as well as LW/BW ratio were examined. 
Macroscopically, JnkΔhepa livers were yellowish albeit decreased visible nodules 
compared with Jnkf/f mice after DEN/TAA treatment (Fig. 23B, F-G). LW was 
increased in both mice after the treatment of DEN/TAA, and LW of Jnkf/f mice 
was significantly increased compared with JnkΔhepa liver, after DEN/TAA 
treatment. Interestingly, BW of Jnkf/f mice increased but significantly decreased 
in JnkΔhepa mice (Fig. 23C-E). LW/BW ratio increased in both Jnkf/f and JnkΔhepa 
animals. However, no statistical differences were found in the LW/BW ratio 
between both mice strains.  
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Figure 23. Liver weight and reduced tumorigenesis in JnkΔhepa mice treated with 
DEN/TAA. A) Mice received a fixed dosage of 25mg/Kg via intraperitoneal injection (IP) 
according to the body weight at the 14th day postpartum, followed by administration of 
TAA in drinking water (300mg/L) since 8-week-old. Both Jnkf/f and JnkΔhepa male mice 
treated as vehicle, all of the mice were sacrificed at 26-week-old (n=6). B) Phenotypes 
of the livers were accessed via taking photographs combined with the ruler. C) BW, D) 
LW, and E) LW/BW ratio of Jnkf/f and JnkΔhepa mice were calculated as well as control 
littermates. F) Tumor burden for each individual mouse was characterized by 
calculating total number of visible tumors ≥ 5 mm in diameter per mouse, together with 
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the mean ± SEM and graphed (*/#p <0.05; **p <0.01; ****p <0.0001). 
6.21 DEN/TAA promote the formation of CCA in JnkΔhepa 
mice 
Histological examination revealed that JnkΔhepa mice livers exhibited small 
cysts formation but without any significant changes in the serological 
parameters compared to Jnkf/f vehicle group by H&E staining, the same as 
described earlier. After treatment with DEN/TAA, H&E staining showed that 
cells nuclei in the lesion area of JnkΔhepa mice were abnormally divided, 
cholangioma-like structures were detected in JnkΔhepa liver parenchyma 
accompanied with ductular dilation as well as strong infiltration of immune cells, 
which was different with TAA single treatment (Fig. 24A). It is widely believed 
that that HCC does not produce mucins, whereas CCA may produce 
glycoproteins128, PAS staining areas are characteristic. PAS staining is used for 
detecting structures where is containing high proportion of carbohydrate 
macromolecules. Positive routine stain for hepatocytes (PAS without diastase) 
as show in Jnkf/f mice, but glycogen was rich produced combined with positive 
mucin after DEN/TAA. After treatment with DEN/TAA, positive PAS stain was 
observed, accompanied by positive mucins secreted around the hyperplastic 
cholangiocellular and ductular dilation in JnkΔhepa livers (Fig. 24B). Serum 
markers of liver damage ALT, AST, ALP, LDH were also analyzed. Interestingly, 
DEN/TAA treated-JnkΔhepa mice, manifested exacerbated levels of AST, ALT, 
ALP, as well as LDH, compared to Jnkf/f mice after the treatment of DEN/TAA 
(Fig. 24C-F). These results suggested that loss function of Jnk1/2 in 
hepatocytes is sensitive to DEN/TAA-induced liver damage. 
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Figure 24. DEN/TAA exacerbate liver damage in JnkΔhepa mice. A) Pathology of the 
livers was evaluated using H&E staining. Scale bars, 100µm. B) PAS staining was 
presented, positive PAS stain was presented after diastase predigestion, accompanied 
by positive mucins secreted around the hyperplastic cholangiocellular and ductular 
dilation in JnkΔhepa liver. Scale bars, 100µm. C-F) Serum levels of AST, ALT, ALP and 
LDH were from 26-week-old mice. Data were represented as the mean ± SEM and 
graphed. (#p <0.05; **p <0.01; ***p <0.001; ****/####p <0.0001). 
6.22 Modes of cell death due to DEN/TAA related liver 
damage in JnkΔhepa mice 
TUNEL staining was accessed to detect cell death in each group including 
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calculated by ImageJ (Fig. 25A-B). Simultaneously, Caspase-independent 
apoptotic proteins, including CC3 and CC8, were detected via WB. 
Overexpression of both CC3 and CC8 occurred both in Jnkf/f and JnkΔhepa mice, 
suggesting that apoptosis occurred after DEN/TAA treatment. Therefore, we 
next examined necrosis-associated proteins, including pRIP1/RIP1, 
pRIP3/RIP3, and pMLKL. Interestingly, increased protein expression of 
pRIP1/pRIP3/pMLKL was demonstrated in JnkΔhepa group, compared to Jnkf/f 
mice after DEN/TAA treatment (Fig. 25C). These results suggested that Jnk1/2 
in hepatocytes protect from DEN/TAA-induced necroptosis.  
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Figure 25. Necroptosis is induced in JnkΔhepa mice after DEN/TAA treatment. A) 
Cell death was accessed via TUNEL staining after the treatment of DEN/TAA in both 
Jnkf/f and JnkΔhepa mice groups (n=6). B) Data were represented as the mean ± SEM 
and graphed (****/####p <0.0001). C) Biomarkers of apoptosis proteins cleaved-
Caspase 3 (CC3) and cleaved-Caspase 8 (CC8) were analyzed, combined with 
biomarkers of necroptosis pRIP1/RIP1, pRIP3/RIP3, and pMLKL, that were 
demonstrated via WB. Numbers were denoted as the molecular weight (KDa) of 
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6.23 Compensatory proliferation in Jnkf/f and JnkΔhepa mice 
after DEN/TAA 
Markers of proliferation were evaluated by IHC staining. Ki 67 was evaluated 
by IF and IHC staining, and statistical analysis of the Ki 67 was represented 
and graphed (Fig. 26A-B). Data showed that expression of positive Ki 67 cells, 
was less than 3% in Jnkf/f vehicle group, but increased up to nearly 3% in 
JnkΔhepa vehicle group. However, after DEN/TAA treatment, positive Ki 67 cells 
increased to approximately 25% in Jnkf/f liver, and nearly 50% positive Ki 67 
cells were detected in JnkΔhepa liver (Fig. 26C). In Jnkf/f group, positive Ki 67 
cells mainly expressed inside the nodule area by hepatocytes combined with 
less positive cholangiocyte (Fig. 26B). Moreover, expression of protein PCNA 
was evaluated by WB. Overexpression of PCNA was characteristic of both Jnkf/f 
and JnkΔhepa groups after the DEN/TAA treatment, but more pronounced in 
JnkΔhepa livers (Fig. 26G). Furthermore, expression of mRNA Cyclin E1 
increased 2.7-fold in Jnkf/f mice and 4.2-fold JnkΔhepa mice after DEN/TAA. 
Cyclin A2 expression was upregulated 11.5-fold and Cyclin D1 upregulated 4.1-
fold in Jnkf/f liver, while mRNA Cyclin A2 was increased 8.2-fold and Cyclin D1 
increased 2.8-fold in JnkΔhepa mice after DEN/TAA (Fig. 26D-F). Specifically, 
compared to Jnkf/f mice, upregulation of mRNA Cyclin E1 was statistically 
significantly in JnkΔhepa mice (Fig. 26D). These results suggested that the 
deletion of Jnk1/2 in hepatocytes triggers compensatory proliferation in 
response to DEN/TAA-induced liver damage. 
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Figure 26. Proliferation after DEN/TAA treatment in Jnkf/f and JnkΔhepa mice.  
Expression of Ki 67 was evaluated and graphed by both A) IF staining and B) IHC 
staining. IF: Scale bars, 50μm. IHC: Scale bars, 100μm. C) Data were represented as 
the mean ± SEM and graphed. D-F) Biomarkers of cell cycle mRNA Cyclin E1, Cyclin 
A2, Cyclin D1, were expressed according to the results of qRT-PCR, data were 
represented as the mean ± SEM and graphed (#p <0.05; **/##p <0.01; ****p <0.0001). 
G) Protein of PCNA was shown by WB as well. Numbers were denoted as the 
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6.24 Exacerbated fibrosis in JnkΔhepa mice, after DEN/TAA 
treatment 
After hyperproliferation was detected after DEN/TAA in JnkΔhepa mice. Then, 
we focused on the detection of fibrosis in each experimental group. 
Histologically, SR staining was used to analyze the degree of fibrosis. 
Simultaneously, αSMA was detected by IF and IHC staining, while expression 
of mRNA αSMA was measured by qRT-PCR (Fig. 27). Significantly, fibrosis 
was promoted obviously in both Jnkf/f and JnkΔhepa mice groups after the 
treatment of DEN/TAA according to SR staining (Fig. 27A). Compared to Jnkf/f 
mice, JnkΔhepa mice developed significantly more liver fibrosis. The positive SR 
area was calculated and graphed (Fig. 27D). Compared with Jnkf/f mice, 
activated fibrotic response area was upregulated in JnkΔhepa mice via both IF 
and IHC staining. After DEN/TAA, treatment, significant αSMA positive area 
was observed in both Jnkf/f and JnkΔhepa livers, especially in JnkΔhepa livers (Fig. 
27B-C). Consistently, expression of mRNA αSMA was in line with the results of 
IF and IHC staining (Fig. 27E). These results suggested that loss function of 
DEN/TAA promotes liver fibrogenesis in mice with deletion of Jnk1/2 in 
hepatocytes. 
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Figure 27. Deletion of Jnk1/2 promotes fibrosis via DEN/TAA. A) Representative 
Sirius Red staining of paraffin sections from the indicated livers after the treatment of 
DEN/TAA as well as vehicle group mice. Scale bars, 500µm. B) Expression of αSMA 
was accessed via IHC staining. Scale bars, 100µm. C) αSMA was detected by IF 
staining at the same time. Scale bars, 50µm. D) Positive area of fibrosis was calculated 
by ImageJ with photographs of SR staining, data were represented as the mean ± 
SEM and graphed. E) Expression of mRNA αSMA was also detected via qRT-PCR (#p 
<0.05; **p <0.01; ***p <0.001). 
6.25 Cytokine expression profile in Jnkf/f and JnkΔhepa mice 
after DEN/TAA 
After DEN/TAA, strong immune cells infiltration into the liver parenchyma in 
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liver damage combined with the expression of pro-inflammatory cytokines. We 
therefore evaluated the expression level of inflammatory cytokines, including 
TNFα, TGF-β, IL-6 and PDGFα by qRT-PCR (Fig. 28A-D). 
Tgf-β1 expression was increased 3-fold in Jnkf/f livers and increased 1.5-fold 
in JnkΔhepa livers (Fig. 28A). Similarly, Tnf-α expression was increased 11-fold 
in Jnkf/f livers and 6.1-fold in JnkΔhepa livers (Fig. 28B). IL-6 expression was 
increased 6.4-fold in Jnkf/f livers and 1.6-fold in JnkΔhepa livers after the 
treatment of DEN/TAA (Fig. 28D). Furthermore, compared to Jnkf/f livers, 
expressions of mRNA Tgf-β1, Tnf-α, and IL-6 were significantly decreased in 
JnkΔhepa livers. Interestingly, compared to Jnkf/f livers, mRNA expression of 
pdgfα was strongly increased in JnkΔhepa livers, but no statistical difference was 
found (Fig. 28C).  
Figure 28. Expression of proinflammatory cytokines in JnkΔhepa mice after 
DEN/TAA. After DEN/TAA treatment, 26-week-old mice were sacrificed and analyzed 
for markers of inflammation. A-D) Total mRNA was isolated from the indicated livers, 
and the mRNA expression levels of Tgf-β1, Tnf-α, pdgfα and IL-6 were examined by 
qRT-PCR (n=6). Date were represented as the mean ± SEM and graphed (*p <0.05; 
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6.26 Markers of biliary epithelial cells are strongly activated 
in JnkΔhepa livers, after DEN/TAA 
We next investigated markers of cholangiocytes. Typical markers of 
cholangiocytes or oval cells were detected, including CK19, SOX9, YAP1, 
MUC1, MUCIN2 and CD133, accompanied with expression of 
cholangiocarcinoma/tumor-enriched marker such as Dmbt1134. First, CK19, 
SOX9 and MUCIN2 were detected via IHC staining, which showed upregulation 
around the areas of ductogenesis or oval cell reaction triggered by DEN/TAA 
compared to vehicle groups. CK19, SOX9 and MUCIN2 were significantly 
upregulated in JnkΔhepa compared with Jnkf/f livers (Fig. 29A-C). Expression of 
mRNA Ck19 was upregulated 2-fold in JnkΔhepa mice compared to Jnkf/f mice. 
After DEN/TAA treatment, mRNA Ck19 was increased 2.5-fold in Jnkf/f mice and 
was significantly upregulated 4-fold in JnkΔhepa mice, in line with expression of 
CK19 in IHC and WB (Fig. 29D, J). Additionally, expression of mRNA Yap1 was 
upregulated 2-fold in JnkΔhepa mice, compared to Jnkf/f mice. After DEN/TAA, 
Yap1 expression increased 4-fold in Jnkf/f mice, while it was significantly 
upregulated 5.9-fold in JnkΔhepa mice (Fig. 29E). Typical biomarkers of 
cholangiocyte/BECs and cholangiocarcinoma/tumor-enriched were evaluated 
by qRT-PCR, such as CD133, MUC1, ErbB2 and Dmbt1. Interestingly, after 
treatment with DEN/TAA, expression of these four markers, was strongly 
upregulated in JnkΔhepa mice compared to vehicle group, CD133 expression 
increased 5.3-fold, MUC1 increased 35.2-fold, ErbB2 increased 152.2-fold, 
Dmbt1 increased 160-fold, separately (Fig. 29F-I). These results suggested 
that oval cells or Cholangiocyte/BECs were significantly activated in JnkΔhepa 
mice after DEN/TAA treatment. Overexpression of cholangiocyte markers 
including CK19, YAP1, MUC1, MUCIN2 as well as CD133, accompanied with 
expression of cholangiocarcinoma/tumor-enriched marker Dmbt1 and ErbB2, 
together with the accumulation of SOX-9 positive cells in JnkΔhepa liver after 
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challenged with DEN/TAA, suggested that DEN/TAA might induce 
mesenchymal epithelial transition in mice with hepatocyte-specific deletion of 
Jnk1/2. 
Figure 29. Cholangiocytes/BECs or oval cells were strongly activated in JnkΔhepa 
mice by challenged with DEN/TAA. A) Representative IHC staining for biomarker of 
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MUCIN2. Scale bars, 100µm. D-I) Expression of mRNA Ck19, as well as Yap1, Muc1, 
ErbB2, Dmbt1 and CD133 were investigated by qRT-PCR, (#p <0.05; **/##p <0.01; 
###p <0.001; ****/####p <0.0001). J) Protein of CK19 was shown by WB. Numbers 
were denoted as the molecular weight (KDa) of proteins. GAPDH served as loading 
control. 
6.27 Involvement of the Notch signaling pathway in 
DEN/TAA-induced liver damage in JnkΔhepa livers 
The Notch and Wnt/β-Catenin signaling pathway involved and played a vital 
role in the development of CCA135. Activation of the Notch and Wnt signaling 
pathways stimulate the proliferation of the hepatic progenitor cell compartment. 
In particular, Notch signaling is related to the cell fate of BECs, while Wnt can 
trigger the differentiation toward hepatocytes136. Since conversion of oval cells 
to biliary epithelial cells requires Notch signaling135, we assessed the relevance 
of Notch1 (A6) in each mice group via IHC staining. At the same time, 
expression of mRNA Notch 1/3 accompanied with the ligand Jag1, and target 
effectors of Notch signaling Hes1 and Hey1, as well as HeyL were detected via 
qRT-PCR (Fig. 30). Interestingly, Notch1/A6 staining was positive in clusters of 
immune cells as well as combined with ductular dilation in JnkΔhepa livers. 
Compared to vehicle groups, livers sections stained for A6 by IHC were 
obviously detected in both Jnkf/f and JnkΔhepa mice challenged with DEN/TAA, 
and positive A6 cells were strongly activated in JnkΔhepa mice. This revealed a 
strong activation of oval cells as indicated by overexpression of A6 positive cells 
in JnkΔhepa liver, less evident in Jnkf/f livers (Fig. 30A). This effect was mediated 
by the upregulation of Notch1/3 expression accompanied by upregulated Jag1 
expression which was linked to the modulation of the transcription factors Hes1 
and Hey1 through fold change of mRNA, but decreased in HeyL expression in 
JnkΔhepa mice after challenge with DEN/TAA (Fig. 30B-G). Simultaneously, 
protein expression of phospho-β-Catenin and β-catenin from whole liver 
extracts of each group mice were examined by WB. Overexpression of p-β-
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Catenin was detected in Jnkf/f mice, but decreased in JnkΔhepa mice after treated 
with DEN/TAA (Fig. 30H). Overall, these findings suggested that deletion of 
Jnk1/2 in hepatocytes combined with chronic spontaneous hepatocytes 
damage induced a regenerative response with compensatory hepatocyte 
proliferation and activation of cholangiocyte of oval cells via Notch and Wnt/β-
Catenin signaling pathway, eventually triggering the formation of CCA. 
Figure 30. Activation of Notch and Wnt/β-Catenin in JnkΔhepa mice. A) 
Representative IHC staining for biomarker of oval cells Notch1/A6, was evaluated by 
IHC staining after DEN/TAA, compared to vehicle group. Scale bars, 100μm. B-G) 
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downstream effectors of Notch signaling Hes1 and Hey1, as well as HeyL, were 
detected by qRT-PCR (*/#p <0.05; **/##p <0.01; ***p <0.001; ****/####p <0.0001). H) 
Protein expression of p-β-Catenin and β-Catenin from whole liver extracts of each 
group mice were analyzed by WB with the indicated antibodies. Numbers were 
denoted as the molecular weight (KDa) of proteins. GAPDH served as loading control. 
6.28 The ERK signaling pathway was activated in JnkΔhepa 
mice, after DEN/TAA administration 
As mentioned earlier, DEN/TAA triggered liver tumorigenesis in both Jnkf/f 
and JnkΔhepa mice. Based on loss function of JNK1/2 in hepatocytes, we 
detected the expression of MAPK/JNKs signaling pathway. After the treatment 
of DEN/TAA, overexpression of pJNK1 and pJNK2 were detected from whole 
liver extracts of the Jnkf/f mice via WB, but without expression in JnkΔhepa mice. 
Simultaneously, WB analysis for pERK1/2 showed increased expression of 
proteins in JnkΔhepa livers compared to the Jnkf/f animals (Fig. 31). Collectively, 
activation of ERK signaling pathway might be involved in the formation of liver 
tumor in JnkΔhepa mice, after DEN/TAA. 
Figure 31. Overexpression of ERK1/2 is characteristic of mice with compound 
Jnk1/2 deletion in hepatocytes after DEN/TAA treatment. Male 26-week-old mice 
were sacrificed and analyzed under the treatment of DEN/TAA. Protein expression of 
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Numbers were denoted as the molecular weight (KDa) of proteins. GAPDH served as 
loading control. 
 6.29 c-MYC plays a role of carcinogens in the formation of 
CCA in JnkΔhepa mice 
 In our project, we pursued to create new animal model mimicking CCA for 
further mechanism study. In the DEN/TAA experiment group, expression of 
protein c-MYC was demonstrated in IHC staining together with expression of 
mRNA c-Myc by qRT-PCR. Simultaneously, tumor suppressor Klf6 and p21 
which has been shown to prevent cell cycle arrest and promote DNA repair 
gene, thus acting as tumor suppressor132, 133, expression of mRNA Klf6 and p21 
was tested by qRT-PCR (Fig. 32C, E). C-MYC protein expression was 
characteristic of JnkΔhepa compared to Jnkf/f livers after DEN/TAA. However, in 
vehicle groups, IHC staining was negative (Fig. 32A). Parallel to this, 
expression of mRNA c-Myc upregulated in experimental groups compared to 
vehicle groups, and more significantly in JnkΔhepa mice, in line with the 
expression of c-MYC (Fig. 32D). Glutamine synthetase(GS), a diagnostic 
biomarker of HCC in human137, has been shown by IHC staining compared with 
each group after the treatment of DEN/TAA. Expression of GS has been shown 
in both Jnkf/f mice and JnkΔhepa mice. After DEN/TAA, the characteristics of map-
like structure positive area nearly disappear instead of mosaic GS expression. 
However, positive GS also appeared around the hyperplastic and dilated 
cholangioma-like cells in JnkΔhepa mice after DEN/TAA (Fig. 32B). Positive GS 
was calculated via ImageJ and graphed (Fig. 32F). Furthermore, markers of 
carcinogenesis including Klf6 and p21, expression of mRNA Klf6 and p21 were 
increased in both Jnkf/f mice and JnkΔhepa mice after DEN/TAA administration, 
but strongly upregulated in Jnkf/f mice (Fig. 32C, E). Taken together, 
overexpression of c-MYC is involved in promoting the formation of CCA in 
JnkΔhepa mice, which may present as carcinogenesis in chronic liver injury. 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 129 / 179 
 
However, biomarkers of Klf6 and p21 may play as tumor suppressors in the 
formation of CCA after deletion of Jnk1/2 in hepatocytes. 
Figure 32. Carcinogenesis in JnkΔhepa mice. A-B) Representative images of paraffin 
liver sections staining for c-MYC and GS were evaluated by IHC. Scale bars, 100µm. 
C-E) Expression of mRNA Klf6 was detected by qRT-PCR, as well as c-Myc and p21. 
F) Quantification of positive GS area was detected via ImageJ. Data were represented 
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6.30 Protumorigenic and profibrogenic effect of DEN/CCl4 
in Jnkf/f and JnkΔhepa mice  
 To confirm that tumorigenesis in JnkΔhepa mice occurs in a proinflammatory 
setting, we subsequently used a second experimental model whereby these 
factors are induced by a single injection of DEN (25mg/Kg) followed by 
repeated administration of CCl4 (0.5ml/Kg). After the administration of DEN and 
CCl4, a significant increase in the incidence of liver tumors was observed, and 
100% of wild type B6C3F1/J mice developed liver tumors, at 5 months of age138. 
DEN, a fixed concentration of 25mg/Kg, was chosen to IP injection in 
experimental group mice on the 14th day postpartum. Subsequently, mice were 
repeated with CCl4 approach to IP injection at a fixed concentration of 0.5ml/kg 
twice per week. Mice were sacrificed at a 22-week, liver and blood were 
collected; nodules grown on the surface of the liver were annotated as well. 
Histopathology of the liver, serum parameters, as well as LW/BW ratio was also 
examined (Fig. 33A-G). Compared to the vehicle groups, similar visible nodules 
≥ 5 mm in diameter were detected, as well as a similar total number of liver 
nodules, in both Jnkf/f and JnkΔhepa mice after the treatment of DEN/CCl4. 
Compared to vehicle groups, LW was increased but BW decreased in Jnkf/f and 
JnkΔhepa after DEN/CCl4 treatment (Fig. 33C-D). Thus, DEN/CCl4 increased 
LW/BW in JnkΔhepa albeit no differences in tumorigenesis (Fig. 33E). 
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Figure 33. Effect of DEN/CCl4 in Jnkf/f and JnkΔhepa mice. A) 8-week-old Jnk
f/f and 
JnkΔhepa male mice were used for the experiments with the administration of CCl4 
(0.5ml/Kg, IP) twice per week after they received IP injections with a fixed dose DEN 
(25mg/Kg) at day 14 postnatally. B) Macroscopic pictures of the livers were taken. C) 
BW, D) LW and E) LW/BW ratio of mice and control littermates were calculated. F) 
Tumor burden for each individual mouse was characterized by calculating total number 
of visible tumors ≥ 5 mm in diameter and graphed. G) Total number of nodules were 
calculated and data was represented as the mean ± SEM and graphed (*p <0.05).  
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6.31 Histology and pathology in Jnkf/f and JnkΔhepa mice 
after DEN/CCl4 
Histopathological examination of the livers was performed using H&E 
staining. Significantly proliferation of cholangiocytes combined with dilated 
ductular tracts in JnkΔhepa mice group was visible, while abnormally 
differentiated hepatocytes were characteristic of Jnkf/f livers (Fig. 34A). No 
statistical differences in serum ALT and AST were found between Jnkf/f and 
JnkΔhepa mice (Fig. 34B-D). However, LDH was significantly decreased in 
JnkΔhepa compared with Jnkf/f mice indicating that hepatocyte damage might be 
enhanced in JnkΔhepa mice after DEN/CCl4 treatment. 
Figure 34. Histology and liver damage in Jnkf/f and JnkΔhepa mice, after DEN/CCl4.  
A) Representative images of liver sections with the indicated phenotypes that were 
stained with H&E. Scale bars, 100µm. B-D) Analysis of serum levels of ALT, AST and 
LDH from 22-week-old mice were accessed. Data were represented as the mean ± 
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6.32 Cell death and compensatory prolifreaton in Jnkf/f and 
JnkΔhepa mice, after DEN/CCl4 treatment 
First, TUNEL staining was analyzed to detect cell death in each group, 
photographs were taken and results calculated. Moreover, and according to the 
alteration pathological structure of the liver after DEN/CCl4, Ki 67 and PCNA 
staining were performed, accompanied by SR to detect the degree of fibrosis. 
Positive TUNEL-cells, Ki 67-cells and SR positive area were calculated and 
graphed (Fig. 35). After DEN/CCl4, TUNEL staining suggested that cell death 
increased both in Jnkf/f mice and JnkΔhepa mice. Compared to Jnkf/f mice, cell 
death was strongly elevated in JnkΔhepa mice challenged with DEN/CCl4 (Fig. 
35A, F). This was in line with the expression of SR staining, which showed that 
SR positive area trended towards an increase in JnkΔhepa compared with Jnkf/f 
mice (Fig. 35E, H). Expression of Ki 67 suggested that positive Ki 67-cells were 
increased to approximately 21.5% in Jnkf/f liver, and nearly 10.7% positive Ki 
67 cells were detected in JnkΔhepa liver challenged with DEN/CCl4 (Fig. 35B-C, 
G). Additionally, expression of protein PCNA was analyzed via IHC. Compared 
to vehicle groups, overexpression of PCNA was demonstrated in both Jnkf/f and 
JnkΔhepa groups after the treatment of DEN/CCl4 (Fig. 35D). Altogether, these 
results showed that there were no differences in cell death or compensatory 
proliferation but a stronger fibrotic response in JnkΔhepa mice. 
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Figure 35. Cell death and compensatory proliferation in Jnkf/f and JnkΔhepa mice 
after DEN/CCl4. A) Cell death was evaluated using TUNEL staining in both Jnk
f/f and 
JnkΔhepa mice groups. Expression of Ki 67 was analyzed and graphed by both B) IF 
staining and C) IHC staining. IF Scale bars, 50μm. IHC Scale bars, 100μm. D) 
Expression of PCNA presented via IHC staining. Scale bars, 100μm. E) 
Representative SR staining of paraffin sections from the indicated livers after 
DEN/CCl4 as well as vehicle groups mice. Scale bars, 500µm. F) Positive TUNEL-cells, 
G) positive-Ki 67 cells and H) SR positive area was calculated, data were represented 
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6.33 Hyperproliferation of BECs and increased cytokine 
signaling are characteristic of JnkΔhepa mice, after DEN/CCl4 
 Expression of CK19 was investigated using IHC staining. Compared to Jnkf/f 
mice, expression of this cholangiocytes marker was upregulated in JnkΔhepa 
livers, after DEN/CCl4, whereas in normal conditions CK19 stains BECs (Fig. 
36A). Furthermore, expression of mRNA Ck19 was in line with the IHC stain for 
CK19 (Fig. 36B). We therefore evaluated the expression level of inflammatory 
cytokines/chemokines, such as TNF-α and TGF-β1 by qRT-PCR. Both 
cytokines were strongly upregulated in experimental groups, compared to 
vehicle groups, especially significantly increased in JnkΔhepa livers. After 
DEN/CCl4 treatment, expression of mRNA Tnf-α was upregulated 12-fold in 
Jnkf/f mice, and strongly increased 18-fold in JnkΔhepa animals (Fig. 36C). 
Similarly, expression of mRNA Tgf-β1 was upregulated 27.3-fold in Jnkf/f mice, 
and significantly increased 105-fold in JnkΔhepa animals challenged with 
DEN/CCl4 (Fig. 36D). These results suggested that BECs hyperproliferation 
and a proinflammatory milieu are characteristic of JnkΔhepa after DEN/CCl4 
treatment. 
Figure 36. Hyperproliferation of BECs and increased cytokine signaling are 
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liver sections for CK19 by IHC staining. Scale bars, 100µm. B) Expression of mRNA 
Ck19 was investigated by qRT-PCR, as well as F) Tnf-α, G) Tgf-β1. Data were 
represented as the mean ± SEM and graphed (#p <0.05; ****/####p <0.0001).  
 
Collectively, JNKs adjust cell fate during liver carcinogenesis and play a vital 
role in balancing the differentiation and transformation of hepatocytes and 
cholangiocytes. This is essential for driving epithelial-mesenchymal transition 
(EMT) to induce the transdifferentiation of oval cells into cholangiocytes/BECs, 
and the formation of large-scale ducto/cystogenesis with common molecular 
characteristics of CCA (Fig. 37). 
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Figure 37. JNK1/2 play a vital role in balancing hepatic cell fate. Deletion of Jnk1/2 
in hepatocytes induces liver biliary hamartoma accompanied with liver dysfunction, 
related to hepatocellular vacuolation and exacerbated hyperproliferation of 
cholangiocyte/BECs via activation of ER-stress, eventually triggering multiple liver 
cysts. Overexpression of JNKs promotes the formation of HCC, while loss function of 
Jnk1/2 in hepatocytes promotes the excessive proliferation of cholangiocyte/BECs and 
the expansion of the bile duct lumen, eventually leading to the formation of CCA in 
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HCC and CCA are the two most common types of hepatic malignancies. Both 
of them have increased in incidence year by year. HCC is the fifth most common 
malignant tumor in Western countries. While the incidence of CCA is on the rise, 
up to 2.1 cases per 100,000 people in Western countries. Especially CCA, the 
cancer of the gallbladder and the biliary tract is nowadays a matter of 
tremendous concern. Lacking specific biomarkers make diagnosis difficult in 
early stages. The prognosis of CCA is miserable and surgery is the only 
effective treatment, but vast majority of patients with advanced disease and 
recurrence after resection are common. At the same time, CCA lacks the 
sensitivity of radiotherapy and chemotherapy, which has become a worldwide 
problem in clinical diagnosis and treatment. Patients who have been diagnosed 
with CCA and undergo radical surgery with 5-year survival are considered to be 
fortunate. Despite the diversity of treatment options, the 5-year survival rate of 
CCA has not been increased, remains only 5-10%, which has not significantly 
changed during the last 30 years56, 139. 
Recent progress has led to a deeper understanding of the role of MAPKs 
signaling pathways in liver tumor diseases. Among them, the JNKs signaling 
pathway involved in the development of CCA is not yet clear. Previously study 
showed that JNK plays an important role in regulating the interaction between 
different pro-apoptotic proteins and anti-apoptotic proteins in response to 
external and internal apoptotic stimuli95. Based on the spontaneous progression 
of JnkΔhepa mice to multiple dilated cysts with age, we used improved CCA 
animal models to explore the important role of JNKs/MAPKs signaling pathways 
involved in the pathogenesis of CCA (Fig. 44).  
Although the exact potential risk factors and molecular mechanisms of CCA 
have not been accurately identified, at least our research results give a potential 
direction. JNKs/MAPKs may become therapeutic targets for the treatment of 
CCA. 
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7.1 Loss function of JNK1/2 in hepatocytes triggers liver 
hamartoma with age in mice through ER-stress. 
 Fibrocystic liver disease is a type of disease associated with autosomal gene 
mutations, including PLD, Caroli's disease and CHF, characterized by the 
presence of multiple liver cysts of different shape and size filled with cystic fluid 
in normal liver tissue. PLD is usually associated with autosomal dominant 
polycystic kidney disease, with a prevalence ranging from 1/1,000,000-1/400, 
and about 8-10% of the patients have polycystic kidney disease41. Current 
research and effective treatments are limited. Even existing drugs can improve 
the symptoms of early patients, but they cannot prevent the progress of the 
disease. Liver transplantation is considered to be the most effective treatment 
at present. The previous PCK rat model140 provides a lot of suggestion to the 
study of PLD, but still no breakthrough progress yet.  
In our study, we specifically knocked out the Jnk1/2 gene of mouse 
hepatocytes to promote their spontaneous progress into multiple liver cysts, 
maybe create a new animal model of PLD (Fig. 5-11). This not only provides a 
new animal model of PLD, but also expands our research direction. However, 
related genes and chromosomes still need to be further explored and clarified. 
Loss function of JNK1/2 in hepatocytes, we tried to detect the possible signaling 
pathway linked to JNKs/MAPKs. Overexpression of Bip/eIF2α/Chop, interacted 
with XBP1s but not IRE1α, showed us a new direction of activation of ER-stress 
(Fig. 12). We hypothesis that loss function of JNK1/2 in hepatocytes. The 
deposition of fibrosis is based on a paracrine interaction, which is mediated by 
the ability of RDC to secrete profibrotic and proinflammatory growth factors, 
including TNF-α141.  
Coincidentally, TGF-β is a key mediator in hepatic fibrogenesis142, while 
TGFβ also induces JNKs/MAPKs signaling pathways via independently of 
Smads143. In the process of liver fibrosis, TGF-β is a main factor to secrete and 
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activate HSCs by fibroblasts and macrophages, and is responsible for 
depositing about 80% of the matrix protein20. As a response to injury, HSCs was 
converted to MF, which is characterized by new expression of αSMA, sensitivity 
to fibrogenic, and active secretion of ECM protein14. Here, we express the ER-
stress signaling pathway activated by highly expressed upstream factors TNF-
α or/and TGF-β. At the same time, overexpression of fibrosis biomarker αSMA 
also provides evidence of cholangiocellular hyperproliferation in JnkΔhepa mice 
group.  
All these data results supported our view that the lack of Jnk1/2 in 
hepatocytes, continuing activation of ER-stress combined with activated Bip, 
contribute to promoting the progression of biliary hamartoma with age in mice. 
7.2 Loss function of JNK1/2 in hepatocytes suppress HCC 
formation but promotes the progression of CCA. 
Previously studies showed, JNKs/MAPKs signaling pathway was thought to 
play a significant role in the development of HCC88. Das et cl90 suggested that 
JNK play a dual role in the development of hepatocellular carcinoma. While, the 
results of another study suggested that lack of JNK1 or JNK2 in hepatocytes 
may increase the tumor development, and the pro-tumor effect of JNK on HCC 
is related to inflammation91. Coincidentally, other data indicated that the JNKs, 
particularly JNK1, contribute to malignant transformation and tumor growth 92. 
Possibly, JNK1 has a larger role than JNK2 in development of liver tumor 93.  
Based on this information, we tried to treat these mice in approach to different 
methods as described above, in order to validate the relevance of JNK1/2 in 
mediating the shift from HCC to CCA. Sustained activation of JNKs/MAPKs 
promoted the formation of HCC was proved by H&E and IHC staining, as well 
as WB (in TAA and DEN/TAA groups). As seen the photographs presented in 
H&E staining, histopathology characteristic structure of the livers was obviously 
different between Jnkf/f mice and JnkΔhepa mice after the treatment of drugs, 
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including TAA, DEN/TAA, DEN/CCl4. It looks more significant proliferation of 
cholangiocytes combined with obvious fibrosis when loss function of JNK1/2 in 
hepatocytes according to the expression of biomarkers of BECs (including 
SOX9, CK19, Notch1 and MUCIN2), and fibrosis detection approach to Sirius 
Red staining (Fig. 16, 27, 29, 35). 
Furthermore, under the administration of TAA/DEN+TAA, GS, which was one 
biomarker of HCC, showed map-like structure in normally liver area near the 
hepatic vein, but this characteristic performance was nearly disappeared in 
Jnkf/f mice, whilst overexpression positives dyed marked on the 
hyperproliferative cholangiocytes in JnkΔhepa liver (such as CK19, SOX9, 
Notch1 and MUCIN2). At the same time, the investigations of mRNA Dmbt1, 
Gabrp, ErbB2 and Muc1 have been identified as oval cell/BECs markers in 
rodent, as well as CCA-enriched genes134, 144 that were coincide with related 
expression of protein, such as Notch1, CK19, SOX9 and MUCIN2. These 
results suggested that the contribution of activated BECs in the 
cholangiocellular hyperproliferation was promoted in JnkΔhepa animals. 
Considering that CCA tissues are characterized by the presence of mucin-
secreting cells, this finding further supports the CCA diagnosis145. As identified 
in our experiments, upregulation of MUCIN2 in IHC staining coincide with 
overexpression of mRNA Muc 1 in JnkΔhepa experimental (DEN/TAA) group. 
Addition, the role of Klf6 in tumor growth regulation has been confirmed through 
a variety of ways. Upregulation of Klf6 in Jnkf/f mice show tumorigenicity in the 
HCC development progress, through developing liver damage (cirrhosis) via 
the formation of scar tissue146, but depressed in JnkΔhepa experimental (TAA, 
DEN/TAA) mice, which means Klf6 was consumed as tumor suppressor. The 
expression of Klf6 can attenuate the tumorigenicity of glioblastoma in vivo and 
in vitro, and can inhibit cell transformation induced by multiple oncogenes147. In 
line with PAS staining, positive mucins secreted around the hyperplastic 
cholangiocellular and ductular dilation (Fig. 21, 24), suggested that cirrhosis 
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induced in liver disease148.  
We therefore inferred that the lack of expression of JNKs promotes the 
proliferation and migration of hepatocytes to cholangiocytes in chronic liver 
disease. Which also means sustained overexpression of JNKs promotes the 
formation of HCC, but loss function of JNKs can shift to a destination of CCA. 
7.3 Cell death was involved in CCA formation in JnkΔhepa 
mice with chronic liver injury. 
 Regulating cell death is a powerful weapon for host defense. Therefore, we 
continued to investigate the mechanism of cell death in these models since 
these livers were characterized by cell death, inflammatory microenvironment 
or/and ECM deposition.  
Since the 1980s, people have known the importance of mitochondrial 
damage in the pathogenesis of APAP-induced necrosis149. At that time, 
previous studies suggested that the mitochondria of the liver were damaged in 
APAP treated mice, and most importantly caused by activation of MAPKs 
pathway. Interference with various MAPK proteins, including MLK3, ASK1, 
MKK4 and JNK, as well as JNK binding Chaperone SH3BP (Sab) significantly 
prevents APAP-induced hepatocyte death150, 151. 
  In normal liver, the JNKs family is minimally or transiently activated, the latter 
usually physiological, whereas sustained activation is pathological. In addition 
to their central role in hepatic physiological responses (such as cell death, 
apoptosis, and cell cycle regulation) 84, 85, JNKs play a carcinogenic role by 
promoting inflammation, proliferation, invasion, and angiogenesis, depending 
on the specific context and duration of JNK signaling pathway activation 86, 87. 
In hepatocytes, the expansion of the cascade of mitochondrial permeability 
and apoptosis occurs in apoptosis induced by death receptors. This involves 
the release of mitochondrial mediators of apoptosis, which leads to the final 
activation of effector Caspase 3/7, positive feedback amplification of Caspase 
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8 activations. The activation of Caspase and then the resulting apoptosis is a 
highly regulated form of cell death, with multiple checkpoints and molecular 
mediators, which are activated through two different pathways (external 
pathway and internal pathway)152. As demonstrated in our study, Cleaved-
Caspase 3 and Cleaved-Caspase 8 were activated in JnkΔhepa mice, more than 
in Jnkf/f mice after the treatment of TAA or/and DEN/TAA. Which means loss 
function of JNKs in hepatocytes promoted cell death related to apoptosis. 
Furthermore, Receptor-interacting protein kinase (RIP) 3 mediated 
programmed necrosis (RIP) 3 (also known as RIPK3) is activated by death 
receptors, pathogen sensors, interferon receptors, Ag-specific TCR and 
genotoxic stress via an alternative death pathway triggered. Necrosis causes 
cell leakage and acts as a "trap door", and is another kind of programmed cell 
death, independent of caspase activity, also is characterized by membrane 
swelling and rupture mediated by RIP1 and RIP3. Once RIP3 kinase activated, 
following with phosphorylating the downstream member pseudokinase MLKL153, 
154. Finally, phosphorylated MLKL undergoes oligomerization and translocation 
to the cell membrane to perform a necroptosis155 (Fig. 18, 26). According to the 
results that the deletion of JNKs cannot prevent cell death as presented by 
TUNEL staining in vivo. Based on TAA treatment, compared to Jnkf/f mice, 
upregulation of cytokines Cleave-Caspase 3/8 indicated apoptosis activated, 
combined with pRIP1/pRIP3/pMLKL which were evidence of necroptosis 
happened to JnkΔhepa mice. However, caspase-dependent apoptosis was no 
more upregulated in DEN/TAA experiment model, but necroptosis was strongly 
activated according to the detection of protein expression, including pRIP1, 
pRIP3 and pMLKL. 
In total, our results suggested that deletion of Jnk1/2 in hepatocytes, promote 
cell death but not protect liver damage after the external stimulation, eventually 
induced the formation of CCA. 
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7.4 Deletion of Jnk1/2 in hepatocytes promotes 
cholangiocellular hyperproliferation combined with 
strongly activated oval cells  
As cell death was involved in the progression of CCA formation in JnkΔhepa 
mice, liver damage with compensatory proliferation may be promoted via 
cholangiocellular hyperproliferation. One of the main consequences of the 
increased liver cells death is compensatory proliferation to compensate loss of 
liver cells. Compensatory proliferation has been implicated in the progression 
of many types of diseases including HCC 156, 157. In our study, along with the 
increased hepatic cell death in JnkΔhepa after the treatment of TAA or/and 
DEN/TAA or/and DEN/CCL4, quantification of cell proliferation with expression 
of Ki 67 and PCNA via IF and/or IHC demonstrated exacerbated proliferation in 
JnkΔhepa livers. Furthermore, increased proliferation was evident in both 
cholangiocytes and hepatocytes in JnkΔhepa mice, especially cholangiocytes, 
which is consistent with the increased ductular proliferation found in these mice. 
These results were strengthened by detection of cholangiocyte biomarkers, 
such as overexpression of CK19, SOX9, Notch1, Muc1 and MUCIN2 in JnkΔhepa 
mice. In fact, CCA development frequently requires conditions of chronic 
inflammation158,  which was proved by dysregulation of pro-inflammatory 
cytokines including Tgf-β1, Tnf-α and pdgfα in JnkΔhepa livers. At the same time, 
these livers were characterized by cell death, inflammatory microenvironment 
and extracellular matrix deposition. Necroptosis-associated hepatic cytokine 
microenvironment induces the shift from HCC to CCA development 159.  
In parallel with proliferating hepatocytes, marked expansion of the biliary 
epithelium, the liver parenchyma of NEMO∆hepa/JnkΔhepa animals were positive 
for CK19 and SOX9 and negative for HNF4α60. Moreover, CCA lesions were 
characterized by mucin-secreting cells, which might aid in CCA diagnosis145. 
Interestingly, analysis of gene expression showed the occurrence of 
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cholangiocarcinoma/tumor-enriched markers including Dmbt1 and Gabrp not 
only in NEMO∆hepa/JnkΔhepa but also in a second model of liver carcinogenesis, 
the DEN model60. Moreover, the microarray highlighted the pivotal role of 
JNK1/2 in modulating cell fate by promoting hepatocarcinogenesis and under-
regulating cascades linked with cholangiocarcinogenesis. All of these results 
ssuggested that activation of strong proliferation and inflammatory 
microenvironment within the hepatic parenchyma involved in the progress of 
CCA formation after loss function of JNK1/2 hepatocytes in chronic liver 
damage. 
7.5 Carcinogenesis was involved in promoting CCA 
formation in JnkΔhepa mice 
As described previously, Ras/Raf/ERK/MAPKs signaling pathway is helpful 
with contributory to the control of G1 phase. Combined with GSK3β, ERK 
played a key role in the critical phosphorylation of S62/T58 controlling c-MYC 
protein levels160. Overexpression of c-MYC is the cause of complete 
tumorigenesis, especially in the formation of CCA as described by Calvisi DF 
recently129. Similarly, c-MYC is one of the most frequently mutated genes in 
tumors and an important regulator of cell cycle and apoptosis, its dysregulated 
expression could be associated with many malignancies. c-MYC is instrumental 
in directly or indirectly regulating the progression through the G1 phase and 
G1/S transition, and transformation by c-MYC results in the perturbed cell 
cycle130. As previous published, Ki 67, one cellular marker for proliferation and 
is strictly associated with cell proliferation. Ki 67 protein is present in all active 
phases of the cell cycle (G1, S, G2, and mitosis), but not in resting (quiescent) 
cells (G0)161. mRNA of cell cycle Cyclin E1 was demonstrated, evident 
upregulation of Cyclin E1 in JnkΔhepa experimental mice, in line with presentation 
of biomarker Ki 67 in IHC staining (TAA, DEN/TAA, DEN/CCl4) which means 
cell proliferation was activated in cell cycle phase G1, which may be prominent 
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leading to CCA. This was in line with the results in our study that deletion of 
Jnk1/2 in hepatocytes promoted the proliferation of cholangiocytes coincide 
with overexpression of mRNA Cyclin E1 (Fig. 26D). On the other hand, PCNA 
was originally identified as an antigen that is expressed in the nuclei of cells 
during the DNA synthesis phase of the cell cycle, which is very important for 
both DNA synthesis and DNA repair162. 
However, Klf6 (Krüppel-like factor 6) is a transcription factor involved in the 
regulation of several cellular processes, is considered as a tumor suppressor. 
mRNA Klf6 expression was accessed by qRT-PCR. After the treatment of 
TAA/DENTAA, Klf6 expression significantly upregulated in Jnkf/f mice, while 
exhibited in JnkΔhepa mice as described above (Fig. 22C, 32C). This was in live 
with expression of p21, functioned as a regulator of cell cycle progression and 
acting as tumor suppressor132, 133. According to these results, we speculated 
that mice loss function of JNK1/2 in hepatocytes were promoted CCA formation 
by activated c-MYC, but may be extenuated by tumor suppressor Klf6 and p21.  
Collectively, c-MYC plays as carcinogen in the formation of CCA, combined with 
dysregulation of cell cycle in chronic liver injury.  
7.6 Deletion of Jnk1/2 in hepatocytes contribute HPCs to 
bile duct repair via EMT transition in the formation of CCA. 
Previously, cholangiocytes may be involved in liver fibrosis 67. During acute 
and chronic cholestasis, liver fibrosis involving an increasing number of 
ductulus, is accompanied by polymorphonuclear leukocyte infiltration and 
increased extracellular matrix deposition, leading to periportal fibrosis and 
finally PBC163. Diaz et al. 164 presented histological data suggesting that EMT 
occurs in human liver fibrosis, particularly in diseases associated with 
prominent bile ductular proliferation including biliary atresia and PBC. Other 
studies indicated that cholangiocellular hyperproliferation play a vital role in the 
induction of fibrosis via EMT 67, 165, 166. So that, EMT may also play an important 
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role in CCA progression, accompanied with dysregulation of JNKs/MAPKs 
signaling pathway. 
EMT is critical then for embryonic development, wound healing, stem cell 
biology - and plays a key role in the tumorigenic process64, 65. The first change 
occurs when epithelial cells lose cell–cell adhesions (at specialized adherent 
junctions) with the disruption of two major components E-cadherin and β-
catenin. We detected the expression of β-catenin via WB and results showed 
dysregulation of the Wnt/β-catenin signaling pathway (Fig. 30H).  
In CCA, developmental changes seen in cholangiocytes may be due to the 
activation of HPCs, the proliferation of bile duct cells, or through ductal 
metaplasia of mature hepatocytes29, 68. However, alongside the progress seen 
in histopathological studies, there is now a better understanding of the origins 
of BECs. Both HPCs69 and CCA stem cells 66 seem to be capable of 
differentiating into BECs, whilst CCA stem cells can also originate from HPCs 
66, 70, 71. Micrographs of in vivo fate-tracking experiments showed the 
contribution of hepatocytes and HPCs to bile duct repair or hepatocyte injury. 
In order to cope with biliary tract injury, signals derived from myofibroblasts 
mediate the activation and proliferation of the HPCs niche. This process can be 
triggered by NOTCH signal transduction, via Jag1, a NOTCH ligand provided 
by the stroma of the portal vein, which induces the differentiation of hepatocytes 
into BECs167-169. As seen in our results presented in Figure 30, which was in 
line with the studies previously published. These results indicate that CCA can 
be derived from common HPCs, which can differentiate into both hepatocytes 
and cholangiocytes 72, 73. Also, chronic inflammatory processes can promote 
the development of CCA by affecting BEC function and proliferation 170, 171.     
Interestingly, upregulation of mRNA dmbt1, muc1 and Gabrp was found in 
experimental group, especially in JnkΔhepa mice, these results also indicated that 
EMT may be modulated through a JNK-dependent mechanism. In line with 
CCA development, at the biochemical level, various morphogenetic and 
environmental signals including TGF-β, WNT, EGFR, and PDGF, inflammatory 
cytokines and integrin receptor ligands promote EMT 74, 75. Furthermore, TGF-
β is also involved in several steps of cancer progression, from tumorigenesis to 
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metastasis, which promotes cancer cell invasion and metastasis through an 
EMT process, although at later stages 76-80.  
The canonical TGF-β pathway relies on the downstream SMAD family172. 
Interestingly, JNK-induced phosphorylation of R-SMAD can activate the EMT 
programming process. Both JNK and p38 can synergize with SMADs to 
promote non-canonical TGF-β-induced apoptosis74, 81, 173, 174. In SMAD-
independent pathways, TGF-β can also induce AKT phosphorylation and 
rapidly activate PI3K, which is possibly involved in SMAD2-induced EMT175. 
Studies on keratinocytes indicate that the PI3K/AKT pathway contributes to 
completion of TGF-β-induced SMADs-dependent EMT. Therefore, we 
examined the expression of protein ERK1/2 in each group.  
As the results showed, loss function of JNK1/2 in hepatocytes triggered the 
activation of ERK/MAPKs signaling pathway in our experiment model, which 
was in line with previous studies suggested that ERK/MAPKs pathway 
contributes to EMT induction, as ERK is required to remove cell adhesion 
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We summarized a novel function of JNK1/2 in cholangiocyte/BECs 
hyperproliferation and transdifferentiation, aiming to open the new pathways 
involved in the targeted inhibition of CCA formation.  
1） JNKs play an important role in hepatic cell fatal of transdifferentiation, 
inhibit JNK signaling pathway via DJNKI1 could revert hepatoblasts 
transdifferentiation.  
2） Deletion of Jnk1/2 in hepatocytes induces liver biliary hamartoma 
accompanied with liver dysfunction, related to hepatocellular 
vacuolation and exacerbated proliferation of cholangiocyte/BECs 
combined with exacerbated liver fibrosis, triggering multiple liver cysts. 
3） Prominent activation of necroptosis combined with strong 
proinflammatory milieu were induced in mice after the deletion of 
Jnk1/2 in hepatocytes in chronic liver injury.  
4） Overexpression of JNKs promotes the formation of HCC, while loss 
function of Jnk1/2 in hepatocytes promotes the excessive proliferation 
of cholangiocyte/BECs and the expansion of the bile duct lumen, 
eventually leading to the formation of CCA in chronic liver disease.  
5） Activation of c-MYC may promote the formation of CCA while 
biomarkers of Klf6 and p21 may play as tumor suppressors after 
deletion of Jnk1/2 in hepatocytes in chronic liver injury. 
6） JNKs adjust cell fate during liver carcinogenesis and play a vital role 








ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 156 / 179 
 
  
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
























ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 158 / 179 
 
  
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 159 / 179 
 
1. Lindor, T. B. K., Zakim and Boyer's Hepatology 7th Edition. Elsevier 2017, 1072. 
2. Launois, B.;  Jamieson, G. G.;  Cherqui, D.;  Randone, B.;  Gayet, B.; Machado, M. 
A. C., The Posterior Intrahepatic Approach in Liver Surgery. Springer: 2013. 
3. Chamberlain, R. S., Essential functional hepatic and biliary anatomy for the surgeon. 
Hesham A. Hepatic surgery. Newark, NJ: InTech 2013, 41-60. 
4. Corness, J. A.;  McHugh, K.;  Roebuck, D. J.; Taylor, A. M., The portal vein in children: 
radiological review of congenital anomalies and acquired abnormalities. Pediatr Radiol 2006, 
36 (2), 87-96, quiz 170-1. 
5. Couinaud, C., Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg 
1999, 16 (6), 459-67. 
6. Lehman-McKeeman, L. D., Absorption, distribution, and excretion of toxicants. Cassarett 
and Doull’s Toxicology: The Basis Science of Poisons 2008, 131-159. 
7. Dooley, J. S.;  Lok, A. S.;  Garcia-Tsao, G.; Pinzani, M., Sherlock's diseases of the liver 
and biliary system. John Wiley & Sons: 2018. 
8. Gumucio, J. J., Structural and functional organization of the liver. Liver and Biliary 
Disease 1996, 3-19. 
9. Schleicher, J.;  Tokarski, C.;  Marbach, E.;  Matz-Soja, M.;  Zellmer, S.;  Gebhardt, 
R.; Schuster, S., Zonation of hepatic fatty acid metabolism—the diversity of its regulation and 
the benefit of modeling. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of 
Lipids 2015, 1851 (5), 641-656. 
10. Tacke, F.; Weiskirchen, R., Update on hepatic stellate cells: pathogenic role in liver 
fibrosis and novel isolation techniques. Expert review of gastroenterology & hepatology 2012, 
6 (1), 67-80. 
11. Braet, F.;  Taatjes, D. J.; Wisse, E., Probing the unseen structure and function of liver 
cells through atomic force microscopy. Semin Cell Dev Biol 2018, 73, 13-30. 
12. Wisse, E., Ultrastructure and function of Kupffer cells and other sinusoidal cells in the 
liver. 1977. 
13. Klaas, M.;  Kangur, T.;  Viil, J.;  Maemets-Allas, K.;  Minajeva, A.;  Vadi, K.;  Antsov, 
M.;  Lapidus, N.;  Jarvekulg, M.; Jaks, V., The alterations in the extracellular matrix 
composition guide the repair of damaged liver tissue. Sci Rep 2016, 6, 27398. 
14. Mallat, A.; Lotersztajn, S., Cellular mechanisms of tissue fibrosis. 5. Novel insights into 
liver fibrosis. Am J Physiol Cell Physiol 2013, 305 (8), C789-99. 
15. Sørensen, K. K.; Smedsrød, B., The liver sinusoidal endothelial cell: basic biology and 
pathobiology. The Liver: Biology and Pathobiology 2020, 422-434. 
16. Jenne, C. N.; Kubes, P., Immune surveillance by the liver. Nat Immunol 2013, 14 (10), 
996-1006. 
17. Cheung, A. C.;  Lorenzo Pisarello, M. J.; LaRusso, N. F., Pathobiology of biliary 
epithelia. Biochim Biophys Acta Mol Basis Dis 2018, 1864 (4 Pt B), 1220-1231. 
18. Elborn, J. S., Cystic fibrosis. Lancet 2016, 388 (10059), 2519-2531. 
19. Bilzer, M.;  Roggel, F.; Gerbes, A. L., Role of Kupffer cells in host defense and liver 
disease. Liver Int 2006, 26 (10), 1175-86. 
20. Kisseleva, T.; Brenner, D. A., Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 
2008, 233 (2), 109-22. 
21. Kieffer, D. A.;  Martin, R. J.; Adams, S. H., Impact of Dietary Fibers on Nutrient 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 160 / 179 
 
Management and Detoxification Organs: Gut, Liver, and Kidneys. Adv Nutr 2016, 7 (6), 1111-
1121. 
22. Carpentier, R.;  Suner, R. E.;  van Hul, N.;  Kopp, J. L.;  Beaudry, J. B.;  Cordi, S.;  
Antoniou, A.;  Raynaud, P.;  Lepreux, S.;  Jacquemin, P.;  Leclercq, I. A.;  Sander, M.; 
Lemaigre, F. P., Embryonic ductal plate cells give rise to cholangiocytes, periportal 
hepatocytes, and adult liver progenitor cells. Gastroenterology 2011, 141 (4), 1432-8, 1438 
e1-4. 
23. Boyer, J. L., Bile formation and secretion. Compr Physiol 2013, 3 (3), 1035-78. 
24. Itoh, T., Stem/progenitor cells in liver regeneration. Hepatology 2016, 64 (2), 663-8. 
25. Banales, J. M.;  Huebert, R. C.;  Karlsen, T.;  Strazzabosco, M.;  LaRusso, N. F.; 
Gores, G. J., Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol 2019, 16 (5), 269-
281. 
26. Jensen, J. M.;  Brix, F.; Kohr, P., General and specific aspects of experimental dose 
measurement in total body irradiation (TBI). Strahlenther Onkol 1986, 162 (4), 250-3. 
27. Mederacke, I.;  Hsu, C. C.;  Troeger, J. S.;  Huebener, P.;  Mu, X.;  Dapito, D. H.;  
Pradere, J. P.; Schwabe, R. F., Fate tracing reveals hepatic stellate cells as dominant 
contributors to liver fibrosis independent of its aetiology. Nat Commun 2013, 4, 2823. 
28. Raynaud, P.;  Carpentier, R.;  Antoniou, A.; Lemaigre, F. P., Biliary differentiation and 
bile duct morphogenesis in development and disease. Int J Biochem Cell Biol 2011, 43 (2), 
245-56. 
29. Roskams, T. A.;  Theise, N. D.;  Balabaud, C.;  Bhagat, G.;  Bhathal, P. S.;  Bioulac-
Sage, P.;  Brunt, E. M.;  Crawford, J. M.;  Crosby, H. A.;  Desmet, V.;  Finegold, M. J.;  
Geller, S. A.;  Gouw, A. S.;  Hytiroglou, P.;  Knisely, A. S.;  Kojiro, M.;  Lefkowitch, J. H.;  
Nakanuma, Y.;  Olynyk, J. K.;  Park, Y. N.;  Portmann, B.;  Saxena, R.;  Scheuer, P. J.;  
Strain, A. J.;  Thung, S. N.;  Wanless, I. R.; West, A. B., Nomenclature of the finer branches 
of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004, 
39 (6), 1739-45. 
30. Franchitto, A.;  Onori, P.;  Renzi, A.;  Carpino, G.;  Mancinelli, R.;  Alvaro, D.; 
Gaudio, E., Recent advances on the mechanisms regulating cholangiocyte proliferation and 
the significance of the neuroendocrine regulation of cholangiocyte pathophysiology. Ann 
Transl Med 2013, 1 (3), 27. 
31. Roskams, T. A.;  Libbrecht, L.; Desmet, V. J., Progenitor cells in diseased human liver. 
Semin Liver Dis 2003, 23 (4), 385-96. 
32. Kisseleva, T.; Brenner, D. A., Is it the end of the line for the EMT? Hepatology 2011, 53 
(5), 1433-5. 
33. Zeisberg, M.;  Yang, C.;  Martino, M.;  Duncan, M. B.;  Rieder, F.;  Tanjore, H.; 
Kalluri, R., Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal 
transition. J Biol Chem 2007, 282 (32), 23337-47. 
34. Poncy, A.;  Antoniou, A.;  Cordi, S.;  Pierreux, C. E.;  Jacquemin, P.; Lemaigre, F. P., 
Transcription factors SOX4 and SOX9 cooperatively control development of bile ducts. Dev 
Biol 2015, 404 (2), 136-48. 
35. Mansini, A. P.;  Peixoto, E.;  Thelen, K. M.;  Gaspari, C.;  Jin, S.; Gradilone, S. A., 
The cholangiocyte primary cilium in health and disease. Biochim Biophys Acta Mol Basis Dis 
2018, 1864 (4 Pt B), 1245-1253. 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 161 / 179 
 
36. Medzhitov, R., Origin and physiological roles of inflammation. Nature 2008, 454 (7203), 
428-35. 
37. Masyuk, T.;  Masyuk, A.; LaRusso, N., Cholangiociliopathies: genetics, molecular 
mechanisms and potential therapies. Curr Opin Gastroenterol 2009, 25 (3), 265-71. 
38. Santos-Laso, A.;  Izquierdo-Sanchez, L.;  Lee-Law, P. Y.;  Perugorria, M. J.;  
Marzioni, M.;  Marin, J. J.;  Bujanda, L.; Banales, J. M., New Advances in Polycystic Liver 
Diseases. Semin Liver Dis 2017, 37 (1), 45-55. 
39. van Aerts, R. M. M.;  van de Laarschot, L. F. M.;  Banales, J. M.; Drenth, J. P. H., 
Clinical management of polycystic liver disease. J Hepatol 2018, 68 (4), 827-837. 
40. Masyuk, T. V.;  Masyuk, A. I.; LaRusso, N. F., Polycystic liver disease: The interplay of 
genes causative for hepatic and renal cystogenesis. Hepatology 2018, 67 (6), 2462-2464. 
41. Masyuk, T.;  Masyuk, A.; LaRusso, N., Polycystic Liver Diseases: Genetics, 
Mechanisms, and Therapies. The Liver: Biology and Pathobiology 2020, 408-421. 
42. Cadamuro, M.;  Fiorotto, R.; Strazzabosco, M., Cholangiocyte Biology and 
Pathobiology. The Liver: Biology and Pathobiology 2020, 391-407. 
43. Lorenzo Pisarello, M.;  Masyuk, T. V.;  Gradilone, S. A.;  Masyuk, A. I.;  Ding, J. F.;  
Lee, P. Y.; LaRusso, N. F., Combination of a Histone Deacetylase 6 Inhibitor and a 
Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an 
Animal Model of Polycystic Liver Disease. Am J Pathol 2018, 188 (4), 981-994. 
44. Perugorria, M. J.;  Masyuk, T. V.;  Marin, J. J.;  Marzioni, M.;  Bujanda, L.;  LaRusso, 
N. F.; Banales, J. M., Polycystic liver diseases: advanced insights into the molecular 
mechanisms. Nat Rev Gastroenterol Hepatol 2014, 11 (12), 750-61. 
45. Waanders, E.;  Van Krieken, J. H.;  Lameris, A. L.; Drenth, J. P., Disrupted cell 
adhesion but not proliferation mediates cyst formation in polycystic liver disease. Mod Pathol 
2008, 21 (11), 1293-302. 
46. Masyuk, A. I.;  Masyuk, T. V.;  Lorenzo Pisarello, M. J.;  Ding, J. F.;  Loarca, L.;  
Huang, B. Q.; LaRusso, N. F., Cholangiocyte autophagy contributes to hepatic cystogenesis 
in polycystic liver disease and represents a potential therapeutic target. Hepatology 2018, 67 
(3), 1088-1108. 
47. Banales, J. M.;  Cardinale, V.;  Carpino, G.;  Marzioni, M.;  Andersen, J. B.;  
Invernizzi, P.;  Lind, G. E.;  Folseraas, T.;  Forbes, S. J.;  Fouassier, L.;  Geier, A.;  
Calvisi, D. F.;  Mertens, J. C.;  Trauner, M.;  Benedetti, A.;  Maroni, L.;  Vaquero, J.;  
Macias, R. I.;  Raggi, C.;  Perugorria, M. J.;  Gaudio, E.;  Boberg, K. M.;  Marin, J. J.; 
Alvaro, D., Expert consensus document: Cholangiocarcinoma: current knowledge and future 
perspectives consensus statement from the European Network for the Study of 
Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016, 13 (5), 261-80. 
48. Bridgewater, J.;  Galle, P. R.;  Khan, S. A.;  Llovet, J. M.;  Park, J. W.;  Patel, T.;  
Pawlik, T. M.; Gores, G. J., Guidelines for the diagnosis and management of intrahepatic 
cholangiocarcinoma. J Hepatol 2014, 60 (6), 1268-89. 
49. Komuta, M.;  Govaere, O.;  Vandecaveye, V.;  Akiba, J.;  Van Steenbergen, W.;  
Verslype, C.;  Laleman, W.;  Pirenne, J.;  Aerts, R.;  Yano, H.;  Nevens, F.;  Topal, B.; 
Roskams, T., Histological diversity in cholangiocellular carcinoma reflects the different 
cholangiocyte phenotypes. Hepatology 2012, 55 (6), 1876-88. 
50. Aishima, S.; Oda, Y., Pathogenesis and classification of intrahepatic cholangiocarcinoma: 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 162 / 179 
 
different characters of perihilar large duct type versus peripheral small duct type. J 
Hepatobiliary Pancreat Sci 2015, 22 (2), 94-100. 
51. Rizvi, S.; Gores, G. J., Pathogenesis, diagnosis, and management of 
cholangiocarcinoma. Gastroenterology 2013, 145 (6), 1215-29. 
52. Nakamura, H.;  Arai, Y.;  Totoki, Y.;  Shirota, T.;  Elzawahry, A.;  Kato, M.;  Hama, 
N.;  Hosoda, F.;  Urushidate, T.;  Ohashi, S.;  Hiraoka, N.;  Ojima, H.;  Shimada, K.;  
Okusaka, T.;  Kosuge, T.;  Miyagawa, S.; Shibata, T., Genomic spectra of biliary tract 
cancer. Nat Genet 2015, 47 (9), 1003-10. 
53. Cardinale, V.;  Carpino, G.;  Reid, L.;  Gaudio, E.; Alvaro, D., Multiple cells of origin in 
cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J 
Gastrointest Oncol 2012, 4 (5), 94-102. 
54. Nakanuma, Y.;  Sato, Y.;  Harada, K.;  Sasaki, M.;  Xu, J.; Ikeda, H., Pathological 
classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 
2010, 2 (12), 419-27. 
55. Yuan, D.;  Huang, S.;  Berger, E.;  Liu, L.;  Gross, N.;  Heinzmann, F.;  Ringelhan, 
M.;  Connor, T. O.;  Stadler, M.;  Meister, M.;  Weber, J.;  Ollinger, R.;  Simonavicius, N.;  
Reisinger, F.;  Hartmann, D.;  Meyer, R.;  Reich, M.;  Seehawer, M.;  Leone, V.;  Hochst, 
B.;  Wohlleber, D.;  Jors, S.;  Prinz, M.;  Spalding, D.;  Protzer, U.;  Luedde, T.;  
Terracciano, L.;  Matter, M.;  Longerich, T.;  Knolle, P.;  Ried, T.;  Keitel, V.;  Geisler, F.;  
Unger, K.;  Cinnamon, E.;  Pikarsky, E.;  Huser, N.;  Davis, R. J.;  Tschaharganeh, D. F.;  
Rad, R.;  Weber, A.;  Zender, L.;  Haller, D.; Heikenwalder, M., Kupffer Cell-Derived Tnf 
Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial 
Dysfunction and ROS. Cancer Cell 2017, 31 (6), 771-789 e6. 
56. Khan, S. A.;  Thomas, H. C.;  Davidson, B. R.; Taylor-Robinson, S. D., 
Cholangiocarcinoma. Lancet 2005, 366 (9493), 1303-14. 
57. Sirica, A. E., Cholangiocarcinoma: molecular targeting strategies for chemoprevention 
and therapy. Hepatology 2005, 41 (1), 5-15. 
58. Doherty, B.;  Nambudiri, V. E.; Palmer, W. C., Update on the Diagnosis and Treatment of 
Cholangiocarcinoma. Curr Gastroenterol Rep 2017, 19 (1), 2. 
59. Hama, T.;  Nakanishi, K.;  Sato, M.;  Mukaiyama, H.;  Togawa, H.;  Shima, Y.;  
Miyajima, M.;  Nozu, K.;  Nagao, S.;  Takahashi, H.;  Sako, M.;  Iijima, K.;  Yoshikawa, 
N.; Suzuki, H., Aberrant Smad3 phosphoisoforms in cyst-lining epithelial cells in the cpk 
mouse, a model of autosomal recessive polycystic kidney disease. Am J Physiol Renal 
Physiol 2017, 313 (6), F1223-F1231. 
60. Cubero, F. J.;  Mohamed, M. R.;  Woitok, M. M.;  Zhao, G.;  Hatting, M.;  Nevzorova, 
Y. A.;  Chen, C.;  Haybaeck, J.;  de Bruin, A.;  Avila, M. A.;  Boekschoten, M. V.;  Davis, 
R. J.; Trautwein, C., Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells 
Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma. Hepatol Commun 2020, 
4 (6), 834-851. 
61. Yang, Y. M.;  Kim, S. Y.; Seki, E., Inflammation and Liver Cancer: Molecular 
Mechanisms and Therapeutic Targets. Semin Liver Dis 2019, 39 (1), 26-42. 
62. Manieri, E.;  Folgueira, C.;  Rodriguez, M. E.;  Leiva-Vega, L.;  Esteban-Lafuente, L.;  
Chen, C.;  Cubero, F. J.;  Barrett, T.;  Cavanagh-Kyros, J.;  Seruggia, D.;  Rosell, A.;  
Sanchez-Cabo, F.;  Gomez, M. J.;  Monte, M. J.;  JJ, G. M.;  Davis, R. J.;  Mora, A.; 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 163 / 179 
 
Sabio, G., JNK-mediated disruption of bile acid homeostasis promotes intrahepatic 
cholangiocarcinoma. Proc Natl Acad Sci U S A 2020, 117 (28), 16492-16499. 
63. Hay, E. D., Organization and fine structure of epithelium and mesenchyme in the 
developing chick embryo. Epithel. Mesenchymal Interact. 1968, 2, 31-35. 
64. Brabletz, T.;  Kalluri, R.;  Nieto, M. A.; Weinberg, R. A., EMT in cancer. Nat Rev Cancer 
2018, 18 (2), 128-134. 
65. Zhang, Q.;  Agoston, A. T.;  Pham, T. H.;  Zhang, W.;  Zhang, X.;  Huo, X.;  Peng, 
S.;  Bajpai, M.;  Das, K.;  Odze, R. D.;  Spechler, S. J.; Souza, R. F., Acidic Bile Salts 
Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's 
Cells. Gastroenterology 2019, 156 (1), 130-144 e10. 
66. Kokuryo, T.;  Yokoyama, Y.; Nagino, M., Recent advances in cancer stem cell research 
for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2012, 19 (6), 606-13. 
67. Glaser, S. S.;  Gaudio, E.;  Miller, T.;  Alvaro, D.; Alpini, G., Cholangiocyte proliferation 
and liver fibrosis. Expert Rev Mol Med 2009, 11, e7. 
68. Alvaro, D.;  Mancino, M. G.;  Glaser, S.;  Gaudio, E.;  Marzioni, M.;  Francis, H.; 
Alpini, G., Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. 
Gastroenterology 2007, 132 (1), 415-31. 
69. Lee, J. S.;  Heo, J.;  Libbrecht, L.;  Chu, I. S.;  Kaposi-Novak, P.;  Calvisi, D. F.;  
Mikaelyan, A.;  Roberts, L. R.;  Demetris, A. J.;  Sun, Z.;  Nevens, F.;  Roskams, T.; 
Thorgeirsson, S. S., A novel prognostic subtype of human hepatocellular carcinoma derived 
from hepatic progenitor cells. Nat Med 2006, 12 (4), 410-6. 
70. Zhang, F.;  Chen, X. P.;  Zhang, W.;  Dong, H. H.;  Xiang, S.;  Zhang, W. G.; Zhang, 
B. X., Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: 
immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 
2008, 52 (2), 224-32. 
71. Kumar, M.;  Zhao, X.; Wang, X. W., Molecular carcinogenesis of hepatocellular 
carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? 
Cell Biosci 2011, 1 (1), 5. 
72. Theise, N. D.;  Yao, J. L.;  Harada, K.;  Hytiroglou, P.;  Portmann, B.;  Thung, S. N.;  
Tsui, W.;  Ohta, H.; Nakanuma, Y., Hepatic 'stem cell' malignancies in adults: four cases. 
Histopathology 2003, 43 (3), 263-71. 
73. Chiba, T.;  Kita, K.;  Zheng, Y. W.;  Yokosuka, O.;  Saisho, H.;  Iwama, A.;  
Nakauchi, H.; Taniguchi, H., Side population purified from hepatocellular carcinoma cells 
harbors cancer stem cell-like properties. Hepatology 2006, 44 (1), 240-51. 
74. Zhang, J.;  Tian, X. J.; Xing, J., Signal Transduction Pathways of EMT Induced by TGF-
beta, SHH, and WNT and Their Crosstalks. J Clin Med 2016, 5 (4). 
75. Vaquero, J.;  Guedj, N.;  Claperon, A.;  Nguyen Ho-Bouldoires, T. H.;  Paradis, V.; 
Fouassier, L., Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical 
evidence to regulatory networks. J Hepatol 2017, 66 (2), 424-441. 
76. Jakowlew, S. B., Transforming growth factor-beta in cancer and metastasis. Cancer 
Metastasis Rev 2006, 25 (3), 435-57. 
77. Heldin, C. H.;  Landstrom, M.; Moustakas, A., Mechanism of TGF-beta signaling to 
growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009, 21 
(2), 166-76. 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 164 / 179 
 
78. Seoane, J., Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 2006, 
27 (11), 2148-56. 
79. Sheahan, S.;  Bellamy, C. O.;  Dunbar, D. R.;  Harrison, D. J.; Prost, S., Deficiency of 
G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell 
cycle arrest. BMC Cancer 2007, 7, 215. 
80. Connolly, E. C.;  Freimuth, J.; Akhurst, R. J., Complexities of TGF-beta targeted cancer 
therapy. Int J Biol Sci 2012, 8 (7), 964-78. 
81. Yamamura, Y.;  Hua, X.;  Bergelson, S.; Lodish, H. F., Critical role of Smads and AP-1 
complex in transforming growth factor-beta -dependent apoptosis. J Biol Chem 2000, 275 
(46), 36295-302. 
82. Giannelli, G.;  Koudelkova, P.;  Dituri, F.; Mikulits, W., Role of epithelial to 
mesenchymal transition in hepatocellular carcinoma. J Hepatol 2016, 65 (4), 798-808. 
83. Chen, C.;  Nelson, L. J.;  Avila, M. A.; Cubero, F. J., Mitogen-Activated Protein Kinases 
(MAPKs) and Cholangiocarcinoma: The Missing Link. Cells 2019, 8 (10). 
84. Win, S.;  Than, T. A.;  Zhang, J.;  Oo, C.;  Min, R. W. M.; Kaplowitz, N., New insights 
into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver 
diseases. Hepatology 2018, 67 (5), 2013-2024. 
85. Win, S.;  Than, T. A.;  Min, R. W.;  Aghajan, M.; Kaplowitz, N., c-Jun N-terminal kinase 
mediates mouse liver injury through a novel Sab (SH3BP5)-dependent pathway leading to 
inactivation of intramitochondrial Src. Hepatology 2016, 63 (6), 1987-2003. 
86. Mingo-Sion, A. M.;  Marietta, P. M.;  Koller, E.;  Wolf, D. M.; Van Den Berg, C. L., 
Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, 
decreased proliferation, and apoptosis in breast cancer cells. Oncogene 2004, 23 (2), 596-
604. 
87. Vivanco, I.;  Palaskas, N.;  Tran, C.;  Finn, S. P.;  Getz, G.;  Kennedy, N. J.;  Jiao, 
J.;  Rose, J.;  Xie, W.;  Loda, M.;  Golub, T.;  Mellinghoff, I. K.;  Davis, R. J.;  Wu, H.; 
Sawyers, C. L., Identification of the JNK signaling pathway as a functional target of the tumor 
suppressor PTEN. Cancer Cell 2007, 11 (6), 555-69. 
88. Wang, J.; Tai, G., Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma 
Development. Target Oncol 2016, 11 (6), 723-738. 
89. Cubero, F. J.;  Zhao, G.;  Nevzorova, Y. A.;  Hatting, M.;  Al Masaoudi, M.;  Verdier, 
J.;  Peng, J.;  Schaefer, F. M.;  Hermanns, N.;  Boekschoten, M. V.;  Grouls, C.;  
Gassler, N.;  Kiessling, F.;  Muller, M.;  Davis, R. J.;  Liedtke, C.; Trautwein, C., 
Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an 
experimental model of liver injury. J Hepatol 2015, 62 (1), 140-9. 
90. Das, M.;  Garlick, D. S.;  Greiner, D. L.; Davis, R. J., The role of JNK in the 
development of hepatocellular carcinoma. Genes Dev 2011, 25 (6), 634-45. 
91. Han, M. S.;  Barrett, T.;  Brehm, M. A.; Davis, R. J., Inflammation Mediated by JNK in 
Myeloid Cells Promotes the Development of Hepatitis and Hepatocellular Carcinoma. Cell 
Rep 2016, 15 (1), 19-26. 
92. Chen, F., JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer 
Res 2012, 72 (2), 379-86. 
93. Seki, E.;  Brenner, D. A.; Karin, M., A liver full of JNK: signaling in regulation of cell 
function and disease pathogenesis, and clinical approaches. Gastroenterology 2012, 143 (2), 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 165 / 179 
 
307-20. 
94. Chang, Q.;  Zhang, Y.;  Beezhold, K. J.;  Bhatia, D.;  Zhao, H.;  Chen, J.;  
Castranova, V.;  Shi, X.; Chen, F., Sustained JNK1 activation is associated with altered 
histone H3 methylations in human liver cancer. J Hepatol 2009, 50 (2), 323-33. 
95. Dhanasekaran, D. N.; Reddy, E. P., JNK signaling in apoptosis. Oncogene 2008, 27 (48), 
6245-51. 
96. Zhong, F.;  Tong, Z. T.;  Fan, L. L.;  Zha, L. X.;  Wang, F.;  Yao, M. Q.;  Gu, K. S.; 
Cao, Y. X., Guggulsterone-induced apoptosis in cholangiocarcinoma cells through ROS/JNK 
signaling pathway. Am J Cancer Res 2016, 6 (2), 226-37. 
97. Kamiya, A.; Gonzalez, F. J., TNF-alpha regulates mouse fetal hepatic maturation induced 
by oncostatin M and extracellular matrices. Hepatology 2004, 40 (3), 527-36. 
98. In Guide for the Care and Use of Laboratory Animals, th, Ed. Washington (DC), 2011. 
99. Cubero, F. J.;  Zoubek, M. E.;  Hu, W.;  Peng, J.;  Zhao, G.;  Nevzorova, Y. A.;  Al 
Masaoudi, M.;  Bechmann, L. P.;  Boekschoten, M. V.;  Muller, M.;  Preisinger, C.;  
Gassler, N.;  Canbay, A. E.;  Luedde, T.;  Davis, R. J.;  Liedtke, C.; Trautwein, C., 
Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury. 
Gastroenterology 2016, 150 (4), 968-81. 
100. Donato, M. T.;  Tolosa, L.; Gomez-Lechon, M. J., Culture and Functional 
Characterization of Human Hepatoma HepG2 Cells. Methods Mol Biol 2015, 1250, 77-93. 
101. McGill, M. R.;  Yan, H. M.;  Ramachandran, A.;  Murray, G. J.;  Rollins, D. E.; 
Jaeschke, H., HepaRG cells: a human model to study mechanisms of acetaminophen 
hepatotoxicity. Hepatology 2011, 53 (3), 974-82. 
102. Pfaffl, M. W., A new mathematical model for relative quantification in real-time RT-PCR. 
Nucleic Acids Res 2001, 29 (9), e45. 
103. An, L.;  Wang, X.; Cederbaum, A. I., Cytokines in alcoholic liver disease. Arch Toxicol 
2012, 86 (9), 1337-48. 
104. Kurien, B. T.; Scofield, R. H., Western blotting. Methods 2006, 38 (4), 283-93. 
105. Das, M.;  Jiang, F.;  Sluss, H. K.;  Zhang, C.;  Shokat, K. M.;  Flavell, R. A.; Davis, R. 
J., Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc 
Natl Acad Sci U S A 2007, 104 (40), 15759-64. 
106. Das, M.;  Sabio, G.;  Jiang, F.;  Rincon, M.;  Flavell, R. A.; Davis, R. J., Induction of 
hepatitis by JNK-mediated expression of TNF-alpha. Cell 2009, 136 (2), 249-60. 
107. Stocker, J. T.; Ishak, K. G., Mesenchymal hamartoma of the liver: report of 30 cases and 
review of the literature. Pediatr Pathol 1983, 1 (3), 245-67. 
108. Luedde, T.;  Kaplowitz, N.; Schwabe, R. F., Cell death and cell death responses in liver 
disease: mechanisms and clinical relevance. Gastroenterology 2014, 147 (4), 765-783 e4. 
109. Quante, M.;  Tu, S. P.;  Tomita, H.;  Gonda, T.;  Wang, S. S.;  Takashi, S.;  Baik, G. 
H.;  Shibata, W.;  Diprete, B.;  Betz, K. S.;  Friedman, R.;  Varro, A.;  Tycko, B.; Wang, T. 
C., Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and 
promote tumor growth. Cancer Cell 2011, 19 (2), 257-72. 
110. Petersen, B. E.;  Goff, J. P.;  Greenberger, J. S.; Michalopoulos, G. K., Hepatic oval 
cells express the hematopoietic stem cell marker Thy-1 in the rat. Hepatology 1998, 27 (2), 
433-45. 
111. Tarlow, B. D.;  Finegold, M. J.; Grompe, M., Clonal tracing of Sox9+ liver progenitors in 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 166 / 179 
 
mouse oval cell injury. Hepatology 2014, 60 (1), 278-89. 
112. Ferrarotto, R.;  Mitani, Y.;  Diao, L.;  Guijarro, I.;  Wang, J.;  Zweidler-McKay, P.;  
Bell, D.;  William, W. N., Jr.;  Glisson, B. S.;  Wick, M. J.;  Kapoun, A. M.;  Patnaik, A.;  
Eckhardt, G.;  Munster, P.;  Faoro, L.;  Dupont, J.;  Lee, J. J.;  Futreal, A.;  El-Naggar, A. 
K.; Heymach, J. V., Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With 
Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver 
Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol 2017, 35 (3), 
352-360. 
113. Hyun, J.;  Oh, S. H.;  Premont, R. T.;  Guy, C. D.;  Berg, C. L.; Diehl, A. M., 
Dysregulated activation of fetal liver programme in acute liver failure. Gut 2019, 68 (6), 1076-
1087. 
114. Masyuk, T. V.;  Radtke, B. N.;  Stroope, A. J.;  Banales, J. M.;  Gradilone, S. A.;  
Huang, B.;  Masyuk, A. I.;  Hogan, M. C.;  Torres, V. E.; Larusso, N. F., Pasireotide is more 
effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic 
kidney and liver diseases. Hepatology 2013, 58 (1), 409-21. 
115. Santos-Laso, A.;  Izquierdo-Sanchez, L.;  Rodrigues, P. M.;  Huang, B. Q.;  
Azkargorta, M.;  Lapitz, A.;  Munoz-Garrido, P.;  Arbelaiz, A.;  Caballero-Camino, F. J.;  
Fernandez-Barrena, M. G.;  Jimenez-Aguero, R.;  Argemi, J.;  Aragon, T.;  Elortza, F.;  
Marzioni, M.;  Drenth, J. P. H.;  LaRusso, N. F.;  Bujanda, L.;  Perugorria, M. J.; Banales, 
J. M., Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic 
liver disease: New therapeutic targets. Liver Int 2020, 40 (7), 1670-1685. 
116. Hetz, C.;  Chevet, E.; Oakes, S. A., Proteostasis control by the unfolded protein 
response. Nat Cell Biol 2015, 17 (7), 829-38. 
117. Hernandez-Alvarez, M. I.;  Sebastian, D.;  Vives, S.;  Ivanova, S.;  Bartoccioni, P.;  
Kakimoto, P.;  Plana, N.;  Veiga, S. R.;  Hernandez, V.;  Vasconcelos, N.;  Peddinti, G.;  
Adrover, A.;  Jove, M.;  Pamplona, R.;  Gordaliza-Alaguero, I.;  Calvo, E.;  Cabre, N.;  
Castro, R.;  Kuzmanic, A.;  Boutant, M.;  Sala, D.;  Hyotylainen, T.;  Oresic, M.;  Fort, J.;  
Errasti-Murugarren, E.;  Rodrigues, C. M. P.;  Orozco, M.;  Joven, J.;  Canto, C.;  
Palacin, M.;  Fernandez-Veledo, S.;  Vendrell, J.; Zorzano, A., Deficient Endoplasmic 
Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. Cell 2019, 177 
(4), 881-895 e17. 
118. Uskokovic-Markovic, S.;  Milenkovic, M.;  Topic, A.;  Kotur-Stevuljevic, J.;  Stefanovic, 
A.; Antic-Stankovic, J., Protective effects of tungstophosphoric acid and sodium tungstate on 
chemically induced liver necrosis in wistar rats. J Pharm Pharm Sci 2007, 10 (3), 340-9. 
119. J. F. L. Childs, E. A. S., Controlling orange decay. Ind. Eng. Chem., 1946, 38 (1), pp 82–
87. 
120. Dyroff, M. C.; Neal, R. A., Studies of the mechanism of metabolism of thioacetamide s-
oxide by rat liver microsomes. Mol Pharmacol 1983, 23 (1), 219-27. 
121. Gordon, C. T.;  Tan, T. Y.;  Benko, S.;  Fitzpatrick, D.;  Lyonnet, S.; Farlie, P. G., Long-
range regulation at the SOX9 locus in development and disease. J Med Genet 2009, 46 (10), 
649-56. 
122. Chiang, J. Y., Hepatocyte nuclear factor 4alpha regulation of bile acid and drug 
metabolism. Expert Opin Drug Metab Toxicol 2009, 5 (2), 137-47. 
123. Carotenuto, P.;  Fassan, M.;  Pandolfo, R.;  Lampis, A.;  Vicentini, C.;  Cascione, L.;  
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 167 / 179 
 
Paulus-Hock, V.;  Boulter, L.;  Guest, R.;  Quagliata, L.;  Hahne, J. C.;  Ridgway, R.;  
Jamieson, T.;  Athineos, D.;  Veronese, A.;  Visone, R.;  Murgia, C.;  Ferrari, G.;  
Guzzardo, V.;  Evans, T. R. J.;  MacLeod, M.;  Feng, G. J.;  Dale, T.;  Negrini, M.;  
Forbes, S. J.;  Terracciano, L.;  Scarpa, A.;  Patel, T.;  Valeri, N.;  Workman, P.;  
Sansom, O.; Braconi, C., Wnt signalling modulates transcribed-ultraconserved regions in 
hepatobiliary cancers. Gut 2017, 66 (7), 1268-1277. 
124. Rittie, L., Method for Picrosirius Red-Polarization Detection of Collagen Fibers in Tissue 
Sections. Methods Mol Biol 2017, 1627, 395-407. 
125. Grasl-Kraupp, B.;  Ruttkay-Nedecky, B.;  Koudelka, H.;  Bukowska, K.;  Bursch, W.; 
Schulte-Hermann, R., In situ detection of fragmented DNA (TUNEL assay) fails to 
discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. 
Hepatology 1995, 21 (5), 1465-8. 
126. Fan, Y.; Bergmann, A., Apoptosis-induced compensatory proliferation. The Cell is dead. 
Long live the Cell! Trends Cell Biol 2008, 18 (10), 467-73. 
127. Dolmans, R. A.;  Boel, C. H.;  Lacle, M. M.; Kusters, J. G., Clinical Manifestations, 
Treatment, and Diagnosis of Tropheryma whipplei Infections. Clin Microbiol Rev 2017, 30 (2), 
529-555. 
128. Kasprzak, A.; Adamek, A., Mucins: the Old, the New and the Promising Factors in 
Hepatobiliary Carcinogenesis. Int J Mol Sci 2019, 20 (6). 
129. Wang, J.;  Wang, H.;  Peters, M.;  Ding, N.;  Ribback, S.;  Utpatel, K.;  Cigliano, A.;  
Dombrowski, F.;  Xu, M.;  Chen, X.;  Song, X.;  Che, L.;  Evert, M.;  Cossu, A.;  Gordan, 
J.;  Zeng, Y.;  Chen, X.; Calvisi, D. F., Loss of Fbxw7 synergizes with activated Akt signaling 
to promote c-Myc dependent cholangiocarcinogenesis. J Hepatol 2019, 71 (4), 742-752. 
130. Lutterbach, B.; Hann, S. R., Hierarchical phosphorylation at N-terminal transformation-
sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 1994, 14 
(8), 5510-22. 
131. Reeves, H. L.;  Narla, G.;  Ogunbiyi, O.;  Haq, A. I.;  Katz, A.;  Benzeno, S.;  Hod, 
E.;  Harpaz, N.;  Goldberg, S.;  Tal-Kremer, S.;  Eng, F. J.;  Arthur, M. J.;  Martignetti, J. 
A.; Friedman, S. L., Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently 
inactivated in colorectal cancer. Gastroenterology 2004, 126 (4), 1090-103. 
132. Ehedego, H.;  Boekschoten, M. V.;  Hu, W.;  Doler, C.;  Haybaeck, J.;  Gabetaler, N.;  
Muller, M.;  Liedtke, C.; Trautwein, C., p21 ablation in liver enhances DNA damage, 
cholestasis, and carcinogenesis. Cancer Res 2015, 75 (6), 1144-55. 
133. Willenbring, H.;  Sharma, A. D.;  Vogel, A.;  Lee, A. Y.;  Rothfuss, A.;  Wang, Z.;  
Finegold, M.; Grompe, M., Loss of p21 permits carcinogenesis from chronically damaged liver 
and kidney epithelial cells despite unchecked apoptosis. Cancer Cell 2008, 14 (1), 59-67. 
134. Mu, X.;  Pradere, J. P.;  Affo, S.;  Dapito, D. H.;  Friedman, R.;  Lefkovitch, J. H.; 
Schwabe, R. F., Epithelial Transforming Growth Factor-beta Signaling Does Not Contribute to 
Liver Fibrosis but Protects Mice From Cholangiocarcinoma. Gastroenterology 2016, 150 (3), 
720-33. 
135. Sekiya, S.; Suzuki, A., Intrahepatic cholangiocarcinoma can arise from Notch-mediated 
conversion of hepatocytes. J Clin Invest 2012, 122 (11), 3914-8. 
136. Carpino, G.;  Cardinale, V.;  Folseraas, T.;  Overi, D.;  Floreani, A.;  Franchitto, A.;  
Onori, P.;  Cazzagon, N.;  Berloco, P. B.;  Karlsen, T. H.;  Alvaro, D.; Gaudio, E., Hepatic 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 168 / 179 
 
Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary 
Cholangitis. Am J Pathol 2018, 188 (3), 627-639. 
137. Long, J.;  Wang, H.;  Lang, Z.;  Wang, T.;  Long, M.; Wang, B., Expression level of 
glutamine synthetase is increased in hepatocellular carcinoma and liver tissue with cirrhosis 
and chronic hepatitis B. Hepatol Int 2011, 5 (2), 698-706. 
138. Uehara, T.;  Pogribny, I. P.; Rusyn, I., The DEN and CCl4 -Induced Mouse Model of 
Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. Curr Protoc Pharmacol 
2014, 66, 14 30 1-10. 
139. Shaib, Y.; El-Serag, H. B., The epidemiology of cholangiocarcinoma. Semin Liver Dis 
2004, 24 (2), 115-25. 
140. Lager, D. J.;  Qian, Q.;  Bengal, R. J.;  Ishibashi, M.; Torres, V. E., The pck rat: a new 
model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney 
Int 2001, 59 (1), 126-36. 
141. Fabris, L.; Strazzabosco, M., Epithelial-mesenchymal interactions in biliary diseases. 
Semin Liver Dis 2011, 31 (1), 11-32. 
142. Inagaki, Y.; Okazaki, I., Emerging insights into Transforming growth factor beta Smad 
signal in hepatic fibrogenesis. Gut 2007, 56 (2), 284-92. 
143. Lee, Y. A.; Friedman, S. L., Stellate Cells and Fibrosis. The Liver: Biology and 
Pathobiology 2020, 444-454. 
144. Yovchev, M. I.;  Grozdanov, P. N.;  Joseph, B.;  Gupta, S.; Dabeva, M. D., Novel 
hepatic progenitor cell surface markers in the adult rat liver. Hepatology 2007, 45 (1), 139-49. 
145. Mall, A. S.;  Tyler, M. G.;  Ho, S. B.;  Krige, J. E.;  Kahn, D.;  Spearman, W.;  Myer, 
L.; Govender, D., The expression of MUC mucin in cholangiocarcinoma. Pathol Res Pract 
2010, 206 (12), 805-9. 
146. Strnad, P.;  McElvaney, N. G.; Lomas, D. A., Alpha1-Antitrypsin Deficiency. N Engl J 
Med 2020, 382 (15), 1443-1455. 
147. Kimmelman, A. C.;  Qiao, R. F.;  Narla, G.;  Banno, A.;  Lau, N.;  Bos, P. D.;  Nunez 
Rodriguez, N.;  Liang, B. C.;  Guha, A.;  Martignetti, J. A.;  Friedman, S. L.; Chan, A. M., 
Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. 
Oncogene 2004, 23 (29), 5077-83. 
148. Patel, D.; Teckman, J. H., Alpha-1-Antitrypsin Deficiency Liver Disease. Clin Liver Dis 
2018, 22 (4), 643-655. 
149. Walker, R. M.;  Racz, W. J.; McElligott, T. F., Scanning electron microscopic examination 
of acetaminophen-induced hepatotoxicity and congestion in mice. Am J Pathol 1983, 113 (3), 
321-30. 
150. Dara, L.; Kaplowitz, N., Drug‐Induced Liver Injury. The Liver: Biology and Pathobiology 
2020, 701-713. 
151. Win, S.;  Than, T. A.;  Han, D.;  Petrovic, L. M.; Kaplowitz, N., c-Jun N-terminal kinase 
(JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) 
requires mitochondrial Sab protein expression in mice. J Biol Chem 2011, 286 (40), 35071-8. 
152. Malhi, H.; Gores, G. J., Hepatocyte Apoptosis: Mechanisms and Relevance in Liver 
Diseases. The Liver: Biology and Pathobiology 2020, 195-205. 
153. Sun, L.;  Wang, H.;  Wang, Z.;  He, S.;  Chen, S.;  Liao, D.;  Wang, L.;  Yan, J.;  
Liu, W.;  Lei, X.; Wang, X., Mixed lineage kinase domain-like protein mediates necrosis 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 169 / 179 
 
signaling downstream of RIP3 kinase. Cell 2012, 148 (1-2), 213-27. 
154. Zhao, J.;  Jitkaew, S.;  Cai, Z.;  Choksi, S.;  Li, Q.;  Luo, J.; Liu, Z. G., Mixed lineage 
kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-
induced necrosis. Proc Natl Acad Sci U S A 2012, 109 (14), 5322-7. 
155. Wang, H.;  Sun, L.;  Su, L.;  Rizo, J.;  Liu, L.;  Wang, L. F.;  Wang, F. S.; Wang, X., 
Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon 
phosphorylation by RIP3. Mol Cell 2014, 54 (1), 133-146. 
156. Fausto, N., Mouse liver tumorigenesis: models, mechanisms, and relevance to human 
disease. Seminars in liver disease 1999, 19 (3), 243-52. 
157. Grivennikov, S. I.;  Greten, F. R.; Karin, M., Immunity, inflammation, and cancer. Cell 
2010, 140 (6), 883-99. 
158. Labib, P. L.;  Goodchild, G.; Pereira, S. P., Molecular Pathogenesis of 
Cholangiocarcinoma. BMC Cancer 2019, 19 (1), 185. 
159. Seehawer, M.;  Heinzmann, F.;  D'Artista, L.;  Harbig, J.;  Roux, P. F.;  Hoenicke, L.;  
Dang, H.;  Klotz, S.;  Robinson, L.;  Dore, G.;  Rozenblum, N.;  Kang, T. W.;  Chawla, 
R.;  Buch, T.;  Vucur, M.;  Roth, M.;  Zuber, J.;  Luedde, T.;  Sipos, B.;  Longerich, T.;  
Heikenwalder, M.;  Wang, X. W.;  Bischof, O.; Zender, L., Necroptosis microenvironment 
directs lineage commitment in liver cancer. Nature 2018, 562 (7725), 69-75. 
160. Chang, L.; Karin, M., Mammalian MAP kinase signalling cascades. Nature 2001, 410 
(6824), 37-40. 
161. Cuylen, S.;  Blaukopf, C.;  Politi, A. Z.;  Muller-Reichert, T.;  Neumann, B.;  Poser, I.;  
Ellenberg, J.;  Hyman, A. A.; Gerlich, D. W., Ki-67 acts as a biological surfactant to disperse 
mitotic chromosomes. Nature 2016, 535 (7611), 308-12. 
162. Bowman, G. D.;  O'Donnell, M.; Kuriyan, J., Structural analysis of a eukaryotic sliding 
DNA clamp-clamp loader complex. Nature 2004, 429 (6993), 724-30. 
163. Roskams, T.; Desmet, V., Ductular reaction and its diagnostic significance. Semin Diagn 
Pathol 1998, 15 (4), 259-69. 
164. Diaz, R.;  Kim, J. W.;  Hui, J. J.;  Li, Z.;  Swain, G. P.;  Fong, K. S.;  Csiszar, K.;  
Russo, P. A.;  Rand, E. B.;  Furth, E. E.; Wells, R. G., Evidence for the epithelial to 
mesenchymal transition in biliary atresia fibrosis. Hum Pathol 2008, 39 (1), 102-15. 
165. Burns, W. C.;  Kantharidis, P.; Thomas, M. C., The role of tubular epithelial-
mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007, 185 (1-3), 
222-31. 
166. Robertson, H.;  Ali, S.;  McDonnell, B. J.;  Burt, A. D.; Kirby, J. A., Chronic renal 
allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell 
transition. J Am Soc Nephrol 2004, 15 (2), 390-7. 
167. Planas-Paz, L.;  Orsini, V.;  Boulter, L.;  Calabrese, D.;  Pikiolek, M.;  Nigsch, F.;  
Xie, Y.;  Roma, G.;  Donovan, A.;  Marti, P.;  Beckmann, N.;  Dill, M. T.;  Carbone, W.;  
Bergling, S.;  Isken, A.;  Mueller, M.;  Kinzel, B.;  Yang, Y.;  Mao, X.;  Nicholson, T. B.;  
Zamponi, R.;  Capodieci, P.;  Valdez, R.;  Rivera, D.;  Loew, A.;  Ukomadu, C.;  
Terracciano, L. M.;  Bouwmeester, T.;  Cong, F.;  Heim, M. H.;  Forbes, S. J.;  Ruffner, H.; 
Tchorz, J. S., The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size. Nat 
Cell Biol 2016, 18 (5), 467-79. 
168. Guest, R. V.;  Boulter, L.;  Dwyer, B. J.; Forbes, S. J., Understanding liver regeneration 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 170 / 179 
 
to bring new insights to the mechanisms driving cholangiocarcinoma. NPJ Regen Med 2017, 
2, 13. 
169. Zong, Y.;  Panikkar, A.;  Xu, J.;  Antoniou, A.;  Raynaud, P.;  Lemaigre, F.; Stanger, 
B. Z., Notch signaling controls liver development by regulating biliary differentiation. 
Development 2009, 136 (10), 1727-39. 
170. Al-Bahrani, R.;  Abuetabh, Y.;  Zeitouni, N.; Sergi, C., Cholangiocarcinoma: risk factors, 
environmental influences and oncogenesis. Ann Clin Lab Sci 2013, 43 (2), 195-210. 
171. Isomoto, H.;  Kobayashi, S.;  Werneburg, N. W.;  Bronk, S. F.;  Guicciardi, M. E.;  
Frank, D. A.; Gores, G. J., Interleukin 6 upregulates myeloid cell leukemia-1 expression 
through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42 (6), 1329-38. 
172. Heldin, C. H.;  Miyazono, K.; ten Dijke, P., TGF-beta signalling from cell membrane to 
nucleus through SMAD proteins. Nature 1997, 390 (6659), 465-71. 
173. Zhang, Y. E., Non-Smad pathways in TGF-beta signaling. Cell Res 2009, 19 (1), 128-39. 
174. Yamashita, M.;  Fatyol, K.;  Jin, C.;  Wang, X.;  Liu, Z.; Zhang, Y. E., TRAF6 mediates 
Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 2008, 31 (6), 918-24. 
175. Bakin, A. V.;  Tomlinson, A. K.;  Bhowmick, N. A.;  Moses, H. L.; Arteaga, C. L., 
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-






ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 171 / 179 
 
  
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  

























ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 173 / 179 
 
  
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 174 / 179 
 
10.1 Publications 
10.1.1 Conference abstracts 
Poster presentation at the International Liver Congress 2019 in Vienna 
Austria, abstract published: 
1)  Chen, C., Nelson, L. J., Avila, M. A., & Cubero, F. J. (2019). FRI-426-
Overexpression of c-Jun N-terminal Kinase-1 coincides with the acquisition of 
cholangiocytic markers in experimental cholangiocarcinoma. J Hepatol, 70(1), 
e581. 
2)  Leticia Colyn, Gloria Álvarez-Sola, Maria U Latasa, Iker Uriarte, Marina 
Bárcena-Varela, Maria Arechederra, Maddalen Jimenez, Sergio Morini, Simone 
Carotti, Julen Oyarzabal, Felipe Prosper, Matteo Canale, Andrea Casadei 
Gardini, Maria Iraburu Elizalde, Jesus Urman, Chaobo Chen, Francisco Javier 
Cubero, Leonard J Nelson, Bruno Sangro, María Luz Martínez-Chantar, Jesús 
María Banales, Jose Marin, Carmen Berasain, Maite G Fernandez-Barrena, 
Matías A Avila. (2019). PS-043-Dual targeting of G9a and DNM-
methyltransferase-1 for the treatment of experimental cholangiocarcinoma. J 
Hepatol, 70(1), e27-e28. 
3)  Raquel Benedé, Olga Estévez, Laura Moran Blanco, Nuria López-
Alcántara, Feifei Guo, Chaobo CHEN, Ricardo Macias-Rodriguez, Astrid Ruiz-
Margain, kang Zheng, Pierluigi Ramadori, Francisco Javier Cubero, Yulia 
Nevzorova (2019). THU-254-Cumulative effects of western diet and alcohol 
abuse: A novel model of ASH/NASH-derived liver injury. J Hepatol, 70(1), e274. 
4)  F Guo, K Zheng, R Benedé-Ubieto, O Estévez Vázquez, P Ramadori, MM 
Woitok, C Chen, C Trautwein, C Liedtke, FJ Cubero, YA Nevzorova (2019). c-
Myc overexpression in hepatocytes is associated with spontaneous 
development of non-alcoholic steatohepatitis (NASH) in mice. Zeitschrift für 
Gastroenterologie, 57(01), P3-4. 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 175 / 179 
 
10.1.2 Original Publication 
1)  Chen C, Nelson LJ, Ávila MA, Cubero FJ, Mitogen-Activated Protein 
Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells. 2019 Sep 
28;8(10):1172. DOI: 10.3390/cells8101172. PMID: 31569444. 
2)  Francisco Javier Cubero, Mohamed Ramadan Mohamed, Marius M. 
Woitok, Gang Zhao, Maximilian Hatting, Yulia A. Nevzorova, Chaobo Chen, 
Johannes Haybaeck, Alain de Bruin, Matias A. Avila, Mark V. Boekschoten, 
Roger J. Davis Christian Trautwein, Loss of c‐Jun N‐terminal Kinase 1 and 
2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation 
Resembling Cholangiocarcinoma. Hepatol Commun.2020. 4(6): 834-851. DOI: 
10.1002/hep4.1495. PMID: 32490320. 
3)  Manieri E, Folgueira C, Rodríguez ME, Leiva-Vega L, Esteban-Lafuente L, 
Chen C, Cubero FJ, Barrett T, Cavanagh-Kyros J, Seruggia D, Rosell A, 
Sanchez-Cabo F, Gómez MJ, Monte MJ, G Marin JJ, Davis RJ, Mora A, Sabio 
G. JNK-mediated disruption of bile acid homeostasis promotes intrahepatic 
cholangiocarcinoma. Proc Natl Acad Sci U S A. 2020 Jun 29:202002672. doi: 
10.1073/pnas.2002672117. Epub ahead of print. PMID: 32601222. 
4) Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, 
Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, 
Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini 
S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJ, Martinez-Chantar ML, 
Banales JM, Arnes R, Huch M, Patino J, Dar AA, Nosrati M, Oyarzábal J, 
Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena 
MG, Avila MA. Dual targeting of G9a and DNMT1 for the treatment of 
experimental cholangiocarcinoma. Hepatology. 2020 Nov 22. doi: 
10.1002/hep.31642. Epub ahead of print. PMID: 33222246. 
ROLE OF THE C-JUN TERMINAL KINASES (JNK1/2) IN THE DEVELOPMENT  
OF CANCER OF THE BILIARY TRACT  
 176 / 179 
 
10.1.3 Awards 
04.2019     Free registration award of the EASL (European Association for 
the Study of the Liver) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TESIS DOCTORAL 
MADRID, 2020. 
 
